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Abstract 
 
In order to design new therapies in the fight against infectious diseases it is necessary to 
understand how the human immune response controls infection. Mouse models, 
particularly gene-targeted mice, are invaluable in studies into immune responses 
(Goosen and Bujard, 2002). A central regulator of immune responses is IL-4R, the 
receptor for the IL-4 and IL-13, Th2 cytokines (Paul, 1997). The generation of IL-4R 
deficient mouse models has been invaluable in identifying the roles of IL-4/IL-13 and IL-
4Ra in numerous studies (Mohrs et al., 1999). In order to enhance these findings the 
development of new models and molecular tools targeting specific cell populations and/or 
taking advantage of new genetic technologies allow for the spatial and temporal deletion 
or reconstitution of the gene of interest. In this study, we generated a new mouse 
model, which allows both inducible and cell-specific deletion and reconstitution of IL-4R 
expression. This model has the potential to add a new dimension to our understanding of 
IL-4R biology. This has been achieved by using the established Tet System (Goosen 
and Bujard, 1992) where the crossing of two complementary transgenic mouse lines 
enable the generation of the final double transgenic model. The first line expresses the 
transactivator, tTA, from the Tet-Off expression cassette driven by the Vav hemapoeitic 
specific promoter (Wiesner et al., 2005). The second mouse line expresses IL-4R cDNA 
under the dictates of a cytomegalovirus (PCMV) minimal promoter supplemented with 
seven tet operon (TetO) sequences which serves as a binding site for the transactivator. 
Backcrossing these lines to an IL-4R-/- BALB/c genetic background, the two transgenic 
lines were crossed, generating a double transgenic mouse on an IL-4R-/- backbone. In 
these double transgenic mice, the transactivator was synthesized in a cell specific 
manner leading to haematopoietic cell IL-4R reconstitution on an IL-4R-/- background. 
As this binding of the transactivator to the TetO is inhibited by tetracycline, oral 
administration of tetracycline can turn off IL-4R expression. 
To investigate the importance of IL-4Ron dendritic cells (DCs), we constructed and 
characterised vectors to generate a dendritic cell (DC) specific IL-4R deficient mouse 
model (CD11c-Cre-IL-4Rlox/-). In this model, Cre recombinase transgene expression will 
be directed exclusively to DCs due to the incorporation of the appropriate cell specific 
promoter (CD11c). Cre expression will lead to the inactivation of the lox P flanked IL-4R 
gene. Here we describe the molecular cloning and characterisation of the eukaryotic 
expression vectors containing the mouse dendritic cell specific promoter (CD11c, Broker 
et al., 1997). Vectors were designed for optimal expression, directed via CD11c, of the 
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Cre Recombinase and Green Fluorescent Protein (GFP) transgenes. In vitro functional 
analysis of these constructs confirmed cell specific transcription and translation of the 
transgenes.  
In the final part of the project soluble receptors were generated for the blocking of IL-4 
and IL-13 signalling. Such blockers have proven to be powerful tools in studying cytokine 
function (Goldenberg et al., 1999; Grunig et al., 1998). Here we aimed to build on this 
body of knowledge by generating Fc-tagged soluble receptor blockers for IL-4R, IL-
13R2 and the IL-2R-IL-4R receptor complex. These Fc-tagged blockers allow the 
inhibition of cytokine function in vitro and in vivo. The design and generation of these 
fusion proteins were analogous to those previous described IL-4 and IL-13 cytokine 
blockers but with specific refinements. These refinements are in the construct design 
where we specifically used cDNA of a BALB/c genetic background (to skew the 
immunological Th1 / Th2 response), and a mutated human Fc-tag which decreases non-
specific binding by the recombinant proteins. All three cytokine blockers demonstrated 
cytokine blocking activity and biological functionality was confirmed for two of the 
generated blockers. 
Together these strategies allow for the precise determination of the role of IL-4R and 
its associated cytokines in immune responses and will provide useful information which is 
likely to be of use in the development of new medical treatments.  
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Chapter 1: General Introduction. 
 
1.1 The immune system. 
 
Immunology is the study of the systems involved in host protection from foreign 
macromolecules or invading organisms and the ensuing host defense responses. The 
immune system can be divided into the innate and adaptive responses. The host immune 
response, being either innate or adaptive, depends on the ability to distinguish between 
self and non-self molecules (summarized in Janeway et al., 2002). Self molecules are 
those components of the host body that can be distinguished from foreign substances by 
the immune system (Smith, 1997). In contrast, non-self molecules are those recognized 
as foreign molecules. 
 
All cells in the immune system have a common origin in the bone marrow. These include 
the myeloid (neutrophils, basophils, eosinpophils, macrophages and dendritic cells) and 
lymphoid (B lymphocyte, T lymphocyte and Natural Killer) cells (Kondo et al., 2003). Both 
groups differentiate along distinct pathways (Figure 1.1). The myeloid stem cell gives rise 
to erythrocytes, platelets, neutrophils, monocytes/macrophages and dendritic cells 
(Akashi et al., 2000), in contrast the lymphoid stem cell gives rise to the Natural Killer, T 
cells and B cells (Igarashi et al., 2002; Kondo et al., 1997; Kouro et al., 2002). T cell 
development initiates with the precursor T cells migrating to the thymus. In the thymus 
these cells differentiate into two distinct types of T cells, the CD4+ T helper (Th) cell and 
the CD8+ pre-cytotoxic T cell. Furthermore, two types of Th cells are produced in the 
thymus the Th1 cells, which assist the CD8+ pre-cytotoxic cells to differentiate into 
cytotoxic T cells, a d Th2 cells, which facilitate in B cell differentiation into plasma cells, 
which subsequently secrete antibodies. 
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Figure 1.1 Immune system cell development. 
 
All hematopoietic cells are derived from pluripotent stem cells. These cells branch into 
two main lineages, one specific for lymphoid cell development and the other specific for 
the myeloid cells. The lymphoid stem cell differentiates into either T cells or B cells 
depending on the immediate microenvironment. T cell development takes place in the 
thymus and B cells develop in the foetal liver and bone marrow. The plasma cells which 
develop from the precursor B cells are characterised as the most differentiated antibody-
forming cell. The natural killer (NK) cells are also derived from the common lymphoid 
stem cell. The myeloid cells differentiate into the committed cells shown on the left. 
Figure adapted from Microbiology & Immunology On-Line, 
http://pathmicro.med.sc.edu/ghaffar/innate.htm. 
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1.1.1 Innate Immunity. 
 
The innate immune system consists of the cells and mechanisms that provide the host 
immediate, non-specific defence against infection by other organisms. The innate system 
therefore recognizes, and reacts to pathogen or antigen presence in a generic way 
(Kapetanovic and Cavaillon, 2007). The key elements of innate immunity include 
anatomical barriers, secretory molecules and cellular components. The physical 
anatomical barriers include the skin and internal epithelial layers, movement associated 
with the gastro-intestinal tracts and the oscillation of broncho-pulmonary cilia. 
Additionally, these protective surfaces are associated with chemical agents. 
Consequently, the first lines of defence against foreign organisms are the physical and 
chemical barriers being the skin and molecules such as the low molecular weight proteins 
the defensins (Yang et al., 2007), found in the lung and gastrointestinal tract displaying 
antimicrobial activity and the surfactants in the lung which act as opsonins (Peng et al., 
2007). 
Upon penetration of these barrier layers the main effector immune cells involved in the 
subsequent response are phagocytic cells that respond rapidly by engulfing microbial 
pathogens and killing them independently from antibodies (Alberts et al., 2002; Janeway 
et al., 2002). Amongst the phagocytic cells are: 
 Neutrophils: Characteristically neutrophils are the first cells recruited to acute 
inflammatory sites and are the most highly adherent, motile, phagocytic 
leukocytes (Kansas, 1996).  
 Antigen presenting cells characteristically lack antigen-specific receptors. Instead, 
they capture, process and present antigens to T cell receptors. APCs include 
macrophages, dendritic cells and B cells. 
 Monocytes/Macrophages: Macrophages process protein antigens and present 
antigen peptides to T cells. Monocytes/macrophages are highly adherent, motile 
and phagocytic; involved in assembly and regulation of other cells of the immune 
system, such as T lymphocytes. They serve as antigen processing-presenting 
cells; and act as cytotoxic cells when armed with specific IgG antibodies. 
Macrophages, differentiated monocytes, are recruited to sites of inflammation 
and are capable of becoming further specialized through cytokine stimulation 
(Gordon, 1986; Savill et al., 2002; Ziegler-Heitbrock, 1989). 
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 Dendritic cells: Amongst the most important antigen-presenting cells are the 
highly specialized dendritic cells. Tissue dendritic cells consume antigen at 
infection sites and are activated by the innate immune response. Subsequently, 
these cells migrate to local lymphoid tissue and mature into cells that are highly 
effective at presenting antigen to re-circulating T cells. These mature dendritic 
cells are distinguished by surface molecules, known as co-stimulatory molecules 
that synergize with antigen in the activation of naive T cells (Janeway et al., 
2001; Savina and Amigorena, 2007). Dendritic cells are in constant 
communication with other components of the host immune system. This 
interaction can be at a distance via cytokines, for example, the stimulation of 
dendritic cells in vivo with microbial extracts stimulates the dendritic cells to 
rapidly produce IL-12 (Reis e Sousa et al., 1997). Subsequent signaling via the 
secreted IL-12 directs the naive CD4 T cells towards a Th1 phenotype. The 
ultimate consequence is priming and activation of the immune system for attack 
against the antigens presented on the dendritic cell surface. The type of dendritic 
cell also dictates the profile of the cytokines produced. The lymphoid dendritic 
cell has the ability to produce huge amounts of IFN in quantities exceeding 
production by any of the other blood cells (Siegel et al., 1999). Dendritic cell 
communication can also be via direct cell-to-cell contact based on the interaction 
of cell-surface proteins, illustrated in the interaction of the DC receptor CD40 with 
CD40L present on the lymphocyte (Lefrançois et al., 1999). Dendritic cells thus 
serve as an important link between the innate and adaptive immune systems, by 
their antigen presentation to one of the key effector cell types of the adaptive 
immune system; the T cells (Guermonprez et al., 2002).  
 
In addition to the phagocytic cells, mast cells, basophils and eosinophils, natural killer 
cells and γδ T cells also play important roles in the innate response (Beutler, 2004). For 
example:  
 Eosinophils: The eosinophils participate in hypersensitivity reactions via 
cytotoxicity, which is mediated by large cytoplasmic granules. These granules 
contain the eosinophilic basic and cationic proteins (Gleich et al., 1995).  
 Basophils and mast cells are involved in the production of cytokines that have 
roles in host defense against antigens and stimulation of allergic inflammation. 
These cells present surface membrane receptors for IgE antibodies and contain 
numerous large cytoplasmic granules, containing heparin and histamine. When 
cell-bound IgE antibodies cross-link to antigens, the cells degranulate and 
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produce low-molecular weight vasoactive mediators, like histamine through which 
they exercise immune effector functions (Galli et al., 1999; Metcalfe et al., 1997). 
 Natural Killer Cells: NK cells are large circulating granular lymphocytes that 
nonspecifically kill certain types of tumor cells and pathogen or virus-infected 
cells. This killing function is enhanced by cytokines such as IL-2 and IFN-. 
Additionally microorganisms stimulate NK cells to produce a number of cytokines 
such as, IL-2, IFN-, IFN-, and TNF-. (Alberts et al., 2002; Baron et al., 1996; 
Janeway et al., 2002).  
Although both innate and adaptive immune systems function to protect against antigens 
the response elicited by the two systems differ and one of the most distinguishing factors 
between the adaptive and innate systems is the immunological memory demonstrated by 
the adaptive system (Mayer, 2006). This enables a swift response upon subsequent 
exposure to the same antigen. Yet it is important to recognize that most immune 
responses rely on the combined interplay between the various components of both the 
innate and adaptive immune systems. 
 
 
1.1.2 Adaptive Immunity. 
 
Adaptive immunity can be described as antigen or pathogen specific. This specificity is 
conferred on the system by pre exposure to the pathogenic target. These specific 
responses are typically rapid and effective. A range of cells that include the B 
lymphocytes, T cells and dendritic cells orchestrates the response. 
 
1.1.2.1  B lymphocytes. 
 
The antibody producing B cells confer the humoral immunity; these cells differentiate into 
plasma cells to secrete antibodies (figure 1.2). Antibodies circulate the host blood and 
tissue fluids binding specifically to their antigen and are involved in processing antigenic 
proteins and presenting the peptide antigen fragments, some of which are complexed 
with MHC class II molecules and then presented on the cell surface to CD4+ T cells.  
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Figure 1.2 B lymphocyte development. 
The figure illustrates the development of the B cell subsequent to antigen presentation. 
Figure obtained from The Immune System. NIH Publication No. 03–5423. 
 
B cell development is characterized by recombination of immunoglobulin H and L chain 
genes and expression of specific surface monomeric IgM molecules. At this stage of 
development, B cells are highly susceptible to the induction of tolerance. This specific 
tolerance being the process whereby B lymphocytes recognizing self antigens are deleted 
before they develop into fully immunocompetent cells. Mature B cells are characterized 
by surface IgD molecules; these mature cells are capable of differentiation into antibody-
producing plasma cells subsequent to antigen exposure (Dal Porto et al., 2004; 
Raghaven and Bjorkman, 1996).  
B cell activation into antibodies capable of producing and secreting cells is antigen-
dependent. Specific antigens bind to surface Ig molecule, this leads to the B cell 
differentiating into plasma cells that produce and secrete antibodies of the same antigen-
binding specificity. B cell interaction with T helper cells leads to their proliferation and 
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isotype class switching of the immunoglobulin that is produced, yet retaining the same 
antigen-binding specificity.  
Following binding to the antigen the antibody can function in one of the following ways; 
1) neutralization of the pathogenic features of the antigen (e.g. toxins), 2) facilitation of 
the ingestion by the phagocytic cells, 3) adherence to and stimulation of complement 
molecules to produce opsonins or 4) contributing to antibody-dependent cellular 
cytotoxicity. Hence, antibody interaction with other parts of the immune system, allows 
the recognition and elimination of antibody-antigen complex (Hofer et al., 2006). The 
receptor to which antigen epitopes bind on T-lymphocytes is the T-cell receptor (TCR) 
(Rudolph et al., 2006). TCR only recognizes the antigen when it is presented by host cells 
in combination with major histocompatibility complex (MHC) molecules (Cresswell et al., 
2005). This recognition leads to the release of cytokines or the elimination of the 
presenting cell-antigen complex (Janeway et al., 2001).  
 
1.1.2.2  T lymphocytes. 
 
T cells that have not encountered antigens are described as naïve T cells, these are 
activated to produce armed effector T cells when they encounter their specific antigen 
which presents in the form of a peptide:MHC complex on the surface of an activated 
antigen-presenting cell (Hughes et al., 2006).  
T lymphocytes fall into three functional classes that detect antigens derived from 
different types of pathogen (Figure 1.3). Antigens from intracellular pathogens that 
multiply in the cytoplasm are passed to the cell surface by MHC class I molecules and 
presented to CD8 T cells. These differentiate into cytotoxic T cells that eliminate the 
infected target cells (Luther and Cyster, 2001). This process is mediated by the release of 
cytotoxic proteins such as perforin and granzyme, or the induction of apoptosis due to 
Fas ligand binding (Wong and Pamer, 2003).  
Antigen peptides from pathogens multiplying in intracellular vesicles, and those derived 
from ingested extracellular bacteria and toxins, are carried to the cell surface by MHC 
class II molecules and presented to CD4 T cells. Following this activation, characteristic 
cytokine and chemokine secretion profiles permit the classification of CD4+ T helper (Th) 
cells into two major subpopulations (Paul and Seder, 1994). These two types of effector 
T cell are the Th1 and Th2 cells. Typically antigens presented via macrophages and 
dendritic cells to T cells are inclined to stimulate the differentiation of Th1 cells which are 
associated with intracellular pathogens. 
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Figure 1.3 Antigen presentation and T lymphocyte activation. 
 
Subsequent to antigen presentation naïve T cells differentiate into helper T cells or 
cytotoxic T cells. Each group has distinct cytokine profiles and functions in either humoral 
or cellular immunity. Figure adapted from The Immune System. NIH Pub No. 03–5423. 
 
 
Conversely, extracellular soluble antigens, associated with nematode infections, tend to 
stimulate the production of Th2 cells (Figure 1.4) (Mosmann et al., 1986; Swain et al., 
1988). Both Th1 and Th2 cells originate from the same naïve IL-2 producing CD4+ T cell 
precursors. (Kondo et al., 1997; Kondo et al., 2003) 
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1.1.2.3  T lymphocytes and Th1/Th2 differentiation. 
 
Th1 cells are involved in cell-mediated immunity; these cells are characterized by the 
production of pro-inflammatory cytokines like IFN-, IL-2, and TNF-. Pro-inflammatory 
cytokines stimulate the microbial properties of macrophages, and leads to increased B 
cell production of IgG antibodies effective at opsonising extracellular pathogens for 
uptake by phagocytic cells. Thus cytokines secreted by Th1 cells activate cytotoxic T cells 
and macrophages to stimulate cellular immunity and inflammation (Stevens et al., 1988). 
Additionally Th1 cells also secrete IL-3 and GM-CSF, which leads to increased leukocyte 
production by the bone marrow. Th2 cells initiate the humoral immune response by 
activating naïve antigen-specific B cells to produce IgM antibodies. Th2 cells secrete IL-4, 
IL-5, IL-6, and IL-10, cytokines that are involved in the induction of antibody production 
by B cells (Katona et al., 1988).  
 
The transcription factors, T-bet and GATA-3, play a critical role in the differentiation to 
either a Th1 or a Th2 cell. T-bet transcriptional activity has been shown to be beneficial 
for the development of Th1 cells (Szabo et al., 2000). In contrast, GATA-3 activity 
promotes the differentiation to Th2 cells (Zheng and Flavell, 1997). T-bet increases the 
production of Th1 cells by activation of cytokine gene transcription, like IFN- which is 
required for Th1 function (Szabo et al., 2002). In parallel, it blocks the activity of GATA-3 
(Usui et al., 2006). 
 
Th1 and Th2 cytokines are antagonistic in activity; the secretion of IL-4 stimulates Th2 
activity and suppresses Th1 activity, while IL-12 promotes Th1 activities. The Th1 
cytokines IL-12 and IFN- inhibits proliferation of Th2 cells. IFN- and IL-2 stimulate B 
cells to secrete IgG2a and inhibit secretion of IgG1 and IgE whereas IL-4 stimulates B 
cells to secrete IgE and IgG1 (Hsieh et al., 1993). In contrast, the Th2 cytokine IL-10 
inhibits Th1 secretion of IFN- and IL-2; additionally it suppresses MHC II expression 
(Alberts et al., 2002). The balance between Th1 and Th2 activity may manoeuvre the 
immune response on the path of cell-mediated or humoral immunity.  
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Figure 1.4 T cell differentiation. 
 
Antigen presenting cells initiates the process of naïve CD4+ T helper cell differentiation 
along the Th1 or Th2 pathway. The cytokines IL-12 and IFN- promote Th1 cell 
development and IL-4 promotes the differentiation to Th2. Upon differentiation, the Th1 
and Th2 cells produce cytokines leading to different and often opposing responses 
ranging from stimulation of B cells and antibody production to phagocytosis.  
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Other T cell subsets include Tr1, Th3 and natural CD4+CD25+ regulatory T cells (Tregs), 
these cells are involved in the regulation of immune responses and have important 
functions in prevention of autoimmunity and excessive effector responses to pathogens. 
Tr1 and Th3 cells produce and secrete immunosuppressive cytokines including IL-10 and 
TGF-(McGruirk and Mills, 2002; O’Garra et al., 2004; Sakaguchi et al., 1995).  
Regulatory T cells (TRegs) are a key subset of CD4+ T cells. TRegs are characterized by 
the expression of the transcription factor FOXP3 (Forkhead box P3) and the IL-2 receptor 
and unlike activated effector T cells low levels of CD127 (Seddiki et al., 2006; Wing et al., 
2006). Studies in mouse models have implicated TRegs in the inhibition of allergic 
responses and it has been suggested that they control Th2-cell responses in humans. 
This inhibition is achieved through the inhibitory cytokines IL-10 and TGFβ leading to 
atopy that is a result of an imbalance between Th2 cells and TRegs (Bacchetta et al., 
2007; Larche et al., 2007). 
Th17 cells are another newly identified type of CD4+ T cell. These cells secrete IL-17A 
and IL-17F, which are associated with neutrophilic inflammation(Stockinger et al., 2007) 
It has been shown that IL-17A is over expressed in asthmatic airways in association with 
neutrophil influx (Bullens et al., 2006), additionally it stimulates the production of the IL-
8, a neutrophil chemo attractant, by airway smooth muscle cells (Dragon et al., 2007). 
Furthermore, these cells have demonstrated functions in autoimmunity and it has been 
suggested that they may function in the clearance of pathogens not recognized by the 
Th1 and Th2 cells (Bettelli et al., 2006) 
 
Despite the means in which the antigen co-stimulatory signals are presented, the main 
factors affecting the development of Th subpopulations are the cytokines and 
chemokines present in the immediate T cell environment. New advances in the use of 
knockout mice and inducible systems may lead to a better understanding of the 
properties and interactions of the individual cytokines and chemokines that play a role in 
Th cell activation.  
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1.2 Cytokines and immune system communication. 
 
Both the innate and adaptive immune responses can be characterised by their cytokine 
responses. The cytokine super family of proteins forms an integral part of the signaling 
network between cells and is essential in generating and regulating the immune 
response (Figure 1.5). Cytokines are small soluble proteins that are produced in response 
to an immune stimulus. They act at the cellular level by binding to membrane receptors, 
and inducing a cellular response. This response is activated by altering the gene 
expression profiles of cytokine-regulated genes (Taniguchi, 1995).  
 
 
 
 
Figure 1.5 Influence of cytokines on immune response. 
 
Upon T cell activation IL-2 is secreted leading to proliferation of these activated T cells. 
With IL-4 secretionTh2 cells are produced secreting IL-4, IL-5 and IL-13, thus supporting 
an innate or humoral immune environment. Conversely, IL-12 secreted by antigen 
presenting cells skews the response to an adaptive immune response associated with the 
production of IFN-, TFN- and lymphotoxin. 
 
 
Numerous cytokines have been identified and are characterized by their diverse 
functions. Responses to cytokines include modulation of membrane protein expression, 
proliferation, effector molecule secretion and differentiation of B and T lymphocytes 
(O’Shea et al., 2002). 
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Cytokines are referred to as interleukins, growth factors, colony-stimulating factors, 
tumor necrosis factors, interferons and chemokines. Important examples of these include 
the following: 
 Interferons. IFN and IFN are produced by virally infected cells. They are mainly 
involved in inhibition of virus replication in the infected cells and induction of 
resistance to viral infection in uninfected cells (Bogdan, 2000). IFN, which is 
produced by T cells, stimulates antigen-presenting cell MHC expression. 
 Chemokines. MIP-1, MIP-1, MCP-1, and RANTES are involved in the 
attraction and migration of leukocytes to sites of infection (Pestka et al., 2004).  
 TGF, the transforming growth factor promotes growth of fibroblasts while colony-
stimulating factors mediate proliferation and differentiation of macrophages, 
monocytes, bone-marrow stem cells and leukocyte precursors (Janeway et al., 
2002). 
 
The major groups of interleukins are responsible for the stimulation of immune cell 
proliferation and differentiation. This group includes Interleukin 1 (IL-1), which is 
produced by T cells (Nakae et al., 2001), and IL-2, which stimulates proliferation of 
antigen-activated T and B cells. Additionally, IL-4, IL-5, and IL-6 stimulate proliferation 
and differentiation of B cells and Granulocyte Monocyte Colony-Stimulating Factor (GM-
CSF), which stimulate hematopoiesis (Aria et al., 1990). 
 
 
1.3 Interleukin-4 and Interleukin-13. 
 
The hematopoietin family of cytokines, namely; IL-3, IL-4, IL-5, IL-13, and GM-CSF are a 
group of soluble proteins produced by effector Th cells. Similarity in cytokine structure 
lead to this grouping (Alberts et al., 2002). The genes of the cytokines in this group are 
also closely linked in the genome and all are produced by Th2 cells. Furthermore, these 
cytokines bind related receptors known as the class I cytokine receptors. All are to some 
degree involved in lymphocyte activation and differentiation, the apparent overlapping 
biological functions can be attributed to the shared receptor subunits (Malabarba et al., 
1996). 
 
Of particular importance in the current study are the roles of IL-4 and IL-13 and their 
associated receptor complexes in Th2 immunity, therefore these cytokines are further 
discussed in the following section. 
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1.3.1 Interleukin-4. 
 
The Interleukin-4 (IL-4) gene is located on human chromosome 5 and murine 
chromosome 11. Alternative splicing events, shown to be tissue-specific, leads to the 
transcription and translation of different isoforms of IL-4 (Yatsenko et al., 2004). IL-4, 
originally named B-lymphocyte stimulating factor-1, was identified due to its ability to 
induce proliferation of resting B-cells co-stimulated with anti-IgM antibodies (Howard et 
al., 1982). Roles for IL-4 have now been described in a wide range of cells.  
 
IL-4 is produced and secreted by activated T cells, mast cells, eosinophils and basophils. 
IL-4 function has effects on, amongst others, B cells, T cells, macrophages, mast cells, 
fibroblasts and endothelial cells are diverse (Delespesses et al., 1989; Monroe et al., 
1988; Spits et al., 1987; Yoshimoto and Paul, 1994). These include the induction of 
expression of immune receptors such as of MHC II molecules on resting B cells (Noelle et 
al., 1984), IL-4R (Ohara and Paul, 1988), CD80 and CD86 (Stack et al., 1994).  
Additionally, IL-4 increases cell surface expression and secretion and of IgE and IgG1 
(Pene et al., 1988) and regulates heavy chain class switching of these immunoglobins 
(Lebman et al., 1988), while suppressing production of IgM, IgG2a, IgG2b and IgG3 
(Snapper et al., 1988). Such effects have important consequences in inducing immediate 
hypersensitivity (allergic) reactions while producing protection against helminth infections 
(Haas et al., 1999; Maizels and Yazdanbakhsh, 2003).  
Mast cell proliferation and the production of G-CSF and M-CSF (Essner et al., 1989, 
Standiford et al., 1990) can also be driven by IL-4, while it exerts an inhibitory effect on 
monocyte production of IL-1, IL-6, IL-8 and TNF (Miossec et al., 1992).  
Furthermore, IL-4 plays critical roles in T-cell function:  these effects include stimulation 
of T cell proliferatio  (Mitchell et al., 1989), the development of antigen-specific cytotoxic 
T cells (Horohov et al., 1988; Widmer et al., 1987), and differentiation of naïve CD T cells 
to the Th2 phenotype. These IL-4 driven responses are associated with the down 
regulation of the inflammatory actions of Th1 cells, thus supporting humoral immunity 
(Le Gros et al., 1990).  
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1.3.2 Interleukin-13. 
 
IL-13 shares various structural characteristics with IL-4 and belongs to the same -helix 
protein family. Similar to IL-4, the IL-13 gene is also located on human chromosome 5 
and murine chromosome 11. Of great importance is the shared receptor α subunits 
between IL-4 and IL-13(McKenzie et al., 1993). Furthermore IL-13 functions can 
frequently be similar to those driven by IL-4, but key differences are apparent. 
 
IL-13 is produced by T cells, mast cells, NK cells, basophils and dendritic cells (de Waal 
Malefyt et al., 1995). The requirement of the IL-4R chain in IL-13 signal transduction 
explains in part the shared biological functions of IL-4 and IL-13. Similar to IL-4, IL-13 up 
regulates MHC class II molecules and it also induces the expression of surface IgM, 
CD23, CD71 and CD72 (de Waal Malefyt et al., 1995; McKenzie et al, 1993). On 
monocytes IL-13 up regulates the expression of the adhesion molecules CD11b and 
CD11c (de Waal Malefyt et al., 1993).  
IL-13 also has important anti-inflammatory activities. Examples are the inhibition of the 
synthesis of TNF- and the macrophage inflammatory protein-1 (MIP-1), cytokines 
involved in the inhibition of nitric oxide production by LPS-activated murine macrophages 
and superoxide anion production by human monocytes (Doherty et al., 1993; Doyle et 
al., 1994). The inhibition of nitric oxide production by murine macrophages leads to 
increased uptake of iron and diminishing effector function (Weiss et al., 1997). 
Furthermore IL-13 increases the expression of the mannose receptors on both human 
and murine monocytes and macrophages (Doyle et al., 1994). It induces vascular cell 
adhesion molecule (VCAM)-1 on vascular epithelium which then directs lymphocyte, 
monocyte, basophil and eosinophil migration to sites of inflammation (Ying et al., 1997).  
 
These IL4 / IL13 shared functional similarities lead to the view that IL-13 was 
functionally redundant from IL-4. However, IL-13 exerts effector functions that 
distinguish it from IL-4 (Wynn, 2003). Host resistance to the N.brasilienis and T.muris 
gastrointestinal nematodes is mediated by Th2 cytokine responses and IL-13 has an 
essential role (Urban et al., 1998). IL-13 is also the central mediator of allergic asthma, 
regulating eosinophilic inflammation, alveolar mucus secretion, and airway hyper 
responsiveness to a greater degree than IL-4 (Willis-Karp et al., 1998). 
Despite this and in contrast to IL-4 it fails to have any biological effect on T cells 
(Zurawski et al., 1993), including lack of activation of T cell proliferation (de Waal Malefyt 
et al., 1995). 
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1.4 IL-4R. 
 
Functional effects of cytokines are dependent on their initiation of intracellular signaling 
through binding to their specific receptors. In the case of IL-2, IL-4 and IL-13 this 
signaling event begins with the dimerization of the appropriate receptor chains 
subsequent to receptor binding. IL-2, IL-4 and IL-13 all require IL-4R as part of their 
heterodimeric receptor complexes and subsequent signaling (Figure 1.6).  
 
The type I receptor consists of the 140 kDa IL-4R and the common IL-2Rchain 
(Mosley et al., 1989). This complex binds IL-4 with high affinity (Kd~50-100pM), 
however physiological signaling depends upon IL-4-mediated heterodimerization of the 
IL-4R with an additional chain (Lai et al., 1996). In most cells the dominant chain 
involved in this heterodimerization is the common  chain which was first identified as 
part of the IL-2 receptor (Russell et al., 1993). The IL-13 receptor complex does not use 
the common  chain; however the IL-4R chain is a component of the IL-13R complex 
(Obiri et al., 1997). IL-4R chain alone can bind IL-4 but not IL-13. The other cell 
surface polypeptides involved in the IL-13 receptor complex are IL-13R1 (Aman et al., 
1996; Hilton et al., 1996) and IL-13R2.  
 
The type II receptor consists of IL-4Rchain and the 70 kDa IL-13R1 chain. This 
complex binds both IL-4 and IL-13 with high affinity (Hilton et al., 1996). The IL-13R1 
chain exclusively binds IL-13 but with low affinity (Zuwarski et al., 1993). IL-13R1 is 
expressed on the cell surface of a broad range of cells yet no expression has been shown 
on mouse T or B cells. This could explain the lack of IL-13 responsiveness in these cells 
(Murata et al., 1998 and Vita et al., 1995). 
 
The third receptor chain is the 60 kDa IL-13R2, which binds IL-13 with high affinity in 
the absence of IL-4R (Caput et al., 1996). Importantly, the majority of lymphoid cells 
show a lack of IL-13R2 expression (Guo et al., 1997). The IL-13R complexes function as 
secondary receptors for IL-4. This is in contrast to the IL-4R complex, which consisting of 
the IL-4Rchain and the common  chain, is only specific for IL-4, despite the fact that 
the common  chain is a shared component of IL-2, IL-4, IL-5, IL-7 and IL-9. This was 
shown by competitive binding studies where IL-4 displayed preferential binding when 
compared to IL-13. Furthermore, blocking access to the IL-4R chain, by means of 
monoclonal antibody binding, lead to a lack of IL-4 / IL-13 functionality (Feng et al., 
1995). 
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Figure 1.6 IL-4, IL-2 and IL-13 receptor complexes 
 
IL-4 binds with IL-4Rsubunit in combination with either Type I receptor, the common 
chain or with the Type II receptor, IL-13R1. IL-13 interacts with IL-13R1 in 
combination with IL-4R or with IL-13R2. IL-2 binds to either IL-4R in combination 
with c, with c in combination with IL-2R, IL-2R with IL-2 chains  and c or with IL-
2R
 
 
The cytoplasmic domain of IL-13R2 differs from that of IL-13R1 in that it does not 
possess either signaling motifs or signaling molecule binding sequences; it was thus 
proposed that IL-13R2 acts like a decoy receptor similar to the properties shown by the 
IL-1 type II receptor (Colotta et al., 1994) and subsequent studies with IL-13R2 
knockout mice indicated this lack of signaling (Rahaman et al., 2002). Yet, this view of 
the IL-13R2 function was shown to be incorrect with data demonstrating IL-13 signaling 
via IL-13R2 (Fichtner-Feigl et al., 2006; Wilson et al., 2007). Additionally it was shown 
that IL-13R2 expression was regulated by IL-13 and that the absence of this receptor 
chain leads to an elevation in IL-13-dependent liver fibrosis during Schistosoma mansoni 
infection (Chiaramonte et al., 2003).  
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1.4.1 Soluble receptors. 
 
The membrane-bound IL-13 and IL-4 receptors both have soluble isoforms. These 
secreted receptor molecules have bee identified as physiological regulators of IL-13 and 
Il-4 involved in modulation of the immune responses normally controlled by IL-4 and IL-
13 cytokines (Maliszewski and Fanslow, 1990). 
 
The secreted form of IL-13R2 was identified as a 45-50 kDa protein in the serum and 
urine of mice. This protein bound IL-13 with a 300-fold higher affinity than that shown by 
a recombinant IL-13R2 protein. It displayed structural differences to the cell surface 
receptor and was antigenically distinctive from the IL-13R2. Additionally it acted as a 
potent inhibitor of IL-13 cytokine binding to its cell surface receptor (Zhang et al., 1997). 
The soluble IL-4R is a 30-40 kDa truncated form of the membrane bound receptor that 
results from alternative mRNA splicing of transcript from the gene which encodes both 
the membrane-bound and secreted isoforms (Wrighton et al., 1992). It displays 
comparable IL-4 binding affinity to that shown by the membrane IL-4R and functions 
by neutralizing the biological effects of IL-4 in vitro (Fanslow et al., 1990; Keegan et al., 
1991; Mosley et al., 1989). The soluble IL-4R isoform also functions as an IL-4 
antagonist with a characteristic role in IL-4 ligand-receptor interaction in vivo. This was 
demonstrated by treatment of Leishmania major infected mice with this isoform. A 
surplus of the soluble receptor protein rendered the mice clinically resistant to L. major 
and shifted the pattern of cytokines towards a Th1 type, in this way provided long-lasting 
resistance against re-infection (Gessner et al., 1994). 
 
It is recognized that recombinant soluble receptors can interfere with the biological 
functions of cytoki es and this makes them appropriate candidate molecules for the 
future treatment of certain pathological conditions where cytokine activity needs to be 
modulated. 
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1.4.2 IL-4R and cytokine signaling pathways. 
 
As mentioned IL-4R is the receptor for both IL-4 and IL-13, belonging to the type I 
cytokine receptor family. IL-4R is expressed in low numbers (100-5 000/cell) on a 
variety of both Th1 and Th2 cells (Lowenthal et al., 1988). IL-4R expression in a majority 
of cells is in association with the common  chain, which is required for IL-4 signal 
transduction (Kondo et al., 1993).  
Subsequent to cytokine-receptor binding there are four main cytokine signaling 
pathways. These are the Ras/mitogen-activated protein kinase (Ras/MAPK) and 
phosphoinositide-3-kinase (PI-3-kinase) pathways which are important for cellular 
proliferation (Deane and Fruman, 2004), the signal transducer and activator of 
transcription (STAT) pathways which stimulate gene transcription, the pathways 
originating from activation of the receptor associated kinases like Janus kinases (JAKs) 
and lastly the pathways involved in apoptosis which are activated by amongst others 
Ligand and TRAIL (Aggarwal, 2003).  
 
The major mechanisms by which hematopoietin cytokine receptors (amongst them IL-
4R) transduce intracellular signals (Figure 1.7) re virtually identical and can be 
attributed to the fact that these receptors lack endogenous kinase activity (Nelms et al., 
1999). This leads to the requirement for receptor-associated kinases for the initiation of 
signaling. The main signaling molecules involved in this pathway are members of the 
Janus family of cytoplasmic tyrosine kinases (JAKs) (Ihle, 1995; Taniguichi, 1995). IL-4 
receptor binding leads to heterodimerization of the IL-4R chain with the c chain 
(Kammer et al., 1996), this initiates Jak-1 association with the IL-4R chain and Jak-3 
with the c chain. In parallel binding of IL-13 to IL-13R leads to the association with 
Jak-2 (Murata et al., 1996; Miyazaki et al., 1994).  
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Figure 1.7 IL-4 and IL-13 Jak/Stat signaling pathway. 
 
After receptor heterodimerization Jak tyrosine kinases are phosphorylated leading to the 
association of the Stat signal transducing proteins. These proteins are phosphorylated by 
the Jak kinases and proceed to form homodimmers. Subsequent to translocation into the 
nucleus these complexes activate GATA-3 which initiates Th2 cytokine transcription. 
 
 
With the activatio  of these signal transducers tyrosine residues in the cytoplasmic 
domain of the IL-4R chain are phosphorylated, these phosphorylated chains act as 
docking sites for signalling molecules (Smerz-Bertling and Duschl, 1995). Subsequently, 
the signal transducing activators of transcription (STATs) bind to the phosphorylated 
receptor via a conserved SH2 domain. Bound STAT6 is then phosphorylated by the 
activated kinases (Darnell, 1997). These phosphorylated STAT6 molecules form 
homodimmers followed by the translocation to the nucleus and subsequent stimulation of 
target gene transcription (Ivashkiv, 1995; Murphy et al., 2000). IL-4-mediated STAT6 
activation regulates the expression of transcription factors GATA-3, which result in the 
production of Th2 cytokines and chromatin remodelling at the IL-4 locus (Ouyang et al., 
2000).  
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STAT6 activation after IL-4 stimulation is selectively impaired in Th1 cells (Kudo et al., 
1997), indicating the status of IL-4 receptor (IL-4R)-mediated signaling during initial 
activation. In Th1 cells, the phosphorlyated IL-4R chain binds the N-terminal 50 amino 
acids of SOCS5 (suppressor of cytokine signaling-5) leading to a reduction of the 
association of Jak-1 with the IL-4R, decreased STAT6 activation and Th2 cell 
differentiation. SOCS5 interaction is independent of tyrosine phosphorylation (Seki et al., 
2002). In certain cell types, signalling is initiated by activation of insulin receptor 
substrates, IRS1/IRS2. Phosphorylation of the IRS molecules leads to interaction with 
cytoplasmic signalling molecules phosphatidylinositol 3-kinase (PIK3C3).These molecules 
form a link between IL-4R and signalling pathways involved in cellular proliferation 
(Izuhara and Harada, 1996).  
 
 
1.5 Molecular manipulation of gene function. 
 
Mice have become important tools in biomedical research and are the most widely used 
laboratory animals in transgenic studies. This is due to the genetic similarity between 
humans and mice including the conservation of most human genes in the mouse 
genome. The accessibility of numerous genetically homogeneous inbred strains (Silver, 
1995), the opportunity for germline gene modification (Isola and Gordon, 1991) and the 
availability of embryonic stem (ES) cells offer flexibility when establishing new 
technologies (Camper et al., 1995). It has become feasible to produce mice with genetic 
alterations ranging from simple gene disruptions to the more complex cell-specific 
inducible systems (Goosen and Bujard, 2002). Transgenic mice are produced in order to 
investigate the role of genetic mutation with the potential to then lead to studies 
questioning the molecular and biochemical mechanisms involved. Furthermore, 
transgenic models can help in designing novel therapeutic strategies for the investigated 
disease. Studies with these transgenic models are unique in offering the opportunity to 
investigate genotype-phenotype relationships relevant for unravelling the biologic role of 
human genes (Hofker and van Deursen, 2003; Muller, 1999). 
 
Landmarks in the development of mouse technology include; the generation of 
transgenic mice, via the stable introduction of genes into the germline of the 
experimental model (Palmiter et al., 1982). This allowed the generation of mice with 
virtually any genotype and the analysis of the consequences of these mutations in the 
milieu of a developing and intact model. Secondly, the development of pluirpotent 
embryonic stem (ES) cell cultures which lead to gene targeting via homologous 
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recombination in these cells, permitting the precise modification of the gene of interest. 
Developing from this was the generation of gene knockout (Mansour et al., 1988) and 
tissue-specific knockout models. Lastly the systems for inducible transcriptional activation 
in mice (Goosen et al., 1993), which afford the researcher with the most flexibility in 
terms of modification of gene function. 
 
1.5.1 Conventional transgenics. 
 
Transgenic technology, referred to as the techniques involved in the stable introduction 
of genes into the germline of the mouse (Gordon et al., 1980), can be split into two 
experimental categories; the “gain-of-function” mutations and the “loss-of-function” 
mutations. 
 
The generation of transgenic mice characterised with “gain-of-function” mutations is 
associated with the microinjection of the gene of interest into the one-celled zygote. This 
technology was developed from the direct microinjection of a DNA fragment consisting of 
the promoter of the mouse metallothionein-I gene linked to the cDNA of rat growth 
hormone into the pronuclei of fertilized mouse eggs (Bronson and Smithies, 1994; 
Palmiter et al., 1982). The technique of DNA microinjection results in random integration 
of the injected DNA fragment or transgene which gives rise to founder lines which have 
to undergo extensive characterisation, many of which then display variable expression of 
the integrated gene (Muller, 1999). Conventional transgenic as a science has not 
changed a great deal and is often limiting, since it represents “gain-of-function” models 
and genetic disease is more likely characterized by “loss-of-function” which is beyond the 
scope of this conventional transgenic technology (Moreadith and Radford, 1997). 
 
1.5.2 Gene targeting using embryonic stem cells. 
 
The generation of transgenic mice characterised with “loss-of-function” mutations 
employs embryonic stem cells. Some of the initial limitations in transgenic research were 
overcome with strategies combining embryonic stem cells and gene targeting technology.  
 
Pluripotential embryonic stem cell lines were derived from mouse blastocytes (Evans and 
Kaufmann, 1981; Martin, 1981), and subsequently, it was shown that these cultures 
were able to develop into functional germ-line chimeras after blastocysts injection. These 
cells showed germline competence and transmission of genetic material to the next 
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generation, thus introduction of mutations in these cells could allow for the generation of 
mice with a predetermined genotype (Bradley et al., 1984).  
The principles of homologous recombination were developed in yeast and homologous 
recombination in mammalian cells, between an artificial targeting vector and an 
endogenous gene, was first demonstrated for the -globin locus (Smithies et al., 1985). 
Subsequently, gene targeting via homologous recombination in murine embryonic stem 
cells (Thomas and Capecchi, 1987) was achieved for the selectable hypoxanthine 
phosphoribosyl transferase (HPRT) gene locus. In a seminal study (Mansour et al., 1988) 
the gene of interest was interrupted by the homologous recombination of a neomycin 
selection cassette in a position that would disrupt transcription, in this way generating a 
“loss-of-function” mutation (Figure 1.8). Gene targeting allows the precise modification of 
the target gene where, in principle and has been used to generate numerous knockout 
models (see http://www.jax.org). This constitutive inactivation of gene function leads to 
models which are always deficient in the deleted gene product.  
Embryonic stem cells can also be used for the targeted insertion or “knock-in” of 
transgenic sequences. Here the DNA sequence can be placed under the control of the 
regulatory elements of the particular endogenous locus. The transgene can be inserted, 
leaving the target locus functional or conversely, the transgene can replace a region of 
the target gene, thereby disrupting the functionality of the endogenous gene 
(Ledermann, 2000). This was illustrated by the disruption of the murine Int-2 gene via 
the insertion of the lacZ gene, thus enabling transgene transcription driven by the 
endogenous promoter and subsequent in situ expression studies (Mansour et al., 1988). 
This approach has also been employed to study the role of cytokines and their receptors 
in determining hematopoietic cell fate (Stoffel et al., 1999). The thrombopoietin receptor 
gene, Mpl, was replaced with a chimeric construct encoding the extracellular domain of 
Mpl and the cytoplasmic domain of the granulocyte colony-stimulating factor (Gcsfr). This 
lead to chimeric receptor binding to thrombopoietin and subsequent signalling via the 
Gcsfr intracellular domain. This study illustrated, in vivo, that the cytoplasmic domain of 
Gcsfr can functionally replace Mpl signalling, in this way supporting normal 
megakaryopoiesis and platelet formation. 
 
. 
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Figure 1.8 Gene targeting via homologous recombination in ES cells. 
 
This technique disrupts the target gene in the murine germline by insertion of a 
selectable marker. In principle every gene can be silenced in this way, which has lead to 
the mouse being the species of choice for biomedical research. A. The target vector 
containing the neo cassette is electroporated in to ES cells. B. The selectable marker is 
inserted into the genome via homologous recombination. C. Following clone selection the 
ES cells are microinjected into blastocysts and transferred to pseudo pregnant females.    
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The drawbacks in this approach include potential embryonic lethality if the gene product 
is essential for development (Fortschegger et al., 2007). Conventional knockout methods 
also affect every cell in the animal which makes distinguishing between primary and 
secondary changes in phenotype difficult. Additionally, the constitutively deficient animal 
may compensate for the loss of gene product consequently rendering the resulting 
phenotype comparable to a wild-type animal even if the gene product has an important 
function (Guidi et al., 2004). These problems can be avoided by tissue-specific and 
inducible gene disruption techniques. 
 
1.5.3 Conditional transgenics. 
 
Conditional gene targeting builds on the conventional transgenic strategies and allows for 
control of the gene targeting event both in a tissue-specific and temporal manner. Here 
gene function modulation is conditional to a certain stimulus. The conditional 
manipulation of individual gene activities can be divided into two basic strategies; the 
first of these targets the genes directly by site-specific recombination resulting in 
activation, inactivation or modification of target gene function and the second 
quantitatively and reversibly controls the gene’s function, in most part leaving the 
endogenous gene function untouched within its genetic context (Gossen and Bujard, 
2002; Lebermann, 2000; Ryding et al., 2001;).  
 
 1.5.3.1  Site-specific recombinase systems. 
 
The most widely employed method to achieve tissue-specific gene targeting is the use of 
site-specific recombinase systems. These systems consist of two elements namely the 
recombinase enzyme and the DNA sequence it recognizes. Recognition is by a consensus 
sequence and the recombinase catalyzes recombination between two of its recognition 
sites to bring about the modification of the associated DNA. Modifications can range from 
DNA deletion (Figure 1.9) and insertion to inversion or translocation (Hofker and van 
Deursen, 2003). DNA segments can be inverted or deleted in cis or can be connected in 
trans. This broadens the scope of function from basic deletion of DNA segments to 
applications like chromosome engineering and recycling of selectable markers (Aduin and 
Bradley, 1996; Yu and Bradley, 2001). The type of modification depends on the 
orientation and location of the recognition sites.  
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Figure 1.9 The model of Cre and Flp site-specific recombinase inactivation. 
 
The figure illustrates the most generally applied approach whereby gene function is 
inactivated by the deletion of DNA fragments located between the repeated 
recombination sites. The loxP or FRT sites are recognized by recombinases Cre or Flp and 
excised from the genome. 
 
 
Presently, there are two members of the integrase family of site-specific recombinases; 
the Cre-loxP system from the bacteriophage P1 (Lakso et al., 1992; Orban et al., 1992; 
Sauer and Henderson, 1989) and the Flp-FRT system from the budding yeast 
Saccharomyces cerevisiae (Dymecki, 1996; O’Gorman et al., 1991) being applied in 
conditional control of gene expression via site-specific DNA recombination. Both Cre and 
Flp recognize a 34bp consensus sequence consisting of two 13bp inverted repeats 
flanking an 8bp nonpalindromic core defining the orientation of the of the recognition 
site. These systems are both derived from evolutionary distant species and this and the 
recognition site length of 34bp make them remarkably specific (Gossen and Bujard, 
2002; Nagy, 2000). Additionally no accessory proteins or high-energy cofactors are 
required for activity and both Cre and Flp recombination functions have been shown to 
function in mice, with Flp needing a temperature optimum of 37°C (Buchholz et al., 
1998).  
Of these two recombinase systems the Cre-loxP system is most widely used and one of 
the most impressive applications of this system in mice is its use in the inactivation of 
gene expression in a temporally and spatially controlled manner (Lewandoski, 2001; 
Lobe and Nagy, 1998, Nagy, 2000). 
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Limitations of gene-targeting that can be circumvented with this approach include; 
embryonic lethality and problems that arise if the gene phenotype affects multiple 
tissues. Certain biological questions can also be addressed in a manner not afforded with 
gene targeted models alone (Gossen and Bujard, 2002). 
 
 1.5.3.2  Tissue specific knockouts. 
 
One of the most powerful strategies developed in mouse technology was the 
combination of conventional gene targeting techniques and the conditional site-specific 
recombination systems to achieve cell type-specific knockouts. 
Here standard gene targeting techniques are used to produce a model in which an 
essential region of the target gene is floxed (flanked by the loxP sequences); in this way 
tissue-specific cre expression will lead to inactivation of the floxed allele. Before the 
recombination event this conditional allele usually displays a wild-type phenotype since, 
in most cases, the loxP sites are placed in the introns. The mouse line carrying this 
conditional allele is then crossed with an effector mouse line that expresses cre in a 
tissue-specific manner. Cre expression leads to Cre catalysing the site-specific 
recombination between the loxP sites in this manner deleting the sequences flanked by 
the loxP sites and resulting in gene silencing (Kwan, 2002; Muller, 1999). Therefore the 
progeny from this cross will only display inactivation of the conditional allele in the cells 
expresses cre (Gu et al., 2001; Takeda et al., 1998). 
 
The cDNA encoding the site-specific Cre recombinase in the effector mouse line is either 
introduced as a regulated transgene driven by a tissue-specific promoter or the gene is 
inserted by “knock-in” gene targeting adjacent to a suitable endogenous promoter 
(Ledermann, 2000). An example of this is the “knock-in” of cre behind the Cd19 locus 
which enabled B-cell specific expression (Rickert et al., 1997). Since the loxP sites are 
generally placed in introns and the target gene displays a wild-type phenotype until the 
expression of Cre and the ensuing recombination event occurs, an advantage of this 
approach is the elimination of potential embryonic lethality caused by the target gene 
inactivation (Gossen and Bujard, 2002).  
 
Figure 1.10 illustrates the approach starting with the gene targeting and the 
recombination events in ES cells, leading up to the inter crossing of the mouse lines and 
generation of the subsequent cell-specific knockout model. 
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The two primary disadvantages of the Cre/lox system are that not all tissue specific 
promoters display complete specificity (Sauer, 1998) where basal levels of expression in 
other cell types can sometimes cause unintended gene expression. Secondly, Cre-
induced recombination is an irreversible genetic modification. These limitations can be 
overcome by systems that would allow the control of gene transcriptional events from 
the “outside” at will. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                     (Strachan and Read, 1999) 
 
Figure 1.10 Combining gene targeting and the Cre-loxP recombination system 
to inactivate a gene in a desired cell type.  
 
A. The standard homologous recombination method using mouse ES cells, in which three 
loxP sites are introduced along with a marker M at a target locus A. The Cre recombinase 
is transfected and transient expression leads to the recombination between the 
introduced loxP sites resulting in different products. Type I recombinants are used to 
generate mice in which the target locus is flanked by loxP sites. These mice can then be 
inter crossed with previously constructed transgenic mice (B) carrying an integrated 
construct consisting of the Cre recombinase gene linked to a tissue-specific promoter. 
Offspring which contain both the loxP-flanked target locus plus the Cre gene will express 
the Cre gene tissue-specific manner resulting in recombination between the loxP sites 
and inactivation of the target locus A. 
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1.5.4 Conditional control of transcription. 
 
Ideally and perfect genetic transcriptional switch would result in low basal gene 
expression in the “off” mode and high levels of gene transcription in the “on” mode. 
Additionally the switch should be specific but reversible for the target gene and show no 
interference with other cellular components. This criteria was achieved by the binary 
transgenic systems where the gene expression is controlled by the interaction between 
two components, namely an effector transcribed from the regulatory element and the 
target transgene on which it acts which is located on the response element (Gossen and 
Bujard, 2002; Lewandoski, 2001). The most widely used transcription activation systems 
are those controlled by tetracyclines. These systems have been applied to cultured cells 
of plant, avian, insect and mammalian origin but also on whole organisms like Drosophila 
and mice (Bello et al., 1998; Love et al., 2000).  
 
Two key characteristics of the Tet regulatory system (Goosen et al., 1995) distinguishes 
it from other transcription activation systems, firstly the binding specificity and affinity 
displayed between the Tet repressor (Tet R) and the tet operon (tetO), its specific 
binding site, and additionally between the Tet repressor and the inducing agent being 
tetracycline or doxycycline. Secondly, the inducing agents, some of which have been 
used in human medical field for years, have been well characterized in terms of their 
chemical and physiological properties (Gossen and Bujard, 2002; Hofker and van 
Deursen, 2003). In terms of transgenic studies the tetracycline analogues, doxycycline 
and anhydrotetracycline are used in preference to tetracycline owing to the higher tTA 
binding affinities and lower toxicities shown by these analogous (A-Mohammadi et al., 
1997; Gossen and Bujard, 1993) 
 
There are two basic complementary tetracycline-inducible expression systems, namely 
the tTA or Tet-Off system (Gossen and Bujard, 1992) and the rtTA or Tet-On system 
(Gossen et al., 1995). Both systems require two building blocks: the ligand dependent 
transactivator (r)tTA as the effector and a tetOCMV minimal promoter cassette, which 
regulates the expression of the target transgene. The effector is a fusion of sequences 
that encode the VP16 transactivation domain and the Escherichia coli tetracycline 
repressor (TetR) protein, which specifically binds to both doxycycline or tetracycline and 
the 19bp operator sequence (tetO) of the tet operon in the target gene. This binding 
results in the activation of transcription. In the Tet-Off system, the inducing agent 
doxycycline prevents binding of the transactivator tTa to the tetO, in this way inactivating 
transcription. In contrast, the presence of doxycycline is required for the binding of the 
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rtTa (reverse tetracycline controlled transactivator) to tetO and the subsequent activation 
of gene expression in the Tet-On system (Gossen et al., 1995) (Figure 1.11).  
 
 
 
 
Figure 1.11 Induced expression via the Tet-Off and Tet-On Systems.  
 
A. In the Tet-Off system, the basal state is maintained in the presence of doxycycline, 
which prevents binding of the tTa protein to tetO, and induced, by Dox removal. B. In 
the Tet-On system transcription is activated in the presence of Dox, which permits 
binding of the rtTa transactivator protein to the tetO.  
 
 
The main distinction between the Tet-Off and Tet-On systems is the kinetics of target 
gene activation. In the Tet-Off system the transgene is only fully inactivated by the 
continuous administration of doxycycline. Activation occurs with doxycycline removal and 
is thus dependent on the rate of doxycycline clearance. It has been shown that this 
clearance can range from 24 hours up to 1 week in mice depending on the tissue type of 
interest. In contrast with the addition of doxycycline in the Tet-On system there is a 
rapid activation of target gene transcription, as fast as 1 hour, whereas the subsequent 
inactivation depends on the doxycycline clearance form the tissues of interest (Kistner et 
al., 1996; Hasan et al., 2001). However, the rtTA in the Tet-Off system retains some 
affinity for the tetO sequences even in the absence of doxycycline. This retains affinity 
results in a continuous low level of basal expression, unacceptable in most systems, an 
example be the regulated expression of toxins (Keyvani et al., 1999). 
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The Tet-inducible expression systems are continually being modified (Baron and Bujard, 
2000; Goosen and Bujard, 2001) with different transactivator domains, trans-repression 
domains, codon-usage modifications and variations to the configuration of tetO 
sequences (Baron et al., 1997; Urlinger et al., 2000; Wells et al., 1999). One of these 
modifications now allows for the simultaneous expression of two target transgenes. This 
was achieved by flanking the tetO sequences with two minimal promoters (Baron et al., 
1995) (Figure 1.12). This system enables the transcriptional activation in cultured cells 
and transgenic mice to be examined by means of one promoter driving the expression of 
both the target gene and a reporter gene such as green fluorescent protein or luciferase 
(Krueger et al., 2006; Lavon et al., 2000) 
 
Strategies are also being developed as an alternative to the use of Cre transgenic lines. 
Thus circumventing the need to generate and characterize the Cre transgenic lines. 
Recombinant adenoviral vectors are being used to deliver Cre to somatic tissues in mice 
carrying floxed alleles (Chang et al., 1999; Wang et al., 1996). Additionally, to achieve 
temporal regulation and promoter specificity Cre variants that only function in the 
presence of an exogenous inducer have been generated. In this combined system 
expression of cre, from the Cre variants occurs only when the drug tetracycline is 
administered, allowing researchers to start and stop expression of the gene at any time. 
This was achieved by fusing the Cre coding region with a mutated ligand-binding domain 
(LBD) from either the progesterone (Kellendonk et al., 1996) or the estrogen receptor 
(Feil et al., 1996). These mutated forms of the LBD will only bind and localize to the 
nucleus in the presence of synthetic steroids, RU486 and tamoxifen respectively. No 
binding is shown in the presence of endogenous steroids. Another advancement in the 
pursuit for controlling gene expression spatially and temporally was by combining the 
Cre/loxP and the tetracycline-regulated transcriptional systems (Belteki et al., 2005; Mao 
et al., 2005; Utomo et. al., 1999; Yu et al., 2005). Here transcription is activated by the 
administration of doxycycline, as the Tet-On system is utilized, this induction of cre 
expression with doxycycline in the rtTa system results in tight regulation of the 
translational and subsequent recombination event. 
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Figure 1.12 Inducible transcription via the bi-directional pBI-L Tet vector. 
 
The vector expresses a gene of interest and luciferase, GFP or any other reporter from a 
bidirectional tetO promoter. In the presence of doxycycline, the tTa is prevented form 
binding to the tetO operon. With the removal and subsequent clearance of the 
doxycycline the Dox, induced suppression is lifted and transcription of both the target 
gene and the reporter is activated. 
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1.6 Molecular manipulation of IL-4R. 
 
Conventional gene targeting and site-specific recombination techniques have also been 
employed to produce a model where IL-4R is transcriptionally inactivated. The floxed 
IL-4R model was generated using homologous and site-specific recombination in 
embryonic stem cells, the targeting strategy yielded a silent mutation whereby the loxP 
sites were placed in introns and 5’and 3’ ends of exons. The IL-4R lox/lox mice thus 
display a wild-type phenotype in the absence of Cre/loxP recombination. With 
recombination the IL-4R expression is eliminated in all cells of the resulting model (IL-
4R -/-). The IL-4R -/- mice are ineffective in functions associated with the IL-4 and IL-
13 cytokine binding to this receptor. Use of this model established that the IL-4R chain 
is a vital component of both the IL-4 and the IL-13 receptor complexes and thus the 
associated receptor complex signaling (Mohrs et al., 1999). 
Infectious disease studies with IL-4-/- and the above mentioned IL-4R-/- mice have lead 
to novel findings, as illustrated below. 
 
1.6.1 Leishmania donovani. 
 
Amongst the infectious diseases, studies using Leishmania major as a model have 
contributed a great deal of the determining data on the role of IL-4 in the host protective 
response. The first evidence of a role for IL-4 in infection was shown by studies with this 
intracellular prorozoan parasite, when it was established that host protection is mediated 
by Th1 cytokines and inhibited by the Th2 cytokines (Scott et al., 1988). It was shown 
that apart from MHC molecule antigen presentation, mediation between cytokines 
determines the developmental immune skewing to either the Th1 or Th2 effector 
phenotype (Reiner. and Locksley, 1993). Researchers were given the opportunity to 
further dissect the role of IL4 in Leishmania donovani infection by the development of IL-
4-/- and IL-4Ra-/- mice. Studies with these mice have provided invaluable information 
including demonstrating that IL-4 is vital for the optimal resolution of the primary 
L.donovani infection and that both IL-4 and IL-13 play important roles as positive 
regulators of immunity to L. donovani. Furthermore that the absence of the functional IL-
4R through which both IL-4 and IL-13 signal resulted in delayed maturation of the 
associated granuloma formation (Stäger et al., 2003). This dissection of cytokine function 
could be facilitated greatly by the use of mice where IL-4R gene expression is spatially 
and temporally controlled. They have the potential to broaden the scope of analysis into 
the IL-4 and IL-13 effects at both the onset and later stages of the granulomatous 
response thus determining the precise role of IL-4R signalling in the induction of anti-
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leishmanial responses. The IL-4R lox/lox model was also used as backbone to generate a 
conditional tissue-specific IL-4R -/- by inter crossing these with mice with mice where 
the expression of cre recombinase is restricted to the CD4+T cells. Tissue specificity was 
gained by the use of Lck driven cre expression (Radwanska et al., 2007). Studies using 
L.major and this model showed that the infected mice deficient in IL-4R expression on 
CD4+T cells developed the disease phenotype associated with mice that are genetically 
resistant to L.major infection, in this way confirming the importance of this receptor in 
L.major disease progression.  
 
1.6.2 Nippostrongylus Brasiliensis. 
 
Initial analysis of the host response against Nippostrongylus brasiliensis showed that the 
Th2 cytokines IL-4 and IL-13 have a protective role in the host response against the 
intestinal nematode parasites (Finkelman et al., 2004). But the use of IL-4-/- and IL-13-/- 
mice greatly elucidated the cytokine roles and demonstrated that IL-13 is more important 
than IL-4 as an inducer signalling pathway that stimulates parasite expulsion (Urban et 
al., 1998). Furthermore, knockout mice were also instrumental in the finding that worm 
expulsion requires IL-4Respression by non-bone marrow (goblet cells, intestinal 
epithelium, smooth muscle, vascular endothelium) derived cells but not by marrow-
derived cells (T cells, B cells, mast cells dendritic cells or macrophages) (Katona et al., 
1988; Urban et al., 2001) and that both IL-4 and IL-13 effect these cells in ways that 
contribute to expulsion (Urban et al., 1998; Urban et al., 2000).  
Yet, evidence is lacking as to whether any of these effects or cell types are sufficient 
and/or essential for expulsion. Thus generating mice that selectively express IL-4R 
would contribute to the identification of the cell types participating in worm expulsion 
and could also elucidate the IL-4/IL-13/IL-4R-dependent mechanism of host protection 
via worm expulsion. An example of this is the conditional model where the mice are 
deficient in IL-4R expression exclusively in smooth muscle cells. This model has been 
used to study the role of the receptor, on these cells, in functions mediated in response 
to Nippostrongylus brasiliensis infection (Horsnell et al., 2007).  
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1.6.3 Schistosoma mansoni. 
 
Investigation in to host immune response to Schistosoma mansoni showed that both IL-4 
and IL-13 are necessary for the induction Th2 inflammatory response which is a 
prerequisite for granuloma formation (Chiaramonte et al., 1999; Wynn et al., 1999). 
However, as above , the use of IL-4-/- mice led to the finding that IL-13, in contrast to IL-
4, was more important in the regulation of collagen synthesis in parasite egg-induced 
granuloma formation (Chiaramonte et al., 1999(b)). Macrophage/neutrophil-specific IL-4 
receptor deficient mice were generated to investigate the role of the receptor and 
signaling via IL-4/IL-13 on myeloid cells during Th2 immune responses using 
Schistosoma mansoni infection of these mice (Herbert et al., 2004). Results from the 
studies demonstrated that host survival was dependent on IL-4R signaling in 
macrophages. 
The use of cell-specific IL4R-/- mice further demonstrated that subsequent to exposure 
to S. mansoni eggs T-cell-specific IL-4R signaling is essential for Th cell polarization. 
Furthermore using these mice enabled the differentiation between the role of the T cells 
and cells like macrophages in host survival (Leeto et al., 2006). 
 
It would thus be beneficial to combine the IL-4R-/- model with models where the IL-4R 
expression can be spatially and temporally deleted and reconstituted in certain cell 
populations. This could be achieved by combining the IL-4R-/- model with a model 
where the Tet system is used to induce expression in a cell-specific manner. Such 
strategies have the potential to overcome limitations inherent in conventional gene 
targeted mice, in addition such models could provide the tools necessary to investigate 
the precise role of IL-4R signalling in the generation and maintenance of organ specific 
immune responses, potentially providing a design paradigm for future analysis of the role 
for cytokines in immune-mediated regulation of infectious disease. Lastly, the resulting 
disease models could facilitate the design of novel therapeutic strategies to potentiate 
protection against debilitating infectious organisms. 
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Chapter 2: Inducible deletion of IL-4R expression. 
 
Aim: Generation of new transgenic line, which would allow the inducible cell-specific 
reconstitution of IL-4R. 
 
2.1 Introduction. 
 
Studies with IL-4 knockout (IL-4-/-) and IL-4R knock out (IL-4R-/-) models have lead to 
novel findings. In the case of intestinal nematode parasites, such as Nippostrongylus 
Brasiliensis, the Th2 cytokines IL-4 and IL-13 were shown to have a distinct role in 
protection against these parasites. Additionally, IL-13 was shown to be more important 
than IL-4 as an inducer in the signalling pathway that stimulates the parasite’s expulsion 
(Urban et al., 1998 and Finkelman et al., 1999). Using Schistosoma mansoni, with these 
models, led to the findings that both IL-4 and IL-13 are required for the induction of the 
Th2 inflammatory response necessary for granuloma formation (Chiaramonte et al., 1999 
a, b). However, there are weaknesses with the current knock out models. The existing 
models fail to discriminate between effects exerted during certain stages of the immune 
response and give no clear definition of exact cellular targets of cytokine action. Recent 
advances have made it possible to improve on the conventional IL-4R-/- mice using 
genetic manipulation and generating inducible cell-specific models allowing deletion as 
well as gene reconstitution. This will enable the investigation of the role of IL-
4Rsignaling in the initiation and maintenance of organ-specific and non-polarized 
immune responses during infection. 
The current chapter deals with the generation of a mouse model, which will enable the 
inducible and cell-specific deletion or reconstitution of IL-4R expression. The model 
described here has the potential to provide the means to analyze and define the role of 
IL-4R signalling and cytokine/cytokine receptor pathways in various murine infectious 
disease models. In order to achieve this, the Tet System, developed by Gossen and 
Bujard (1992), is being utilized (Figure 2.1). The end goal being to generate a model 
which would allow for the cell-specific, here hemapoeitic, and inducible reconstitution or 
deletion of IL-4R. Briefly, two transgenic (Tg) mouse lines were involved in the 
generation of the final double transgenic model. The first line expresses the 
transactivator, tTA, from the Tet-Off expression cassette. For the purposes of this study, 
we obtained the previously generated and characterised Vav-tTa transgenic line. In this 
line the expression of tTa is driven by the Vav hemapoeitic specific promoter (Wiesner et 
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al., 2005). The second mouse line expresses the IL-4R cDNA under the dictates of a 
cytomegalovirus (PCMV) minimal promoter supplemented with seven tet operon (TetO) 
sequences. The operon serves as a binding site for the transactivator. After backcrossing 
both these lines to the IL-4R-/- BALB/c genetic background, the two transgenic lines will 
be crossed to generate a double transgenic mouse on the IL-4R-/- backbone. In these 
double transgenic mice, the transactivator will be synthesized in a cell specific manner 
leading to cell specific IL-4R reconstitution in the IL-4R-/- background. As this binding 
of the transactivator to the TetO is inhibited by tetracycline, oral administration of 
tetracycline will extinguish IL-4R expression. Ultimately, having this system on the IL-
4R-/- background will allow for the reconstitution of the IL-4R gene in a cell specific 
and tetracycline-repressible manner.  
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Figure 2.1 Tet-Off inducible systems. 
 
In the Tet-Off system, the uninduced basal level of transcriptional activation is maintained in the 
presence of doxycycline. This prevents the binding of the tTa effector protein to the TetO 
sequences in the pBi-Luc / pBi-IL-4R vector. Tight binding is permitted with the removal of 
doxycycline, this induces high-level transcription. Panel A, The regulatory mouse, where the pTet-
Off vector expresses the tTa transactivator protein. Panel B, The response mouse, where, if 
crossed with the regulatory mouse, tTa binds to TetO inducing target gene expression via the PCMV 
bi-directional promoter. Panel C, Addition of doxycycline. The doxycycline binds to the tTA in this 
way preventing tTa binding to TetO and subsequent target gene expression. With the removal of 
the doxycycline the tTa binding is restored and target gene expression reactivated. 
 
Regulatory mouse 
Response mouse 
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2.2 Methods and Materials. 
 
2.2.1 Cloning of the constructs.  
 
2.2.1.1  Plasmid purification. 
All molecular biological manipulations were performed according to established protocols 
(Ausubel et al., 1995). Chemicals and reagents were Molecular Biology Grade. Small-
scale plasmid purifications were performed using a SV Wizard Plasmid Purification preps 
and a Wizard Maxiprep kit (Promega Corp., Madison, USA) was used for large-scale 
purifications, using protocols supplied with each kit.  
 
2.2.1.2  Primer design.  
Synthetic oligonucleotide primers were supplied by the Oligonucleotide Synthesis Facility, 
Department of Molecular and Cell Biology, University of Cape Town. 
The template used for the primer design was the 2501bp cDNA encoding the 
transmembrane IL-4R (as described by Schulte et al., 1997, and cloned into the 
pM5neo eukaryotic expression vector obtained from Prof. A. Gessner). For cloning and 
subsequent expression using the pBi-L vector (Baron et al., 1995, CLONTECH 
Laboratories, Inc) the Kozak ribosomal binding sequence (Kozak, 1987) was included to 
improve subsequent expression. In order to do this the original primer used (in the 
above mentioned publication) was modified as follows; the sense primer used in this 
paper was discarded and a new one designed which included this Kozak consensus 
sequence and the Mlu I restriction enzyme sequence. The reverse primer sequence was 
modified by the addition of the Eco RV restriction site. 
 
2.2.1.2.1 The transmembrane isoform of murine IL-4R. 
 
 
Table 2.1 Sequences of oligonucleotides used for the amplification of IL-4R. 
 
 
Name 
 
 
 
Sequence 
 
 
 
IL-4R reverse 
 
 
 
 
5’ GGG GATATC CCCTGGCCTCAGCACAGACCTC ‘3 # 
 
 
IL-4R forward 
 
 
 
5’ GGG ACGCGT ACCATGG GGCGGCTTTGCACCAAGTTCCTGAC ‘3* 
 
 
* The sequence corresponding to the Mlu I RE site is bold and the Kozak sequence  
   is underlined. 
# The sequence corresponding to the Eco RV restriction site is in bold.  
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2.2.1.3  Vector Description. 
The pBi-L vector, into which the IL-4R cDNA was subsequently cloned, is a response 
plasmid used to express both the gene of interest and luciferase from a bidirectional tet-
responsive promoter (Baron et al., 1995) in CLONTECH’s Tet-Off™ Gene Expression 
Systems (CLONTECHniques XI(3):2–5). This system was used in order to utilize the 
tetracycline-regulated expression systems described by Gossen & Bujard (1992). The pBi-
L vector contains the bidirectional promoter Pbi-1 which is responsive to the tTA 
regulatory protein in the Tet-Off systems. This promoter contains the Tet-responsive 
element (TRE), which consists of seven copies of the 42-bp tet operator sequence (tetO). 
The TRE element is between two minimal CMV promoters (PminCMV), which lack the 
enhancer that is part of the complete CMV promoter. This leads to, Pbi-1 being silent in 
the absence of binding by the tTA regulatory protein. PminCMV1controls the expression of 
the gene of interest while PminCMV2controls the expression of luciferase. Gene expression 
can thus be monitored indirectly via the luciferase reporter function.  
 
2.2.1.4  Polymerase Chain Reaction (PCR). 
2.2.1.4.1 Amplification of coding region for the transmembrane isoform of murine  
  IL-4R. 
The amplification of the coding region for the transmembrane isoform of the murine IL-
4RcDNA fragment was performed by the Polymerase Chain Reaction (PCR) using the 
BD AdvantageTM 2 PCR Kit (BD Biosciences Clontech) and 1ng pM5neo plasmid (obtained 
from Prof. A. Gessner) as template. This eukaryotic expression vector contains the 
2501bp cDNA encoding the transmembrane isoform of IL-4R (Schulte et al., 1997). The 
coding region was generated from RNA isolated from a BALB/c mouse. The choice of 
polymerase was based on the 2501bp length of the desired product. The BD 
AdvantageTM 2 PCR Kit allows efficient and accurate amplification of DNA templates using 
long PCR. The PCR mix contains the TITANIUM Taq polymerase which allows automatic 
hot-start PCR and proofreading activity.The reaction was preformed in a 50µl volume 
containing 10 × BD Advantage 2 PCR Buffer, 50 × dNTP Mix (10mM each), 50 × BD 
Advantage 2 Polymerase Mix (all from BD Biosciences Clontech) and 0.75µM of each 
primer. For the target size of 2501bp the following cycling parameters were used: an 
initial denaturation step at 95°C for 1min, followed by 30 cycles consisting of 95°C 
incubation for 30s, an annealing step at 65°C for 2min, and an extension step at 72°C for 
3min. A final step of 72°C for 5min was included to complete partial extension reactions. 
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2.2.1.5  Restriction and ligation of the coding sequence into the pBi-Luc  
  eukaryotic expression vector. 
The amplified fragments corresponding to IL-4R were recovered from a 1% (w/v) low 
melting agarose gel (section 2.1.7) and purified with the Wizard SV Gel Extraction Kit 
(Promega). The procedure was performed according to the manufacturer’s 
recommendations. The isolated fragments were then digested with 10U of the restriction 
enzymes Mlu I and Eco RV (Roche Diagnostics GmbH, Mannheim, Germany) for 6h at 
37°C. The digested fragments were recovered from a 1% (w/v) low melting agarose gel, 
and purified with the Wizard SV Gel Extraction Kit (Promega). A plasmid linearized by Mlu 
I / Eco RV cleavage was dephosphorylated in a 30µl reaction volume consisting of 1 × 
Shrimp Alkaline Phosphatase reaction buffer (Promega), 300ng pBi-Luc (Clontech) and 
0.3U of Shrimp Alkaline Phosphatase (SAP). The mixture was incubated at 37°C for 
15min, and the enzyme inactivated by incubation of the reaction at 65°C for 15min. 
Approximately 61ng of the purified fragment (in three-fold molar excess to vector) was 
mixed with 50ng dephosphorylated of pBi-Luc (Clontech), 1µl 10 × Ligation Buffer 
(Promega) and 1µl of T4 DNA Ligase (Promega, 3 Weiss U/µl) in a total volume of 10µl. 
An experimental control (background control) was included where the digested IL-4R 
insert fragment was omitted. The ligation reaction was allowed to proceed overnight at 
4°C. Following ligation, 5µl of the ligation mix was added to 50µl of calcium chloride 
competent DH5α E.coli cells (Invitrogen, Gibco BRL, U.S.A.). The suspension was 
incubated on ice for 30min after which the cells were heat-shocked, according to the 
methodology of Inoue and co-workers (1990) at 42°C for 45sec. The transformed cells 
were immediately placed on ice (4°C) for a further 2min and 900µl of room temperature 
SOC medium [0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10mM NaCl2, 2.5mM KCl, 
10mM MgCl2,  20mM MgSO4 and 20mM glucose] was added. Cells were incubated with 
shaking (200rpm) at 37°C for 1h. Following incubation, 100µl of the transformed cells 
were plated onto LB agar plates containing 50µg/ml ampicillin. Plates were incubated for 
14h at 37°C. Plasmid DNA was isolated (see section 2.1.1) from overnight cultures 
containing 5ml LB medium supplemented with 50µg/ml ampicillin and colonies chosen 
randomly from the incubated plates. Positive constructs were identified by restriction 
enzyme screening with the restriction enzymes Mlu I and Eco RV (Roche), and verified by 
a secondary PCR screening with the oligonucleotide primers initially used to amplify the 
inserts. The correct fragments from both procedures were verified by electrophoresis on 
a 1% (w/v) agarose gel stained with ethidium bromide (0.5µg/ml) as described below 
(section 2.1.6). Plasmids found to contain correct inserts were sequenced by automated 
nucleotide sequencing pBi-IL-4R. Glycerol stocks were prepared of the E.coli DH5α cells 
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containing the pBi-IL-4R plasmids with the coding regions for IL-4R and stored at -70 
°C. 
 
2.2.1.6  Agarose gel electrophoresis. 
All DNA samples including PCR products, restriction enzyme (RE) digestion and RE 
screening products, were verified by agarose gel electrophoresis through a 0.8 or 1% 
(w/v) agarose gels (gel percentage was dependant on fragment size) in 1 × TAE 
electrophoresis buffer. Samples were electrophoresed at constant voltage of 150V for 
45min at room temperature. Gels were stained with ethidium bromide (0.5µg/ml). DNA 
was visualised by short wavelength UV transillumination (A254nm). 
 
2.2.1.7  Gel isolation and purification of DNA. 
DNA samples including PCR products and samples from RE digestions of fragments to be 
used in ligation were electrophoresed on a 1% low melting point agarose gel in 1 × TAE 
electrophoresis buffer (containing 0.5µg ethidium bromide/ml) at 90V for 1h. DNA was 
visualised by brief exposure to low wavelength UV (A320nm). The appropriate bands were 
excised from the gels with a sterile blade. Gel slices were melted by incubation at 65°C in 
heating block and DNA purified using the Wizard SV Gel Extraction kit (Promega), 
according to the manufactures instructions. DNA concentrations were determined from 
the absorbance of samples at A260nm using the conversion factor for double stranded DNA 
(1OD unit = 50µg/ml).  
 
2.2.2 Cell culture. 
 
2.2.2.2.1 Hek 293T cells. 
The human embryonic kidney 293 cell line (Hek 293T) (obtained from Gordon Brown, 
IIDMM, UCT Medical School) was used for all in vitro transfection and expression studies. 
The cells were cultured in DMEM medium pH7.4, supplemented with 10% Foetal Calf 
Serum (Gibco Life Technologies, Paisely, UK) 10mg/ml streptomycin and 10U/ml 
penicillin at 37°C and 5% CO2. Cells were passaged when cell monolayer reached ~70% 
confluence. Cells were split at a 1:10 ratio by aspirated the growth media from the cells 
and rinsing once with 1 x PBS. The adherent cells were then dislodged from the tissue 
culture flasks (Nalge Nunc International, Naperville, IL, USA) by addition of Trypsin-EDTA 
solution (0.53mM EDTA, 0.05% trypsin) (Gibco) and incubation for 1min at room 
temperature. After gentle tapping of the flask the suspension was diluted in DMEM 
supplemented with 10% FCS to inactivate the trypsin. This suspension was centrifuged 
at 1 200rpm for 8min and the supernatant carefully aspirated from cell pellet. Cells were 
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then resuspended in DMEM / 10% FCS and transferred to the appropriate size tissue 
culture flask.  
 
2.2.2.2.2 Transfection of Hek 293T cells.  
Unless otherwise stated, sub confluent Hek 293T cells (cell monolayer at ~70% 
confluence) were transfected in serum-free conditions using Lipofectamine Reagent 
(Invitrogen Corporation, Carlsbad, CA, USA). Lipofectamine Reagent (Invitrogen) 
employs a lipid-mediated (Felgner and Ringold, 1989) method; the transfection was 
preformed with optimization of the manufacture’s instructions. Briefly, cells were plated 
at 2x105cell/well in a 6 well tissue culture plate (Nalge Nunc International) and incubated 
at 37°C in a humidified 5% CO2 for 18-24h. Subsequently, two tubes with 0.75ml DMEM 
media/well were prepared. 1ug isolated plasmid DNA, diluted to a working concentration 
of 1ug/ml in distilled H2O, was added to one tube and to the other 5ul of Lipofectamine 
Transfection Reagent (Invitrogen). The reaction mixtures from the two tubes were 
combined and incubated at room temperature for 20min. The adherent Hek 293T cells 
were washed twice with 3ml/well serum-free DMEM media. The 1.5ml reaction mixture 
was then carefully plated onto the cells. The cells were incubated at 37°C in a humidified 
5% CO2 incubator for 24h. After over night incubation the serum-free media was 
aspirated from the cells and cells were re-incubated after the addition of 3ml DMEM 
supplemented with 10% Foetal Calf Serum (Gibco Life Technologies). The antibiotic 
800µg/ml G418 (Sigma) was used to select (maintainace concentration of 400µg/ml) 
stable eukaryotic cell lines that have been transfected with the pTet-Off vector which 
contains the gene for neomycin resistance. With co-transfection with either the pBi-IL-
4R or the control pBi-Gl vector 200µg/ml Hygromycin B was also added to the media as 
these vectors contain the hygromycin resistance gene.  
 
 
2.2.3 In vitro and in vivo determination of transgene functionality. 
 
2.2.3.1  Template preparation for qRT-PCR assays. 
2.2.3.1.1 RNA Isolation. 
Total RNA was extracted from transfected Hek 293T cells or splenocytes of transgenic 
mice using TriReagent (Molecular Research Company, Cincinnati, USA) as per the 
manufacture’s instructions. The collected tissue was homogenized on ice in 2ml 
TriReagent for every 100mg of tissue. 200μl of chloroform was added for every 1ml of 
lysate and vortexed thoroughly. The samples were incubated at room temperature for 
15min and centrifuged at 13 500rpm for 15min at 4oC. The top aqueous layer was 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 2 
 46
transferred to a new tube and an equal volume of 100% isopropanol added and mixed. 
The RNA was precipitated out of solution by incubating overnight at –80oC and 
centrifuging at 13 500rpm for 30min at 4oC. The RNA pellet was washed twice in 800μl 
70% ethanol, air-dried and resuspended in 50μl-100μl of DEPC-treated water. All purified 
RNA samples were DNAseI treated and stored at -80°C. The quality of the RNA was 
checked by determining the ratio of the absorbance at A260/A280 and by running 1µg of 
RNA on a 1% agarose gel that contained 2.2M formaldehyde. The concentration of the 
RNA was determined by measuring the A260. All solutions, except TRIS-containing 
buffers, used for the RNA work were treated with DEPC to destroy any endogenous 
RNAses. To each solution, DEPC was added to a final concentration of 0.1% and gently 
shaken overnight at 37oC. The solutions were then autoclaved for 30min to remove any 
traces of DEPC. For TRIS-containing buffers, solutions were prepared using DEPC-treated 
water and an ultra-pure TRIS stock designated for RNA work only. 
  
2.2.3.1.2 DNAseI treatment of isolated RNA. 
The RNA was DNAseI treated to remove contaminating genomic DNA, proteins, residual 
phenol and salts. 1-10µg of total RNA was incubated with DNAseI cocktail (1 X DNAse1 
buffer (Promega, Madison, WI, USA), 10U/μl DNAse1 (Roche Diagnostics GmbH, 
Mannheim, Germany), 1U/μl RNAsin (Promega, Madison, WI, USA) for 60min at 37oC. 
The DNAseI-treated RNA was purified from the digested DNA fragments and 
concentrated using the Qiagen MiniElute RNA cleanup kit (Qiagen, Valencia, CA, USA) as 
per the manufacturer’s instructions. Briefly, the volume of the total RNA was adjusted to 
100 µl by adding RNAse-free water. β-mercaptoethanol was added to Buffer RLT before 
use as per the manufacturer’s instructions. 350μl of Buffer RLT was added to the RNA 
and vortexed. 250μl of 96% ethanol was added and vigorously vortexed to precipitate 
the RNA out of solution. Each sample was then applied to a single RNeasy mini-column 
and centrifuged at 10 000rpm for 15sec at room temperature. The flow-through was 
discarded and the RNeasy mini-column transferred to a new 2ml collection tube. The 
mini-column was washed with 500μl Buffer RPE and centrifuged at 10,000 rpm for 15sec 
at room temperature. The wash step was repeated and the mini-column centrifuged at 
10,000rpm for 2min. The mini-column was then transferred to a new 2ml collection tube 
and centrifuged at 10,000rpm for 2min at room temperature to dry the membrane. After 
transfer to a new 1.5ml elution tube, 30μl RNAse-free water was added directly on to the 
membrane and incubated for 5min at room temperature. To elute the RNA the mini-
column was then centrifuged at 10,000rpm for 1min at room temperature. This step was 
repeated and both 30μl RNA elutes pooled. The elimination of contaminating genomic 
DNA was confirmed by RT-PCR using primers that bound to genomic DNA. The quality 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 2 
 47
and quantity of the RNA was checked by spectroscopy and denaturing gel electrophoresis 
using standard methods (Sambrook and Russell, 2001). The A260/A280 ratio was measured 
and an aliquot was run on a 1% agarose gel containing 2.2M formaldehyde. The RNA 
was stored at –80oC until used.  
 
2.2.3.1.3 cDNA Synthesis.  
The genomic DNA free RNA was reverse transcribed into cDNA using the ImProm-II™ 
Reverse Transcription System (Promega, Madison, WI, USA) as per the manufacturer’s 
instructions. 0.5µg of Oligo (dT)15 primer was added to 1-10µg of genomic DNA free 
RNA in a final volume of 20μl. The sample was denatured at 70oC for 10min then 
immediately cooled on ice (4°C) for 5min. 20μl of cDNA synthesis cocktail (ImProm-II™ 
5X Reaction Buffer, 4mM MgCl2, 0.5mM each dNTP, 1U/μl RNAsin, 2.0μl ImProm-II™ 
Reverse Transcriptase) was added to the sample and samples then incubated at 25oC for 
5min to anneal the primers. cDNA synthesis was extended at 55oC for 90min. The 
reaction was heat deactivated at 75oC for 5min and cooled at 4°C. The cDNA 
concentrations were determined from the absorbance of samples at A260nm using the 
conversion factor for double stranded DNA (1OD unit = 50µg/ml). The samples were 
diluted to a 100ng/µl in PCR water, divided into aliquots and stored at –20oC.  
 
2.2.3.2  Transcription assays. 
 2.2.3.2.1 Primers designed for expression assays. 
 
 
Table 2.2 Sequences of oligonucleotides used for the expression studies 
 
 
Name 
 
 
 
Sequence 
 
 
 
Product Size 
 
 
Exon 8 forward 
 
 
 
 
5’ GTA CAG CGC ACA TTG TTT TT ‘3  
 
 
 
 
194bp 
 
 
Exon 8 reverse 
 
 
 
5’ CTC GGC GCA CTG ACC CAT CT ‘3 
 
 
 
 
 
 
 
-actin forward 
 
 
 
5’ TGG AAT CCT GTG GCA TCC AGA AAC ‘3 
 
 
 
 
210bp 
 
 
-actin reverse 
 
 
 
5’ TAA AAC GCA GCT CAG TAA CAG TCC ‘3 
 
 
 
 
 
 
 
IL-4R Tg forward 
 
 
 
5’ TGA CCT ACA AGG AAC CCA GGC ‘3 
 
 
 
 
168bp 
 
 
IL-4R Tg reverse 
 
 
 
5’ GAA CAG GCA AAA CAA CGG GAT ‘3 
 
 
 
 
 
 
 
Luc forward 
 
 
 
5’ AAT CTG ACG CAG GCA GTT CT ‘3 
 
 
 
 
186bp 
 
 
Luc reverse 
 
 
 
5’ CCA GGG ATT TCA GTC GAT GT ‘3 
 
 
 
 
 
 
 
tTa forward 
 
 
 
5’ GGA CGA GCT CCA CTT AGA CG ‘3 
 
 
 
183bp 
 
6 
tTa reverse 
 
 
 
5’ GGC ATC GGT AAA CAT CTG CT ‘3 
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2.2.3.2.2 qRT-PCR 
The 2μl of the cDNA, at a final concentration of 10ng/reaction, was added to 18μl PCR 
cocktail (1 X Sensimix d(T) (Quantace, Neutral Bay, NSW, Australia) containing 1 X SYBR 
GreenI, 4.0mM MgCl2, 0.5μM forward primer, 0.5μM reverse primer, 0.1mg/ml molecular 
grade BSA). PCR products were amplified on the Lightcycler (Roche) using the generic 
programme:1 cycle at 95oC for 10 minutes, 50 cycles of 95oC for 5 seconds, 62oC for 15 
seconds, 72oC for 10-60 seconds depending on PCR product size. Extension time was 
calculated based on the fact that DNA Taq Polymerase can cover 25 base pairs (bp) per 
second: Temperatureextend = (PCR product size in bp) / (25bp/second). Data was 
acquired at 80oC for 1sec. A melting curve analysis was performed at the end of the 
amplification program: 95oC for 0 sec, 75oC for 15sec, 65oC for 15sec and 95oC for 0sec 
with a ramping time of 0.1oC/sec. The -actin gene was used as the housekeeping gene 
for data normalization. The levels of mRNA transcription relative to mRNA levels of a 
housekeeping gene (-actin) were determined. For quantitative analysis data was 
analysed using the “Fit Points” and “Standard Curve Method”. Primer sequences and 
product sizes are given in Table 2.2. 
 
2.2.3.3  Translation assays. 
2.2.3.3.1 Luciferase assay. 
To determine the levels of luciferase expression the Luciferase Assay System was utilised 
(Promega). Prior to performing the assay the Luciferase Assay Reagent (LAR) was 
prepared by adding 10ml of the Luciferase Assay Buffer to a vial of lyophilized Luciferase 
Assay Substrate. To avoid freeze-thaw cycles the reconstituted reagent was dispensed 
into 100µl working aliquots (the reaction requires this volume to initiate enzyme activity) 
and stored at -70°C. 1 x Luciferase Cell Culture Lysis Reagent (CCRL, Promega) was 
prepared by adding 4 volumes of water to 1 volume of the 5 x lysis buffer supplemented 
with 1mg/ml BSA (the addition of BSA ensures that luciferase is not lost from solution by 
absorption). This buffer and the LAR were allowed to equilibrate at room temperature 
before use. Cell lysates were prepared for the both the adherent Hek 293T cells and the 
nonadherent splenocytes by lysis via resuspension with1 x lysis reagent. The suspensions 
were incubated at 4°C for 10min, vortexed for 10-15sec and centrifuged at 12,000 x g 
for 10min at 4°C. The supernatant was transferred to sterile eppendorf tubes and either 
stored at -70°C or used in the assay. 20µl of the cell lysate was dispensed in a 96 well 
half area black plate with clear bottom. Prior to assay the plate reading luminometer 
(Fluroscan Ascent FL, Thermo Scientific, USA) was programmed for a 10sec integration 
time, 2sec lag time and 100µl dispensing volume. The dispensing and aspirating tubing 
was primed with LAR and the dispensing head placed in the appropriate dispensing 
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position. The plate was placed into the luminometer which injected the 100ul LAR per 
well and read wells immediately after injection. The plate was then advanced to the next 
well and the process repeated. The results are given as relative light units (RLU). All 
values obtained from the luminometer indicating luciferase activity were normalized to 
total cell protein content.  
 
2.2.3.3.2 FACS analysis. 
Hek 293T cells were removed from tissue culture well plates (Nalge Nunc) using 
Trypsin/EDTA buffer (Gibco) and incubation for 1min at room temperature. After gentle 
tapping of the flask the suspension was diluted in DMEM / 10% FCS to inactivate the 
trypsin. The suspension was centrifuged at 1,200rpm at 4°C for 8min and the 
supernatant carefully aspirated from cell pellet. The cells were resuspended in 5ml DMEM 
/ 10% FCS. Transgenic mice were sacrificed by cervical dislocation. Spleens were 
removed aseptically and placed in ice cold RPMI 1640 supplemented with 10% FCS 
(Gibco). Single cell suspensions were prepared and filtered through 70µm nylon cell 
strainers (Becton-Dickinson, New Jersey). Cells contaminated with red blood cells were 
resuspended in 5ml Red cell lysis buffer (0.15M NH4Cl, 1.0M NaHCO3, 0.1M Na2 EDTA)  
and underlayed carefully with 2ml heat inactivated FCS. The cells were centrifuged at 1 
200rpm at 4°C for 10min and resuspended in 5ml RPMI 1640 / 10% FCS. Aliquots of 
cells (10µl) were diluted in Trypan Blue and counted on a Neubauer haemocytometer to 
determine concentrations of viable cells. For each staining 1x105 cells were blocked for 
25min in 100µl FACS buffer containing 1% heat inactivated rat serum and 4µg/ml 2.4G2 
(anti-FcRII and –III). The cells were washed in 500µl FACS buffer (PBS supplemented 
with 0.1% BSA and 0.05% Sodium Azide) and resuspended in 100µl FACS buffer 
containing one of the following antibodies to cell surface markers: CD11b-Fitc , B220-Fitc, 
CD4-Fitc, CD124-PE, CD-45-biotin (BD Bioscience, Pharmigen, San Diego, CA). Cells were 
also stained in parallel for the isotype control for CD124: Rat IgG2ακ. Cells were stained 
by incubation in the dark for 30min at 4°C after which the cells were washed with 500µl 
FACS buffer and centrifugation at 1,200rpm for 10min. Pelleted cells were resuspended 
and incubated for a further 15min on ice with 100l of a saturating amount of 
streptavidin-APC (BD Biosciences) in FACS buffer. Cells were washed with 500µl FACS 
buffer and centrifugation at 1,200rpm for 10min. After this final wash, cells were 
resuspended in 300µl FACS buffer supplemented with 7-AAD (Sigma, St. Louis, USA). 
Dead cells stained with 7-AAD were excluded from analysis. Stained cell acquisition was 
preformed using a FACSCalibur flow cytometer (BD Biosciences) and data analyzed using 
CellQuest software (Becton-Dickinson, Ferndale, South Africa). 100,000 cells were 
acquired for analysis.  
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2.2.4 Generation of chimeras. 
 
2.2.4.1  Generation of pBi-IL-4RTg chimeras. 
For protocol see Appendix A. 
 
2.2.4.2  Genotyping of pBi- IL-4RTg and pVav-tTa Tg. 
2.2.4.2.1 Genomic DNA extraction. 
Mouse-tail cuttings, approximately 1cm, were digested overnight in digestion buffer 
(50mM Tris-HCl, pH8; 100mM EDTA; 100mM NaCl, 1% SDS, 0.5mg/ml Proteinase K) at 
56oC with gentle shaking. The samples were centrifuged at 14,000 rpm for 15min and 
the clear supernatant transferred to a clean microcentrifuge tube. An equal volume 
isopropanol was added and thoroughly mixed. The genomic DNA was allowed to 
precipitate out of solution by incubating at room temperature for 30min and centrifuged 
at 14,000 rpm at 4oC for 30min. The genomic DNA pellet was washed in 1ml 70% 
ethanol, air-dried and resuspended in 500μl sterile water. The quantity and quality of the 
genomic DNA was checked by spectroscopy by reading the absorbance at A260 and A280. 
 
2.2.4.2.2 Genotyping PCR. 
All mice were genotyped prior to experiments to confirm their genotype using gene 
specific primers. 2μl of genomic DNA was added to 48μl of PCR cocktail (1 X Supertherm 
PCR Buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.125U/μl Supertherm Taq, 0.25μM forward 
primer and 0.25μM reverse primer). Control reactions included a (i) no template/water 
control, (ii) positive control and (iii) negative control. The PCR products were amplified 
on a MJ thermocycler (Biozym, Hessisch Oldendorf, Frankfurt, Germany). The PCR cycle 
for the pBi-IL-4RTg: 1 cycle at 94oC for 1min; 25 cycles of 94oC for 1min, 58oC for 
1min, 72oC for 1.5min; 1 cycle at 72oC for 5min. The PCR cycle for the pVav-tTa Tg: 1 
cycle at 94oC for 10min (hot start); 30 cycles of 94oC for 30sec, 55oC for 30sec, 72oC for 
1min; 1 cycle at 72oC for 7min. The PCR cycles for the Wild-type and Knock-out alleles: 1 
cycle at 94oC for 1min; 40 cycles of 94oC for 30sec, 57oC for 30sec, 72oC for 1 min; 1 
cycle at 72oC for 5min. The PCR products were analysed by gel electrophoresis. Primers 
used are listed in Table 2.3. 
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Table 2.3 Sequences of oligonucleotides used genotyping Tg mice. 
 
 
Name 
 
 
 
Sequence 
 
 
Glob forward 
 
 
 
5’ TGA GTG TGC TGT TGT TGC TG ‘3 # 
 
Glob reverse 
 
 
 
5’ GGG TCC ATG GTG ATA CAA GG ‘3* 
 
Vav forward 
 
 
 
 
5’ CTC TCT TGC CTG CCT GTG ‘3 # 
 
Vav reverse 
 
 
 
5’ GTA AAC TTC TGA CCC ACT GGA AT ‘3* 
 
 
 
Wild-type allele forward 
 
 
 
 
5’ GTA CAG CGC ACA TTG TTT TT ‘3 # 
 
 
WT reverse 
 
 
 
5’ CTG GGC GCA CTG ACC CAT CT ‘3* 
 
 
Knockout allele forward 
 
 
 
 
5’ GGC TGC TGA CCT GGA ATA ACC ‘3 # 
 
 
KO reverse 
 
 
 
5’ CCT TTG AGAACT GCG GGC T ‘3* 
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2.3 Results. 
 
The following is a brief outline of the steps involved in the generation of the new 
transgenic model: 
1. Transgene design and cloning, including sequence verification. 
2. In vitro determination of transgene functionality. 
3. Generation of chimeras. 
4. Breeding and genotyping. 
5. In vivo functionality assays. 
 
2.3.2.1  Transgenic Construct design and cloning.  
 
In order to generate the pBi-IL-4R inducible mouse model, cloning of the pBi-IL-4R 
response vector was required (illustrated in Figure 2.2). To sub-clone, and ultimately 
express the transmembrane isoform of mIL-4Rthe corresponding coding region was 
amplified using the pM5neo plasmid (Prof. A. Gessner) as template. The pM5neo 
eukaryotic expression vector contains the 2501bp cDNA encoding the transmembrane 
isoform of IL-4R (Schulte et al., 1997). The cDNA was generated from RNA isolated 
from a BALB/c mouse.  
Primers were designed to incorporate Mlu I and Eco RV restriction enzyme sites, to allow 
subsequent ligation into pBi-Luc expression vectors digested with the same set of 
enzymes. In order to improve translation, via an optimized transcription start site, the 
Kozak consensus sequence was incorporated in the forward primer sequence. The 
sequence is contiguous with the ATG start codon and greatly increases the efficiency of 
translation and hence overall expression of the product gene (Kozak, 1986). Primers 
were designed to generate this consensus sequence, at the 5’ end of the amplified IL-
4R cDNA fragment, by the addition of 3 extra bases. 
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Figure 2.2 Flow Diagram of pBi-IL-4R Cloning Strategy. 
 
Transgene design for the inducible reconstitution of IL-4Rin IL-4R mice. The expression 
construct is comprised of the IL-4R cDNA fragment cloned into the multi-cloning site of the pBi-
Luc vector (Baron et al., 1995). The bi-directional vector allows for the simultaneous expression of 
the IL-4R gene and the reporter gene luciferase driven by the minimal tet operon. Panel A, IL-
4R map. Transmembrane isoform indicated. The transmembrane isoform coding region is 2501bp 
in length and codes for 831 amino acids. Panel B, Primer design and PCR of mIL-4R transgene 
using pM5neo as template. Panel C, RE digestion of amplified IL-4R cDNA and ligation into pBi-
Luc. Panel D, The bi-directional mIL-4Rexpression cassette. The Mlu I – Eco RV ligation 
junctions are indicated. 
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Amplification produced the desired 2501bp mIL-4RcDNA fragment (Figure 2.3). The 
fragments were isolated from a low melting agarose gel and digested with the Mlu I and 
Eco RV enzymes. The digested fragments were isolated in the same manner as the PCR 
products and subsequently ligated into the pBi-Luc vector digested with the same 
restriction enzyme set as those used on the amplified mIL-4RcDNA fragment (see 
Figure 2.2 for vector construction scheme).  
The construct was transformed into DH5 E. coli cells, and colonies screened by 
restriction enzyme digestion. The restriction enzyme combination of Mlu I / Acc I   was 
used to identify the pBi-IL-4Rcolonies into which IL-4R had been ligated in-frame 
(Figure 2.4, Panel A). Using these enzymes, which have single recognition sites in the 
insert sequence (Fig.2.4.B), confirmed the orientation of the ligated cDNA fragment in 
the vector, which is important for the in-frame expression of the cloned cDNA. 
Furthermore, insert presence was confirmed with the Mlu I and Eco RV; both enzyme 
recognition sites were present at the ligation junction of positive clones. This digestion 
product, the 2501bp cDNA insert fragment is shown in lane 3. he sequences of inserts 
in positive constructs were subsequently verified by automated nucleotide sequencing 
after which the construct was referred to as pBi-IL-4R.  
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Figure 2.3 Amplification of transmembrane IL-4R cDNA fragment.  
 
PCR was performed to amplify the coding region of the transmembrane isoform of mIL-4R using 
oligonucleotides specific for the sequence and pM5neo as template. A negative, no DNA control 
was included where no DNA template was added to the reaction mixture. 0.7% (w/v) agarose gel 
in 1 × TAE containing ethidium bromide and visualized using short wavelength UV 
transillumination. Lane M, DNA molecular weight marker. Lane 1, Amplified 2501bp IL-4R cDNA 
fragment.  
 
 
 
 
Figure 2.4 Restriction enzyme screening and sequence verification of the pBi-IL-4R 
transgenic construct.  
 
Panel A, pBi-IL4R vector map. Enzymes used in RE screening indicated. The cDNA insert was 
ligated into pBi-Luc. Following transformation and plasmid isolation the colonies were screened via 
RE digestion. The illustration shows the theoretical recognition sites in colonies positive for the 
insert. Panel B, 0.7% (w/v) agarose gel in 1 × TAE containing ethidium bromide and visualized 
using short wavelength UV transillumination. Lanes M, DNA molecular weight marker. Lane 1, 
undigested pBi-IL4RLane 2, Mlu I / Acc I digestion products. Lane 3, Mlu I / Eco RV digestion 
products.  
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2.3.2.2  In vitro expression studies.  
 
Prior to the generation of the chimera mice the functionality of the bi-directional mIL-
4R construct under the control of the Tet system was assessed. All the functionality 
assays were performed in Hek 293T cells. Transfection efficiency was determined 
qualitatively via GFP UV fluorescence using the pGFP-N1 reporter constructs. In this 
reporter construct GFP expression is driven by the constitutively active CMV promoter 
(Figure 2.5.A). Vector transfection was optimized for the reagent used and the efficacy of 
Lipofectamine proved higher than Effectene (Figure 2.5, Panel C and B respectively). 
Transfection efficiency was additionally confirmed via FACS analysis of the fluorescence 
(GFP). 
 
 
 
 
Figure 2.5 Optimization and assessment of Hek 293T cells transfection efficiency.  
 
Panel A, B and C; UV fluorescent images of pGFP-N1 transfected Hek 293T cells. 24h Post 
transfection cells were analysed to assess transfection efficiency. Panel A, GFP fluorescing Hek 
293T cells. Panel B, Hek 293T cells transfected with Effectene transfection reagent. Panel C, Hek 
293T cells transfected with Lipofectamine transfection reagent. Images observed under 20X 
magnification. 
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2.3.2.2.1 Establishment of bi-directional promoter activity. 
 
Binding of the tTA transactivator protein to the TetO operon, an element of the generated 
pBi-IL-4R response vector, leads to the simultaneous expression of the luciferase 
reporter and the gene of interest (in this case IL-4R). Thus, the 
chemiluminscent luciferase assay was used to confirm: 
1. Efficient tTA expression;  
2. TetO operon binding and   
3. Bi-directional promoter functionality.  
Western blots were performed to illustrate tTA expression but this assay proved 
unsuccessful. This could be attributed to the tTA expression being below detectable 
levels, as the transactivator is only needed in very low doses for successful promoter 
activation (Tet Systems Manual). Western Blots would also not have been sufficient since 
these only verify the presence of the tTa protein and does not reveal the functional role 
of the transactivator binding to the bi-directional promoter. 
The Tet system functionality in Hek 293T cells is illustrated Figure 2.6. In the cell only 
and cells transfected with the response, pBi-IL-4R/ pBi-Luc or the regulatory, pTet-Off, 
vectors only (first 4 bars in graph) background levels of chemiluminscence and thus 
luciferase expression was detected. These control experiments also served as an 
indication of the bi-directional promoter leakiness in vitro, as is observed by the 
background levels of luciferase expression shown by the response, pBi-IL-4Ror pBi-Luc 
transfected cells only (bar 3 and 4 respectively). In the cells transfected with both the 
response, pBi-IL-4Ror pBi-Luc, and the regulatory pTet-Off vectors an increased level 
of chemiluminscence and consequently luciferase expression was shown (bars 5 and 7). 
Accordingly, in the presence of doxycycline (bar 6 and 8) basal expression was 
undetectable and similar to that detected in the cell only control (bar 1).  
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Figure 2.6 Induced luciferase expression in Hek 293T cells containing both response 
and regulatory vectors. 
 
All experimental groups were transiently transfected with the vectors indicated. Luciferase 
induction levels were assayed 24h post transfection. Cells were incubated with 2g/ml doxycycline 
12h post transfection. The results represent 1 of 4 independent experiments and show the 
average ± SEM of triplicate values. Statistical differences between groups calculated using 
unpaired Student’s t test defining differences to untransfected Hek 293T cells as significant (***, p 
≤0.0001). RLU refers to relative light units. 
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2.3.2.2.2 Establishment of effective doxycycline concentration and repression over  
  time. 
 
In the presence of doxycycline (Dox) the tTa effector protein, expressed via the Tet-Off 
regulatory vector, is unable to bind to the TetO operon sequences, thus suppressing 
target gene expression. Previously shown data suggests that the optimal concentration 
may vary between different cell lines (Tet Systems Manual). Additionally that full 
repression of gene expression in Tet-Off cell lines can be obtained with 10ng–1μg/ml 
Dox. Thus for the subsequent in vitro assays, using Hek 293T cells, it was necessary to 
determine the concentration of doxycycline which would lead to full suppression of tTa 
binding and transcriptional activation from the bi-directional promoter. For both the pBi-
IL-4R and the control pBi-Luc vectors co-transfected with the pTet-Off regulatory 
vector, complete suppression was obtained with a concentration of 0.01μg/ml Dox 
present in the culture media (Figure 2.7, Panel A.1 and A.2 respectively).  
Furthermore, when determining the decrease in luciferase expression with cells co-
transfected with the pBi-IL-4R and pTet-Off vectors and cultured with 1μg/ml Dox 
efficient suppression was obtained after 12h of culture (Fig.2.7.B). Subsequently, a Dox 
concentration of 0.01μg/ml was used for suppression of target gene expression and 
analyzed 12h after addition of the Dox. 
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Figure 2.7 Doxycycline induced suppression of luciferase expression. 
 
All experimental groups were transiently transfected with the vectors indicated. Panel A.1 and 
A.2, Dose dependent suppression. Doxycycline, at the concentrations indicated, was added 6h 
post transfection and luciferase expression levels assayed 24h post transfection. Panel B, Time 
dependent suppression. Cells were incubated with 1ug/ml doxycycline. Luciferase induction levels 
were assayed at times indicated post transfection. The results represent 1 of 3 independent 
experiments and show the average ± SEM of triplicate values. RLU refers to relative light units. 
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2.3.2.2.3 Establishment of efficient pTet-Off: pBi-IL-4Rplasmid ratio.  
 
It has previously been shown that the ratio of the regulatory plasmid (pTet-Off) vs. the 
response plasmid is critical in transient expression studies. From these data, the 
suggested ratio is up to a 100-fold excess of regulatory plasmid over the response 
plasmid. These conditions assure high intracellular concentrations of the tTA effector 
protein and subsequent increased binding to the TetO operon on the response plasmid. 
Furthermore, these plasmid ratios give low background while maintaining a high 
expression potential. It was shown that in the presence of Dox, the background synthesis 
of reporter enzymes decreases proportionally when the amount of the response plasmid 
is lowered. This is in contrast to unsuppressed levels (i.e. Dox absent for media) which 
are affected less by the relative amount of the plasmid (Prof. H Bujard website).  
Thus, in order to assess the IL-4R transgene expression accurately the ratio at which to 
transfect the regulatory pTet-Off and response pBi-IL-4Rplasmid was determined 
quantitatively via qRT-PCR expression analysis of the luciferase reporter, tTa effector and 
IL-4R transgene. Hek 293T cells were transfected with the regulatory pTet-Off and 
response pBi-IL-4R vectors at plasmid ratios of 1:1, 1:10 and 10:1 respectively. 
Additionally cells were transfected with single vectors as control and with control pBi-Luc 
with pTet-Off at the same ratios as above. The control experiments (Figure 3.8, Panel A 
and A.1) determined the background expression and also the basal level of luciferase 
expression in the absence of doxycycline. With an response vector, pBi-Luc or pBi-IL-4R 
to regulatory vector, pTet-Off, ratio of 1:10 there was a significant increase (when 
compared to cells transfected with the single vectors values of p< 0.05 were obtained) to 
in luciferase expression in the cells transfected with the control plasmid (pBi-Luc) (A) and 
the generated pBi-IL4R plasmid (Panel A.1). This increased reporter expression was 
verified with qRT-PCR (Fig.2.8.A.2) which also indicated a significant difference when 
compared to cells transfected with single vectors only (p< 0.0001). Furthermore, with 
the tTa effector expression (p=0.0033) and the IL-4R transgene expression (p< 
0.0001) was similarly elevated in cells containing a 10-fold excess of the regulatory 
plasmid (Fig.2.8.B and C respectively). These results are in agreement with the expected 
outcomes given by Prof. H.Bujard. 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 2 
 62
 
Figure 2.8 Effect of regulatory and response plasmid ratios on transgene expression. 
 
All experimental groups were transiently transfected with the vectors and ratios indicated. Panel 
A.1, Control experiments. Luciferase expression levels assayed 24h post transfection via 
chemiluminscent assay. RLU refers to relative light units Panel A.2, Luciferase expression levels 
assayed 24h post transfection. Levels of luciferase mRNA relative to mRNA levels of a 
housekeeping gene (actin) were determined by real-time PCR. For both Panel B and C; Levels of 
tTa and IL-4R mRNA relative to mRNA levels of actin were determined by real-time PCR. Panel 
B, tTa effector protein expression levels 24h post transfection Panel C, IL-4R transgene 
expression levels 24h post transfection. Statistical differences between groups calculated using 
unpaired Student’s t test defining differences to cells transfected with single vectors as significant 
(***, p ≤0.0001, **p=0.0033).The results represent 1 of 3 independent experiments and show 
the average ± SEM of triplicate values.  
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2.3.2.3  In vitro inducible repression of IL-4R expression.  
2.3.2.3.1 Transcription efficiency of mIL-4R transgene. 
  
Subsequent to the completion of the pilot studies (section 2.2.2) stable cell lines were 
generated and clones tested for relevant gene expression via quantitative RT-PCR.  
As expected a higher level of tTa mRNA correlated with an increase in transcription from 
the bi-directional promoter, leading to increased levels of the IL-4R transgene mRNA 
(Figure 2.9, Panel A and B respectively).  
In Panel A, no transcription was observed in the untransfected Hek 293T cells. In 
contrast, when compared to the untransfected cells, there was a significant (p< 0.05) 
increase in the levels of transcribed tTa mRNA in both the single and double cell lines. 
This clearly indicated the transcriptional activity of the regulatory plasmid. IL-
4Rtranscription was also significantly elevated, but only in the double cell line 
containing both the response and regulatory vectors (Fig 2.9.B). This confirmed the 
transcriptional activity of the response vector.  
 
2.3.2.3.2 Translation efficiency of mIL-4Rtransgene. 
 
To asses the in vitro functionality of the IL-4R transgene further FACS analysis was 
utilised to determine the translational levels of the transgene. In this, and subsequent 
expression studies, the untransfected Hek 293T cell line was used as control. The IL-4R 
cell surface expression was analyzed using four colour FACS analysis where different cell 
populations were identified by cellular staining with fluorescence labelled antibodies. The 
choice of antibody was based on specificity to the murine IL-4Rmarkers which would 
be present on the double stable expressing cell line only. Isotype controls for the 
antibodies were employed to ensure antibody specificity and additionally functioned as 
negative controls for the staining. To isolate the viable cells, the cells were incubated 
with 7-AAD or propidium iodide which is a marker for non-viable cells.  
The stained pTet-Off-pBi-IL-4R Hek 293T cell line, showed a positive shift in murine IL-
4Rsurface expression when compared to the controls, namely, untransfected cells and 
cells containing the single vector only (Figure 2.10, Panel A). Similarly, the untransfected 
and transfected cell isotype controls also lacked a shift indicating positive murine IL-4R 
surface staining (Fig.2.10, Panel B.1 and B.2 respectively). 
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Figure 2.9 Transgene mRNA levels in stable pTet-Off-pBi-IL-4R Hek 293T cell line. 
 
Single stable and double stable cell lines indicated. Cells were harvested and cDNA synthesized 
from transfected and untransfected Hek 293T cells. Panel A, Regulatory plasmid, pTet-Off 
expression. Levels of tTa effector mRNA relative to mRNA levels of a housekeeping gene (actin) 
were determined by real-time PCR. Panel B, Response plasmid, pBi-IL-4R expression. Levels of 
IL-4R mRNA relative to mRNA levels of actin. Statistical differences between groups were 
calculated using unpaired Student’s t test defining differences against untransfected Hek 293T 
cells as significant (***, p ≤0.0001, *p=0.05).The results represent 1 of 3 independent 
experiments and show the average ± SEM of triplicate values.  
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Figure 2.10 IL-4R transgene expression in Hek 293T cells. 
 
Panel A and B, Histograms indicating the shift in fluorescence due to positive murine IL-4R 
surface expression. Panel A, The cell and vector controls. Hek 293T cells untransfected, and 
transfected with the single vectors only, and stained for murine IL-4R expression. Panel B.1 
and B.2, Isotype controls. Untransfected and double stable Hek 293T cells stained for murine IL-
4R. Lines representing diff rently stained cells are indicated in the legend. Histograms are 
representative of populations gated for viable cells. Results shown are for 1 of 4 independent 
experiments. 
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2.3.2.3.3 In vitro inducible repression of mIL-4R expression.  
 
In the absence of Dox the tTa effector protein expressed via the pTet-Off regulatory 
vector binds uninhibited to the TetO operon located on the pBi-IL-4Ra response vector. In 
this way, target gene expression is initiated from the bi-directional promoter element. We 
had previously established the optimal Dox concentration and the time necessary for 
efficient suppression of target gene expression (see section 2.2.2.2). To proceed with the 
in vitro studies to establish the IL-4R transgene functionality, the inducibility of the 
transgene expression, as opposed to the luciferase reporter studied previously, was 
investigated. The pTet-Off-pBi-IL-4R Hek 293T cell line was incubated with Dox 
(1µg/ml) and as with the luciferase studies; cells were harvested at certain time points, 
and analyzed for IL-4R transgene surface expression via FACS analysis. The stained 
pTet-Off-pBi-IL-4R Hek 293T cell line, showed a positive shift in murine  IL-4Rsurface 
expression when compared to the controls, namely, untransfected cells and the antibody 
isotype control showed the desired lack of a positive fluorescent shift in the lower right 
quadrant of the illustrated dot plot (Figure 2.11, Panel A and B respectively). At 0h, time 
indicating addition of Dox, ~18% of the cells stained positive for murine IL-4Rsurface 
markers (Fig.2.11.C). This percentage decreased to that of ~1.8% at 24h of Dox 
incubation. This confirmed the in vitro functionality and inducibility of the generated pBi-
IL-4Rtransgenicconstruct. 
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Figure 2.11 Inducible IL-4R transgene repression in Hek 293T cells. 
 
Panel A, Untransfected cell control. Histogram indicating the shift in fluorescence due to positive murine IL-4R surface expression on pTet-Off-pBi-IL-4R 
Hek 293T cells. Lines representing different cells are indicated in the legend. Panel B, The antibody isotype control. Dot plot of pTet-Off-pBi-IL-4R cells 
stained for Rat IgG2a, K expression. Panel C, Time dependant suppression of expression, hours represent time after addition of doxycycline. Double stable 
Hek 293T cells stained for murine IL-4R. Percentage values in the lower right quadrant indicating positive mIL-4R surface expression. Histogram and dot 
plots are representative of populations gated for viable cells. Results shown are for 1 of 3 independent experiments. 
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2.3.2.4  Generation and analysis of single transgenic chimeras. 
2.3.2.4.1 Generation of pBi-IL-4RTgchimeras. 
  
Following the in vitro functional analysis of the pBi-IL-4R vector, chimeric mice were 
generated, by Nucleis in France, in a process (complete protocols as supplement to 
Methods section) that involved the following steps (illustrated in Figure 2.12): 
 Targeted insertion of the modified transgene into the hprt docking sites via 
homologous recombination (Panel A). 
 Electroporation of transgene into embryonic stem cells recombinant clones (B). 
Positive clones are identified by HAT selection.  
 Positive cells were microinjected (C) into blastocysts, derived from pseudo 
pregnant females, and implanted into pseudo pregnant mice. 
The advantages of this targeted insertion of the transgene into the hprt docking site are 
two-fold, firstly, the locus demonstrates no intrinsic enhancer activity and secondly it 
provides a permissive chromatin environment that supports promoter dependent 
transgene expression. The inserted transgene is X chromosome-linked. 7 male pBi-IL-
4R chimeric were successfully generated (Fig.2.12.D).  
In order to generate the desired model where IL-4R is expressed in cell-specific and 
inducible manner, the chimeric mice needed to be with an additional transgenic line, the 
regulatory line, which would contribute the transgene to express the tTa effector Due to 
the particular immunoregulatory roles of IL-4 and IL-4R we were interested to achieve 
hematopoietic tissue specific inducible IL-4R expression and it is to this end that we 
obtained the tTA-Vav transgenic line (Prof. D. Largaespada). In this line the tetracycline 
transactivator (tTA) expression is driven by the Vav hematopoietic promoter (Wiesner et 
al., 2005).  
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Figure 2.12 Flow diagram of generation of pBi-IL-4R chimeric mice. 
 
Panel A, The targeted insertion of the pBi-IL-4R into the hprt docking site. Panel B, 
Electroporation of the modified pBi-IL-4R transgene into BPES cells. Panel C, Microinjection of 
the recombinant ES clones into blastocysts. Blastocysts were derived from pseudo pregnant 
female. Panel D, Birth of pBi-IL-4RTg chimeric mice. 
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2.3.2.4.2 Breeding program.  
 
Subsequently, both the pBi-IL-4RTg andpVav-tTavTg founder lines underwent an 
extensive breeding program (illustrated in Figure 2.13). Briefly, the two separate lines 
(pBi-IL-4RTg andpVav-tTaTg) were crossed into the IL-4R-/- BALB/c mouse line 
(Fig.2.13.A). Using the IL-4R-/- background is required for the tissue specific 
reconstitution and deletion of the receptor. Additionally, a BALB/c genetic background 
would be ideal when studying the role of IL-4R in immunity when working with for 
example allergy and nematode parasites, as this genotype skews to a Th2 response. This 
genetic background responds in a highly Th2 biased way, while still being able to 
produce a Th1 response. Another reason for the use of BALB/c mice is also breeding 
convenience, as all IL-4R-/- and cell specific IL-4R-/- models available and in use in the 
laboratory are on a BALB/c background and are thus relevant for the Th2 pathologies 
studied here. 
After positive genotyping analysis confirming genetic background, transgene presence 
and IL-4R-/- knockout status the progeny, of the above-mentioned cross, were inter-
crossed (Fig.2.13.B) to create the final model. This line consisted of a double transgenic, 
pBi-IL-4RTg and pVav-tTaTg, on an IL-4R-/- BALB/c background. 
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Figure 2.13 Breeding scheme for the generation of the final inducible model. 
 
Panel A, Separate mating schemes for the crossing of pBi-IL-4RTg andpVav-tTaTg founder lines into the IL-4R-/- BALB/c background. Panel B, Inter-crossing of 
the pBi-IL-4RTg IL-4R-/- BALB/c andpVav-tTaTg IL-4R-/- BALB/c progeny from the two separate crossings in A. Panel C, Progeny of B result in the final inducible 
model. With a pBi-IL-4RTg / pVav-tTaTg / IL-4R-/- BALB/c genotype. 
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2.3.2.4.3 Stringent control of IL-4R expression in pBi-IL-4RTg / IL-4R-/-  
  BALB/c mice. 
 
The modified CMV minimal promoter driving expression of both the luciferase and IL-
4Rgenes, in pBi-IL-4RTg / IL-4R-/- BALB/c mice, lacks the strong enhancer elements 
typically associated with CMV immediate early promoters (Tet System Manual). 
Furthermore, due to the absence of these enhancer elements, there should theoretically 
be extremely low background expression of luciferase and IL-4R from the TetO, in the 
absence of binding and activation by the TetR domain of transactivator protein tTA.  
In order to test the stringency of the CMV driven target gene expression, FACS analysis 
was employed to establish the extent of the transgene leakiness, and thus non-specific 
expression, in the generated pBi-IL-4RTg / IL-4R-/- BALB/c single transgenic model. 
Following positive genotyping verification, splenocytes from BALB/c, IL-4R-/- BALB/c   
and pBi-IL-4RTg / IL-4R-/- BALB/c mice were analyzed for IL-4Rexpression. The IL-
4R-/- and BALB/c models were included as controls for negative and positive IL-
4Rexpression. Expression was specifically analyzed in granulocytes, T cells and B cells. 
As expected, IL-4Rstaining was clearly apparent in BALB/c mice and absent in IL-4R-
/- mice in all the cell populations. No IL-4Rsurface expression was found in the pBi-IL-
4RTg / IL-4R-/- BALB/c mice. Staining results are indicative of the stringency of 
expression via the Tet system and confirm the lack of transgene leakiness in the 
generated pBi-IL-4RTg / IL-4R-/- BALB/c mice single transgenic line. 
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Figure 2.15 IL-4R transgene leakiness via the CMV promoter. 
 
The IL-4R cell surface expression was analyzed using four colour FACS analysis where different 
cell populations, namely granulocytes, B cells and T cells, were identified by cellular staining with 
fluorescence labelled antibodies. To isolate the viable cells, the cells were incubated with 7-AAD 
which is a marker for non-viable cells. Dot plots indicating the shift in fluorescence due to positive 
murine IL-4R surface expression. The three experimental groups are indicated. Positive staining 
for all groups indicated in the upper right quadrant. Dot plots are representative of populations 
gated for viable cells. Results shown are for 1 of 4 independent experiments. 
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2.3.2.4.4 Genotyping of pBi-IL-4RTg / IL-4R-/- BALB/c and  
  pVav-tTaTg / IL-4R-/- BALB/c. 
  
The genotypes of the genetically modified mice were confirmed via PCR analysis. For the 
pBi-IL-4RTg / IL-4R-/- BALB/c transgenic model the presence of the transgene was 
determined by using  a set of primers (Glob R & F) binding to and amplifying a region 
that includes 43bp of IL-4R coding region and 92bp of b-globin ploy A signal (illustrated 
in Figure 2.14, Panel A). The primers were designed to be specific for the transgene and 
stringent PCR conditions allow for the amplification of a 193bp fragment only in mice 
where the transgene is present. For the identification of mice with the pVav-tTaTg 
transgene PCR primers and conditions were obtained from the researchers involved in 
the generation of this model. The primers, specific for the pVav-tTa transgene, were 
used in combination with primers designed to amplify the endogenous Tsh1 locus as a 
reaction control (Fig.2.14.B).  
To discern between mice with a IL-4R-/- genotype and those still containing the IL-
4Rgene two sets of primers were used, one amplifies the wild-type allele and another 
that amplifies the “knockout allele”. In an IL-4R-/- mouse exons 7, 8 and 9 of the IL-
4Rgene are deleted. The forward primer to the wild-type allele binds in exon 7 and the 
reverse primer in exon 8 resulting in the amplification of a 600bp fragment from DNA of 
a wild-type mouse where these are present (Fig.2.14.C). For the knock-out genotype, the 
forward primer of the knockout allele binds in exon 6 and the reverse primer in exon 10. 
Using DNA from a KO mouse, these primers would amplify 471bp fragment, but the 
~3000bp region between exon 6 and 10 in a wild-type mouse is too vast to amplify. 
Therefore, only BALB/c wild-type mice would contain the 600bp wild-type fragment and 
the 471bp knockout allele would only be present in DNA from mIL-4R-/- mice 
(Fig.2.14.D). 
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Figure 2.14 Genotyping of generated transgenic lines. 
 
Four separate PCRs were used to identify pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg/ IL-4R-/- 
BALB/c. In all panels; 1.2% (w/v) agarose gel in 1 × TAE containing ethidium bromide and 
visualized using short wavelength UV transillumination. A negative (H2O), no DNA control was 
included where no DNA template was added to the reaction mixture. The second negative control 
(-) uses DNA extracted from a BALB/c wild-type mouse. Positive (+) controls using previously 
identified templates positively amplified with the reaction primer set. Panel A, Lanes 1-6, 
amplification products using glob F and R on DNA extracted from  6 pBi-IL-4RTg / IL-4R-/- 
BALB/c / pVav-tTaTg/ IL-4R-/- BALB/c littermates. The 193bp fragment indicates the presence of 
the transgene in lanes 3-6. Panel B, Products using tTa R and F on the same samples as in A. 
The 401bp fragment in lanes 1-6 indicates the presence of the transgene.  
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Figure 2.14 Genotyping of generated transgenic lines. 
 
Four separate PCRs were used to identify pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg/ IL-
4R-/- BALB/c. In all panels; 1.2% (w/v) agarose gel in 1 × TAE containing ethidium bromide 
and visualized using short wavelength UV transillumination. A negative (H2O), no DNA control 
was included where no DNA template was added to the reaction mixture. The second 
negative control (-) uses DNA extracted from a BALB/c wild-type mouse. Positive (+) controls 
using previously identified templates positively amplified with the reaction primer set. Panel 
C, Amplification for the BALB/c wild-type allele, the 600bp fragment is only present in the Wt 
control sample. Panel D, The reaction products from the knock out amplification where the 471bp 
fragment in lanes 1-6 and the KO control indicates the IL-4R-/- genotype.  
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2.3.2.5  Analysis of pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg/ IL-4R-/-  
  BALB/c.  
  
Following the breeding and establishment of the final pBi-IL-4RTg / pVav-tTaTg / IL-
4R-/- BALB/c double transgenic line, the in vivo functionality of the transgenes and the 
Tet system was established. Analysis on a transcriptional and translational level was 
performed to show IL-4R reconstitution confined to hemopoeitic cells.  
 
2.3.2.5.1 Transcriptional analysis. 
 
To assess the transcriptional activity of the incorporated transgenes, namely the murine 
IL-4R (from pBi-IL-4RTg) and the tTA transactivator (from pVav-tTaTg), quantitative 
real time-PCR was performed. In addition to transcriptional levels, this analysis confirmed 
the bi-directional promoter activity via analysis of the luciferase rep rter expression. The 
choice of experimental groups was based on the positive genotyping results, which 
verified transgene presence and the IL-4R-/- BALB/c background. Groups analyzed 
included; the single transgenic lines, namely pVav-tTaTg/ IL-4R-/- BALB/c and pBi-IL-
4RTg / IL-4R-/- BALB/c and three of the pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg 
/ IL-4R-/- BALB/c lines which had been generated from three different pBi-IL-4RTg / 
IL-4R-/- BALB/c founder lines.  
tTA transactivator transcription (Figure 2.16, Panel A) was present in all three lines at 
varying degrees, although the founder line D showed a level below that of the single 
transgenic line (pVav-tTaTg/ IL-4R-/- BALB/c only). As expected, the luciferase mRNA 
was present in all lines (Panel B), the transcription profile reflected that shown by the 
tTA transcripts, with founder line B showing decreased levels when compared to lines D 
and C. pBi-IL-4RTg transcripts (Fig.2.16.C) were present in all three pBi-IL-4RTg / IL-
4R-/- BALB/c / pVav-tTaTg/ IL-4R-/- BALB/c lines, with the line derived from pBi-IL-
4RTg-B displaying the highest level of transcription, as it had with tTA and luciferase. 
These results lead to subsequent analysis being confined to the pBi-IL-4RTg / IL-4R-/- 
BALB/c / pVav-tTaTg / IL-4R-/- BALB/c line derived from pBi-IL-4RTg-B.  
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 2 
 78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Transgene mRNA levels in pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg/ 
IL-4R-/- BALB/c line. 
 
cDNA was synthesised from mRNA extracted from the splenocytes. Different transgenic lines are 
indicated. Panel A, Transactivator tTa transcription.  Levels of tTa mRNA relative to mRNA levels 
of a housekeeping gene (actin) were determined by real-time PCR. Panel B, Levels of luciferase 
mRNA relative to mRNA levels of actin. The results represent 1 of 3 independent experiments and 
show the average ± SEM of triplicate values. 
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Figure 2.16 Transgene mRNA levels in pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg/ 
IL-4R-/- BALB/c line. 
 
Different transgenic lines are indicated. Panel C, mRNA transcription, driven by the bi-directional 
promoter. mRNA levels for IL-4R, relative to mRNA levels of the housekeeping gene actin. The 
results represent 1 of 3 independent experiments and show the average ± SEM of triplicate 
values. 3-4 mice / group were used per experiment. 
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2.3.2.5.2 Translational analysis. 
  
Subsequently transgene functionality was investigated on the translational level. The 
level of IL-4R expression was assessed in hemapoeitic cells only, in this way the 
inducibility of the bi-directional promoter and functioning of the cell specific Vav 
promoter was verified. 
Following genotyping results which confirmed transgene presence or absence and IL-
4R-/- BALB/c background, the IL-4R cell surface expression was analyzed with FACS. 
For the experimental control (Figure 3.17, Panel A) the following groups were analyzed; 
IL-4R, BALB/c, pBi-IL-4RTg / IL-4R-/- BALB/c and pVav-tTaTg / IL-4R-/- BALB/c. 
As expected, only the cells from BALB/c mice showed a positive shift in fluorescence 
indicative of IL-4Rexpression. There was a clear difference in the IL-4Rsurface 
staining, on hemapoeitic cells, for the male and female pBi-IL-4RTg / IL-4R-/- BALB/c / 
pVav-tTaTg / IL-4R-/- BALB/c mice from the B transgenic line (Fig.2.17.B). Both showed 
increased expression when compared to IL-4R mice yet, the male had an improved 
level to that shown by the female cells. This difference in expression was further verified 
by the chemiluminscent luciferase assay where the luciferase expression in the male 
mouse vastly exceeded that in the female mouse (Fig.2.17.C).  
This difference could be attributed to the fact that the pBI-IL-4RTg is an X 
chromosome-linked transgene or possible even variability in transgene expression. 
Further analysis of the pBi-IL-4RTg / IL-4R-/- BALB/c / pVav-tTaTg / IL-4R-/- BALB/c 
mice is needed to address the differences in transcription and translation shown between 
the different lines and sexes. 
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Figure 2.17 pBi-IL-4RTg /pVav-tTa Tg translational analysis. 
 
The IL-4R cell surface expression was analyzed using four colour FACS analysis FACS was 
preformed on cell suspensions obtained splenocytes. The groups analyzed are indicated. Cells 
were gated for the hemapoeitic marker and viable cells were isolated by incubation with 7-AAD, a 
marker for non-viable cells. Panel A and B, Histograms indicating the shift in fluorescence due to 
positive murine IL-4R surface expression. Histograms are representative of populations gated for 
viable hemapoeitic cells. Panel A, The control FACS using the groups indicated. IL-4R expression 
shown in the BALB/c group only.  
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Figure 2.17 pBi-IL-4RTg /pVav-tTa Tg translational analysis. 
 
Panel A and B, Histograms indicating the shift in fluorescence due to positive murine IL-4R 
surface expression. Histograms are representative of populations gated for viable hemapoeitic 
cells. Panel B, The experimental groups indicated. Panel C, Chemiluminscent assay indicating 
luciferase induction levels of the groups indicated. 
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2.4 Chapter Conclusions. 
 
Subsequent to pBi-IL-4R transgenic construct cloning, the clones were successfully 
verified via restriction enzyme screening followed by sequence verification (section 
2.3.2.1, pBi-IL-4R vector map in Appendix A). This was followed by the pilot studies to 
establish the construct and Tet System functionality. These were performed in vitro using 
Hek 293T cells and the results lead to the following conclusions:  
1. The efficient functioning of the Tet system as assessed by the bi-directional 
promoter activity (2.3.2.2.1), via the expression of the reporter luciferase. The 
results of this chemiluminscent luciferase assay confirmed both efficient tTA 
expression and TetO operon binding.   
2. Inducibility of the system shown by the repression of reporter expression over 
time (2.3.2.2.2). These assays also established an effective doxycycline 
concentration for the complete suppression of target gene expression after ~12h 
(Figure 2.7).   
3. Lastly, the pilot studies determined the efficient pTet-Off: pBi-IL-4Rplasmid 
ratio to be used in the generation of stable lines and expression studies using 
transient transfection (2.3.2.2.3). This showed increased luciferase reporter and 
tTa effector expression in cells containing a 10-fold excess of the regulatory 
plasmid, which was in agreement with previous studies.  
The pilot studies, using the reporter expression for most of the assays, lead on to the in 
vitro studies demonstrating inducible repression of the generated pBi-IL-4R transgenic 
construct (section 2.3.2.3).  These confirmed: 
1. Transcription efficiency of mIL-4R transgene (2.3.2.3.1), these results indirectly 
confirmed tTa effector transcription. 
2. Translation efficiency of mIL-4Rtransgene (2.3.2.3.2) and inducible repression 
of mIL-4R expression (2.3.2.3.3).  
Following the in vitro studies which illustrated functionality of the generated pBi-IL-
4Rconstruct, the construct, primers and PCR protocols were sent to Nucleis in France 
where the pBi-IL-4Rchimeras were generated (2.3.2.4.1). After the successfully birth 
and delivery of 7 male chimeras, the extensive and sometimes complicated breeding 
program commenced (2.3.2.4.2). The aim here was firstly to cross the pBi-IL-4RTg 
with the IL-4Rand in this way to generate a line deficient of IL-4R, yet carrying the 
transcriptionally silent pBi-IL-4Rtransgene in all tissues. The next cross was using the 
progeny and breeding these with the pVav-tTa Tg, also on an IL-4Rbackground. In 
this way generating an inducible model where IL-4Rcould only be reconstituted in 
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hemapoeitic cells. After successful genotyping of pBi-IL-4RTg /pVav-tTa Tg IL-
4RBALB/c line (2.3.2.4.3) the in vivo characterisation confirmed functionality of both 
transgenes and thus the Tet system on a transcriptional (2.3.2.5.1) and translational 
level (2.3.2.5.2).  
Although we describe here the successful generation of an inducible and cell specific 
model, it is essential to establish the final line lacking variability in translation before 
studies using this model can commence. 
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Chapter 3: Dendritic Cell Specific Expression of Cre Recombinase. 
 
 
Aim: Cloning and in vitro functional analysis of constructs designed to express Cre 
recombinase and Green Fluorescent Protein (GFP) under the control of the murine 
dendritic cell specific promoter, CD11c.  
 
3.1 Introduction. 
 
Dendritic cells (DCs) consist of a group of antigen presenting cells which function by 
patrolling the tissues of the body, recognising, processing and presenting antigens to T 
cells in the secondary lymphoid tissues (Arpinati et al., 2000; Banchereau et al., 1998). 
Following antigen recognition, immature (naïve) DCs become activated to mature DCs, 
which are characterized by the enhanced expression of MHC II and other co-stimulatory 
molecules. Additionally the secretion of proinflammatory cytokines allows DCs to activate 
naïve and memory T cells, thereby modulating the immune response (Moser and Murphy, 
2000). DCs serve as a vital link between the adaptive and innate immune systems and 
promote both primary and secondary immune responses (Palucka and Banchereau, 
1999). Furthermore, DC functions are required for the homeostatic maintenance of T 
cells and for the development of tolerance to self antigens (Lanzavecchia and Sallusto, 
2004). Important concepts that have emerged from dendritic cell research include 
the following, firstly, that the dendritic cell system comprises of a large collection of 
subpopulations with different functions. This functional diversity is associated to their 
differentiation state as well as their specific location and is a consequence of 
differential interactions with antigens and immune system effector cells (Banchereau 
et al., 2000). Secondly, and more importantly, dendritic cells have emerged as 
promising alternative tools for vaccination and immunotherapy of cancer 
autoimmunity and allergy (Fong and Engelman, 2000; Jonuliet et al., 2001). 
It has been suggested that a candidate cytokine for the enhancement of the 
immunoregulatory capacities of dendritic cells is IL-4 (Morita et al., 2001). Even though 
IL-4R is expressed on the DC cell surface (Fisher et al., 1999), IL-4 was not 
acknowledged as a DC product or seen as important in the maturation of DCs as T cells 
were seen as the main producers of IL-4 during the development of Th2 responses. It 
has been accepted that DCs are generally associated with being IL-12 producers and 
responders. In deed it has been suggested that IL-4 is of minor importance in their 
function (Haas et al., 1999).  
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However, recent studies have shown that immature DC exposure to IL-4 drives DC, to 
become net producers of IL-4 as opposed to IL-12. Thus, IL-4 presence, during the early 
stages of development of DC, could influence the production of cytokines in those cells 
and lead to the production of this Th2-polarizing cytokine in DC (Maroof et al., 2005). A 
recent study also demonstrated IL-4 suppression of type I IFN-induced DC activation and 
their expression of cytokines and antiviral genes via the inhibition of STAT-1 and STAT-2 
phosphorylation. In this way, IL-4 reduced the autocrine loop that is associated with the 
increase in the effects of type I IFNs (Sriram et al., 2007).  
It is thus of great interest to investigate more specifically the interaction and importance 
of IL-4Ron DCs, especially pertaining to Th2 immune response modulation. In order to 
address such questions we describe here the generation of a dendritic cell (DC) specific 
IL-4R deficient mouse model (CD11c-Cre-IL-4Rlox/-). This will be achieved by inter-
crossing newly generated CD11c-CreTg mice with floxed IL-4Rand global IL-4R 
mice (Figure 3.1). In this model, Cre recombinase transgene expression will be directed 
exclusively to DCs due to the incorporation of the appropriate cell specific promoter. Cre 
expression will lead to the inactivation of the lox P flanked IL-4R gene.  
The present study deals with the: 
 1. Molecular cloning and characterisation of eukaryotic expression vectors 
 containing the mouse dendritic cell specific promoter (CD11c). Vectors were 
 designed for optimal expression, directed via CD11c, of the Cre Recombinase and 
 Green Fluorescent Protein (GFP) transgenes. 
 2. In vitro functional analysis of these constructs to show cell specific 
 transcription and translation of the transgenes. 
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Figure 3.1 The generation of the CD11c-IL-4R-/- model. 
 
Panel A, Breeding scheme for the crossing of the newly generated pCD11c-CreTg and the existing 
IL-4R-/- line. Panel B, Inter-crossing of the  CD11c-Cre / IL-4R-/- progeny from A with the IL-
4Rflox/flox- line. Panel C, Progeny of B result in the model. With the genotype of: CD11c-IL-4R-/-
BALB/c. 
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3.2 Methods and Materials. 
 
3.2.1 Cloning of the constructs.  
 
3.2.1.1  Plasmid purification. 
All molecular biological manipulations were performed according to established protocols 
(Ausubel et al., 1995). Chemicals and reagents were Molecular Biology Grade. Small-
scale plasmid purifications were performed using a SV Wizard Plasmid Purification preps 
and a Wizard Maxiprep kit (Promega Corp., Madison, USA) was used for large-scale 
purifications, using protocols supplied with each kit.  
 
3.2.1.2  Primer design.  
Synthetic oligonucleotide primers were supplied by the Oligonucleotide Synthesis Facility, 
Department of Molecular and Cell Biology, University of Cape Town. 
 
3.2.1.3  Modified Cre recombinase primers.  
 
 
 
Table 3.1 Sequences of oligonucleotides used for the amplification of Cre. 
 
 
Name 
 
 
Sequence 
 
Cre reverse 
 
 
 
5’ ATATAT  GCGGCCGCCTA-TGTCCTGATAGCGG ‘3* 
 
 
Cre forward 
 
 
5’ TA  GTCGACCCGCCGCCATGG-CACCCAAGAAGAAG ‘3’# 
 
 
* The sequence corresponding to the Not I restriction site is underlined and the Stop codon is in 
bold. 
 
# The sequence corresponding to the Sal I restriction site is underlined and the modified Kozak 
sequence is in bold.  
 
 
3.2.1.4  Polymerase Chain Reaction (PCR). 
3.2.1.4.1  Amplification of Cre cDNA. 
The amplification of the coding region for the Cre Recombinase cDNA fragment was 
performed by the Polymerase Chain Reaction using 5ng of the pMC-Cre (Gu et al., 1993) 
as template. The reaction was preformed in a 50µl volume containing 1 × SuperTherm 
PCR Buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.125U/μl Supertherm Taq (Medox Biotech 
India Pvt. Ltd. Chennai, India) and 0.5µM of each primer. The following cycling 
parameters were used: an initial denaturation step at 95°C for 1min, followed by 35 
cycles consisting of 95°C incubation for 1min, an annealing step at 58°C for 1min, and an 
extension step at 72°C for 1.5min. A final step of 72°C for 5min was included to 
complete partial extension reactions. 
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3.2.1.5  Restriction and ligation of Cre, GFP and CD11c into a eukaryotic  
  expression vector. 
3.2.1.5.1  Sub-cloning of Cre into the pDrive PCR cloning vector. 
The amplified fragments corresponding to Cre were recovered from a 1% (w/v) low 
melting agarose gel (section 3.1.6) and purified with the Wizard SV Gel Extraction Kit 
(Promega). The procedure was performed according to the manufacturer’s 
recommendations. Approximately 73ng of the purified fragment (in five-fold molar excess 
to 3.85kb vector) was mixed with 50ng of pDrive, 1µl 10 × Ligation Buffer (Promega) 
and 1µl of T4 DNA Ligase (Promega, 3 Weiss Units/µl) in a total volume of 10µl. A 
background control was included where the Cre insert fragment was omitted. The 
ligation reaction was allowed to proceed overnight at 4°C. Following ligation, 5µl of the 
ligation mix was added to 200µl of calcium chloride competent JM109 E.coli cells 
(Invitrogen Corporation, Carlsbad, CA, USA). The suspension was incubated on ice for 
30min after which the cells were heat-shocked, according to the methodology of Inoue 
and co-workers (1990) at 42°C for 45sec. The transformed cells were immediately placed 
on ice (4°C) for 2min and supplemented with 800µl of room temperature SOC medium. 
Cells were incubated with shaking (200rpm) at 37°C for 1h. Following incubation, 50µl of 
the transformed cells were plated onto LB agar plates containing 50µg/ml ampicillin. 
Plates were incubated for 14h at 37°C. Plasmid DNA was isolated (see section 3.1.1) 
from overnight cultures containing 5ml LB medium supplemented with 50µg/ml ampicillin 
and colonies chosen randomly from the incubated plates. Positive constructs for Cre were 
identified by restriction enzyme screening with the restriction enzymes Not I and Sma I 
(Roche Diagnostics GmbH, Mannheim, Germany). The correct fragments were verified by 
electrophoresis on a 0.8% (w/v) agarose gel stained with ethidium bromide (0.5µg/ml) 
as described (section 3.1.5). Plasmids found to contain correct inserts were sequenced 
by automated nucleotide sequencing (DNA Sequencing Unit, Department of Molecular 
and Cell Biology, University of Cape Town) and denoted pDrive-Cre. Glycerol stocks were 
prepared from the E.coli JM109 cells containing the pDrive plasmids with the coding 
regions for Cre recombinase and stored at -70°C. 
 
3.2.1.5.2  Sub-cloning of CD11c into the pGFP-N1 expression vector. 
The 5,5kb DNA fragment containing the regulatory elements of the mouse CD11c 
promoter (Agger et al., 1990) was digested from the pBS-CD11c vector (obtained from 
Prof. Karjalainen). The fragment was digested with 10U Sst I (Roche) at 37°C for 18h. 
The digested fragments were recovered from a 1% (w/v) low melting agarose gel 
(section 3.1.6) and purified with the Wizard SV Gel Extraction Kit (Promega). The purified 
fragment was partially digested with Pst I (Roche) as follows. Six eppendorf tubes were 
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placed and ice, the first tube received double the concentration of purified fragment and 
2U of Pst I. Half of the volume from tube 1 was removed and the aliquot added to tube 2 
from which the serial dilution was continued to tube 6. All 6 tubes were then incubated 
at 37°C for 1h. The pGFP-N1 vector was digested with the same set of enzymes and 
both the Sst I / Pst I digested CD11c fragment and Sst I / Pst I digested pGFP-N1 vector 
were recovered from a 1% (w/v) low melting agarose gel (section 3.1.6) and purified 
with the Wizard SV Gel Extraction Kit (Promega). The procedure was performed 
according to the manufacturer’s recommendations. Approximately 100ng of the purified 
fragment was mixed with 50ng of pGFP-N1, 1µl 10 × Ligation Buffer (Promega) and 1µl 
of T4 DNA Ligase (Promega, 3 Weiss Units/µl) in a total volume of 10µl. A background 
control was included where the CD11c insert fragment was omitted. The ligation reaction 
was allowed to proceed overnight at 4°C. Following ligation, 5µl of the ligation mix was 
added to 200µl of calcium chloride competent DH5 E.coli cells (Invitrogen). The 
suspension was incubated on ice for 30min after which the cells were heat-shocked (as 
described by Inoue and co-workers, 1990) at 42°C for 45sec. The transformed cells were 
immediately placed on ice (4°C) for a further 2min and 800µl of room temperature SOC 
medium was added. Cells were incubated with shaking (200rpm) at 37°C for 1h. 
Following incubation, 50µl of the transformed cells were plated onto LB agar plates 
containing 100µg/ml kanamycin. Plates were incubated for 14h at 37°C. Plasmid DNA 
was isolated (see section 3.1.1) from overnight cultures containing 5ml LB medium 
supplemented with 100µg/ml kanamycin and colonies chosen randomly from the 
incubated plates. Positive constructs for Cre were identified by restriction enzyme 
screening with the restriction enzymes Pst I and Sst I (Roche). The correct fragments 
were verified by electrophoresis on a 0.8% (w/v) agarose gel stained with ethidium 
bromide (0.5µg/ml) as described (section 3.1.5). Plasmids found to contain correct 
inserts were sequenced by automated nucleotide sequencing (DNA Sequencing Unit, 
Department of Molecular and Cell Biology, University of Cape Town) and denoted 
pCD11c-GFP. Glycerol stocks were prepared from the E.coli DH5 cells containing the 
pGFP-N1 plasmids containing the CD11c promoter and stored at -70°C.  
 
3.2.1.5.3  Cloning of the CD11c driven Cre expression vector.  
The Not I and Sal I digestion of pCD11c-GFP separates the GFP fragment from the vector 
sequence when electrophoresed. Thus, the cloning of the Cre insert into the pCD11c-GFP 
is a replacement of GFP open reading frame with that of the Cre cDNA. For this cloning, 
5ug of the pCD11c-GFP and pDrive-Cre constructs were digested separately with a 
restriction enzyme mixture of 6U of Sal I and 6U Not I (Roche). The reaction was 
incubated at 37°C for 6h. The digested products corresponding to Cre insert fragment 
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and the pCD11c-GFP vector were recovered from a 0.7% (w/v) low melting agarose gel 
(section 3.1.6) and purified with the Wizard SV Gel Extraction Kit (Promega), as per 
manufacturer’s recommendations. Approximately 18ng of the purified fragment (in five-
fold molar excess to 8.283kb vector) was mixed with 50ng of digested pCD11c-GFP, 1µl 
10 × Ligation Buffer (Promega) and 1µl of T4 DNA Ligase (Promega, 3 Weiss U/µl) in a 
total volume of 10µl. A background control was included where the Cre insert fragment 
was omitted. The ligation reaction was allowed to proceed overnight at 4°C. Following 
ligation, 5µl of the ligation mix was added to 200µl of calcium chloride competent JM109 
E. coli cells (Invitrogen). The suspension was incubated on ice for 30min after which the 
cells were heat-shocked (Inoue et al., 1990) at 42°C for 45sec. The transformed cells 
were immediately placed on ice (4°C) for a further 2min and 800µl of room temperature 
SOC medium was added. Cells were incubated with shaking (180rpm) at 37°C for 1h. 
Following incubation, 50µl of the transformed cells were plated onto LB agar plates 
containing 100µg/ml kanamycin. Plates were incubated for 14h at 37°C. Plasmid DNA 
was isolated (see section 3.1.1) from overnight cultures containing 5ml LB medium 
supplemented with 100µg/ml kanamycin and colonies chosen randomly from the 
incubated plates. Positive constructs containing the Cre fragment were identified by 
restriction enzyme screening with the restriction enzymes Not I and Sal I (Roche). The 
correct fragments were verified by electrophoresis on a 0.8% (w/v) agarose gel stained 
with ethidium bromide (0.5µg/ml) as described (section 3.1.5). Plasmids found to contain 
correct inserts were sequenced by automated nucleotide sequencing (DNA Sequencing 
Unit, Department of Molecular and Cell Biology, U.C.T) and denoted pCD11c-Cre. 
Glycerol stocks were prepared from the E.coli JM109 cells containing the pCD11c-GFP 
plasmids with the newly cloned pCD11c-Cre recombinase and stored at -70°C. 
 
3.2.1.6  Agarose gel electrophoresis. 
All DNA samples including PCR products, restriction enzyme (RE) digestion and RE 
screening products, were verified by agarose gel electrophoresis through a 0.8 or 1% 
(w/v) agarose gels (gel percentage was dependant on fragment size) in 1 × TAE 
electrophoresis buffer. Samples were electrophoresed at constant voltage of 150V for 
45min at room temperature. Gels were stained with ethidium bromide (0.5µg/ml). DNA 
was visualised by short wavelength UV transillumination (A254nm). 
 
3.2.1.7  Gel isolation and purification of DNA. 
DNA samples including PCR products and samples from RE digestions of fragments to be 
used in ligation were electrophoresed on a 1% low melting point agarose gel in 1 × TAE 
electrophoresis buffer (containing 0.5µg ethidium bromide/ml) at 90V for 1h. DNA was 
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visualised by brief exposure to low wavelength UV (A320nm). The appropriate bands were 
excised from the gels with a sterile blade. Gel slices were melted by incubation at 65°C in 
heating block and DNA purified using the Wizard SV Gel Extraction kit (Promega), 
according to the manufactures instructions. DNA concentrations were determined from 
the absorbance of samples at A260nm using the conversion factor for double stranded DNA 
(1OD unit = 50µg/ml).  
 
3.2.2 Cell culture. 
 
3.2.2.1  Hek 293T cells. 
The human embryonic kidney 293 cell line (Hek 293T) (obtained from Gordon Brown, 
IIDMM, UCT Medical School) was used for as a control cell line in all transfection and 
expression assays. The cells were cultured in DMEM medium pH7.4, supplemented with 
10% Foetal Calf Serum (Gibco Life Technologies, Paisely, UK) 10mg/ml streptomycin and 
10U/ml penicillin at 37°C and 5% CO2. Cells were passaged when cell monolayer 
reached ~70% confluence. To split cells to a 1:10 ratio the media was aspirated from the 
cells and cells then washed once with 1 x PBS. The adherent cells were dislodged from 
the tissue culture flasks (Nalge Nunc International, Naperville, IL, USA)  by addition of 
Trypsin-EDTA solution (0.53mM EDTA, 0.05% trypsin) (Gibco) and incubation for 1min at 
room temperature. After gentle tapping of the flask the suspension was diluted in DMEM 
supplemented with 10% FCS to inactivate the trypsin. Cell suspension was pelleted at 1 
200rpm for 8min and the supernatant carefully aspirated. Cells were then resuspended in 
DMEM supplemented with 10% FCS and transferred to the appropriate size tissue culture 
flask.  
 
3.2.2.2  Tra sfection of Hek 293T cells.  
Hek 293T cells were transfected using Lipofectamine Transfection Reagent (Invitrogen 
Corporation, Carlsbad, CA, USA).which employs a lipid-mediated (Felgner and Ringold, 
1989) method, with optimization of the manufactures instructions. Briefly, to achieve a 
cell monolayer of ~70% confluence the cells were plated at 2x105cell/well in a 6 well 
tissue culture plate (Nalge Nunc International) and incubated at 37°C in a humidified 5% 
CO2 for 18-24h. Subsequently, two tubes with 0.75ml DMEM media/well were prepared. 
1ug isolated plasmid DNA, diluted to a working concentration of 1ug/ml in distilled H2O, 
was added to one tube and 5ul of Lipofectamine Reagent (Invitrogen) to the other. The 
reaction mixtures from the two tubes were combined and incubated at room temperature 
for 20min. The adherent Hek 293T cells were washed twice with 3ml/well serum-free 
DMEM media. The 1.5ml reaction mixture was then carefully plated onto the cells. The 
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cells were incubated at 37°C in a humidified 5% CO2 incubator for 24h. Following over 
night incubation the serum-free media was aspirated from the cells and cells were re-
incubated after the addition of 3ml DMEM supplemented with 10% Foetal Calf Serum 
(Gibco). Clone selection was achieved by the addition of 300µg/ml Zeocin (Invitrogen) 
and 250µg/ml was used for maintenance. 
 
3.2.2.3  D25/sc dendritic cell line. 
The mouse dendritic cell line, D25/sc (obtained from Ulrich Schaible, Germany. Winzler et 
al., 1997) was used to assess the CD11c driven expression. The cells were cultured in 
RPMI 1640 supplemented with 10% FCS (Gibco) 10mg/ml streptomycin and 10U/ml 
penicillin at 37°C and 5% CO2. The adherent cells were passaged when cell confluence 
reached ~60%. To split cells to a 1:10 ratio the media was aspirated from the cells and 
cells then washed once with 1 x PBS. The adherent cells were dislodged from the tissue 
culture flasks (Nalge Nunc International) by addition of Trypsin-EDTA solution (Gibco) 
and incubation for 5min at 4°C. After gentle tapping of the flask the suspension was 
diluted in RPMI / 10% FCS to inactivate the trypsin. Cell suspensions were pelleted at 
800rpm for 8min and supernatants removed. Cells were then resuspended in RPMI / 
10% FCS and transferred to the appropriate size tissue culture flask. Unless otherwise 
stated, sub confluent D25/sc cells (cell monolayer at ~60-70% confluence) were used for 
transfection studies.  
 
3.2.2.4  Transfection of D25/sc cells.  
To optimize transfection efficiency two transfection reagents and electroporation was 
tested. The reagents were; the liposome based reagent, Lipofectamine (Invitrogen) and 
the non-liposomal lipid reagent, Effectene (Qiagen, Valencia, CA, U.S.A). The procedures 
for transfection with these reagents were performed according to the manufacturer’s 
recommendations. For electroporation, the cells were dislodged from the flask by 
addition of Trypsin-EDTA solution (Gibco), as described in section 3.2.1.3. After 
centrifugation the cell pellet was resuspended in RPMI / 20% FCS. 20µg of isolated DNA 
was mixed into 5x106 cells in a final volume of 200µl per electroporation cuvette (Gene 
Pulser® Cuvettes, 0.2 cm gap, Biorad). The cuvette was incubated on ice for 10min. The 
chilled cuvette was placed in the electroporation machine and two different sets of 
conditions were tested; firstly 320kV, 125µF, and 260kV, 975µF. After electroporation the 
cuvettes were placed on ice for 10min. 800µl RPMI / 10% FCS was added to the cuvettes 
and the final volume aliquoted into 5 wells of a 24 well tissue culture plate (Nalge Nunc 
International). The cells were incubated at 37°C and 5% CO2 for 24-48h and 
subsequently assayed for expression. 
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3.2.3 In vitro studies.  
 
3.2.3.1  D25/sc Cell line characterisation. 
Media was aspirated from both Hek 293T and D25/sc cells after which the cells were 
washed once with 1 x PBS. The adherent cells were dislodged from the flask by 
incubation for 1min at room temperature with Trypsin-EDTA solution (Gibco). After 
gentle tapping of the flasks the cell suspensions were diluted in DMEM supplemented 
with 10% FCS in order to inactivate the trypsin. This cell suspension was pelleted by 
centrifugation at 1 000rpm for 8min and the supernatant carefully aspirated from the cell 
pellet. Cells were resuspended in 2ml complete DMEM / 10% FCS, 100U/ml penicillin and 
100µg/ml streptomycin (all reagents supplied by Gibco). Aliquots of cells (10µl) were 
diluted in Trypan Blue and counted on a Neubauer haemocytometer to determine 
concentrations of viable cells. For each staining 1x105 cells were blocked for 25min in 
100µl FACS buffer containing 1% heat inactivated rat serum and 4µg/ml 2.4G2 (anti-
FcRII and –III). The cells were washed in 500µl FACS buffer (PBS supplemented with 
0.1% BSA and 0.05% Sodium Azide) and resuspended in 100µl FACS buffer containing 
one of the following antibodies to cell surface markers: MHC class II-FITC and CD11c-PE 
labelled (BD Bioscience, Pharmigen, San Diego, CA). Cells were also stained in parallel 
for the isotype controls for these antibodies: Hamster IgG and Rat IgG2ακ. Staining was 
preformed by cell incubation in the dark for 30min at 4°C after which the cells were 
washed with 500µl FACS buffer and centrifugation at 1,200rpm for 10min. After this final 
wash cells were resuspended in 300µl FACS buffer supplemented with 7-AAD (Sigma, St. 
Louis, USA). Dead cells stained with 7-AAD were excluded from analysis. Stained cell 
acquisition was preformed using a FACSCalibur flow cytometer (BD Biosciences) and data 
analyzed using CellQuest software (Becton-Dickinson, Ferndale, South Africa). 100,000 
cells were acquired for analysis.  
 
3.2.3.2  CMV promoter activity. 
Transfected Hek 293T cells were harvested by dislodging the cells from the tissue culture 
plates with 1 x Trypsin/EDTA Solution (Gibco). The cells were pelleted from this 
suspension by centrifugation at 1,200rpm for 10min. Aliquots of cells (10µl) were diluted 
in Trypan Blue and counted on a Neubauer haemocytometer to determine concentrations 
of viable cells. 5x105cells/ml were pooled for each experimental group and washed in 
500µl FACS buffer by centrifugation at 1,200rpm for 5min. Cell pellets were resuspended 
in 500µl FACS buffer supplemented with 7-AAD (Sigma). Dead cells stained with 7-AAD 
were excluded from analysis. Acquisition was preformed using a FACSCalibur flow 
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cytometer (BD Biosciences) and data analyzed using CellQuest software (Becton-
Dickinson). 100 000 cells were acquired for analysis. 
 
3.2.3.3  Cell specific transcription. 
3.2.3.3.1  Template preparation - RNA isolation.  
Total RNA was extracted from lymph nodes of a Cre Tg BALB/c mouse using TriReagent 
(Molecular Research Company, Cincinnati, USA) as per the manufacture’s instructions. 
The collected nodes were homogenized on ice in 2ml TriReagent for every 100mg of 
tissue. 200μl of chloroform was added for every 1ml of lysate and vortexed thoroughly. 
The samples were incubated at room temperature for 15min and centrifuged at 
13,500rpm for 15min at 4oC. The top aqueous layer was transferred to a new tube and 
an equal volume of 100% isopropanol added and mixed. The RNA was precipitated out 
of solution by incubating overnight at –80oC and subsequent centrifugation at 13,500rpm 
for 30min at 4oC. The RNA pellet was washed twice in 800μl 70% ethanol, air-dried and 
resuspended in 50μl-100μl DEPC-treated water. All purified RNA samples were DNAseI 
treated and stored at -80°C. The quality of the RNA was checked by determining the 
ratio of the absorbance at A260/A280 and by electrophoresis of 1µg RNA on a 1% agarose 
gel that contained 2.2M formaldehyde. The concentration of the RNA was determined by 
measuring the A260. All solutions used for the RNA work, except TRIS-containing buffers, 
were treated with DEPC to destroy any endogenous RNAses. To each solution, DEPC was 
added to a final concentration of 0.1% and gently shaken overnight at 37oC. The 
solutions were then autoclaved for 30min to remove any residual DEPC. For TRIS-
containing buffers, solutions were prepared using DEPC-treated water and an ultra-pure 
TRIS stock designated for RNA work only. 
 
3.2.3.3.2  DNAseI treatment.  
The RNA was DNAse I treated to remove contaminating genomic DNA, proteins, residual 
phenol and salts. 1-10µg of total RNA was incubated with DNAseI cocktail (1 x DNAse1 
buffer (Promega, Madison, WI, USA), 10U/μl DNAse1 (Roche), 1U/μl RNAsin (Promega) 
for 60min at 37oC. The DNAse I treated RNA was purified and concentrated using the 
Qiagen MiniElute RNA cleanup kit (Qiagen) as per the manufacturer’s instructions (see 
Methods and Materials section 3.3.1.2 for detailed protocol). The elimination of 
contaminating genomic DNA was confirmed by RT-PCR using primers that bound to 
genomic DNA. The quality and quantity of the RNA was checked by spectroscopy and 
denaturing gel electrophoresis using standard methods (Sambrook et al., 2001). The 
A260/A280 ratio was measured and an aliquot was run on a 1% agarose gel containing 
2.2M formaldehyde. The RNA was stored at –80oC until used.  
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3.2.3.3.3  cDNA synthesis. 
The genomic DNA free RNA was reverse transcribed into cDNA using the ImProm-II™ 
Reverse Transcription System (Promega) as per the manufacturer’s instructions. Briefly, 
0.5µg of Oligo (dT)15 primer was added to 1-10µg of DNAse I treated RNA in a final 
volume of 20μl. The sample was denaturing at 70oC for 10min and then cooled on ice for 
5min. 20μl of cDNA synthesis cocktail (ImProm-II™ 5 x Reaction Buffer, 4mM MgCl2, 
0.5mM each dNTP, 1U/μl RNAsin, 2.0μl ImProm-II™ Reverse Transcriptase) was added 
and the samples incubated at 25oC for 5min to anneal the primers. cDNA synthesis was 
extended at 45oC for 90min. The reaction was heat deactivated at 75oC for 5min and 
cooled on ice. The samples were divided into aliquots and stored at –20oC.  
 
3.2.3.3.4  cDNA amplification. 
The amplification of the mRNA transcripts was performed by the PCR using 5ng of the 
synthesized cDNA as template. The reaction was preformed in a 25µl volume containing 
1 × SuperTherm PCR Buffer, 2.5mM MgCl2, 0.2mM dNTPs, 0.25U/μl Supertherm Taq 
(Medox Biotech) and 0.5µM of each primer. The following cycling parameters were used: 
an initial denaturation step at 95°C for 1.5min, followed by 30 cycles consisting of 95°C 
incubation for 1min, an annealing step at 62°C for 1min, and an extension step at 72°C 
for 1.5min. A final step of 72°C for 5min was included to complete partial extension 
reactions. 
 
3.2.3.4  Cell specific translation. 
3.2.3.4.1  CD11c driven GFP expression. 
24h Post transfection media was aspirated from the transfected Hek 293T and D25/sc 
cells after which the cells were washed once with 1 x PBS. The adherent cells were 
dislodged from the plates by incubation for 2min at room temperature with Trypsin-EDTA 
solution (Gibco). Plates were tapped gently and cell suspensions diluted in DMEM / 10% 
FCS in order to inactivate the trypsin. This suspension was pelleted at 1 200rpm for 8min 
and the supernatant carefully aspirated from the cell pellet. Cells were resuspended in 
2ml complete DMEM / 10% FCS (Gibco). Aliquots of cells (10µl) were diluted in Trypan 
Blue and counted on a Neubauer haemocytometer to determine concentrations of viable 
cells. The cells were washed in 500µl FACS and resuspended in 300µl FACS buffer 
supplemented with 7-AAD (Sigma). Dead cells stained with 7-AAD were excluded from 
analysis. Acquisition was preformed with a FACSCalibur flow cytometer (BD Biosciences) 
and data analyzed using CellQuest software (Becton-Dickinson). 100 000 cells were 
acquired for analysis.  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 3 
 98
3.2.3.4.2  Immunofluorescence. 
5x104cells transfected cells were grown on sterile slides overnight in DMEM / 10% FCS 
(Gibco) containing 10mg/ml streptomycin and 10U/ml penicillin at 37°C and 5% CO2. 
The media was removed by aspiration and the cells briefly rinsed with 1 x PBS. Cells 
were fixed by incubation with ice-cold methanol:acetone (1:1, v/v) in the dark for 2min. 
The slides were rinsed 3 times with 1 x PBS, each rinsed lasting 5min. The slides were 
blocked by incubation for 20min with 5% (w/v) PBS-BSA (Sigma). The blocking solution 
was aspirated from slides and slides washed with 1 x PBS. The FITC-labeled Cre antibody 
(Sigma) was diluted 1:200 (v/v) in PBS-BSA and a sufficient volume used to cover the 
glass. Cells were incubated for 30min in the dark at room temperature. The antibody 
solution was aspirated off the cells and slides washed three times with 1 x PBS for 5min 
each wash. The APES coated coverslips were mounted with mounting medium. Slides 
were dried and examined using a fluorescence microscope.   
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3.3 Results. 
 
3.3.1   Vector design and construction. 
 
Separate cloning steps were involved in the generation of the transgenic constructs 
where Cre Recombinase and Green Fluorescent protein (GFP) transcription is driven by 
the dendritic cell specific promoter, CD11c (refer to Figure 3.2). The mouse CD11c 
promoter represents the best marker available for mouse DC. The 5.5kb fragment of the 
CD11c 5’ region provides the regulatory elements required to drive expression of 
transgenes specifically in DC and not in other cell types (Brocker et al., 1997 and Metlay 
et al., 1990). The promoter sequence had previously been cloned (Agger et al., 1990) 
into in a pBSbluescript vector as a 5,5 kb fragment containing the 5’ region of the mouse 
CD11c gene (received from K. Karjalainen, Switzerland).  
This vector, pBS-CD11c, was digested with restriction enzymes that would separate the 
promoter sequence from the vector sequence. The isolated CD11c promoter sequence 
was sub-cloned into the pGFP-N1 eukaryotic expression vector (refer to section 3.1.2) 
which served as the vector backbone. The pGFP-N1 expression vector contains a 
fragment from the rabbit -globin gene. This DNA segment provides the cloned 
transgenes with an intron as well as a polyadenylation signal, which has shown to be 
valuable in the efficient export of the transcripts from the nucleus (Minvielle-Sebastia and 
Keller, 1999; Neugebauer, 2002). 
The Cre and GFP transgenes were present as cDNA fragments in the eukaryotic 
expression vectors pMC-Cre and pGFP-N1, respectively. The Cre transgene was PCR 
amplified, sequenced and cloned into a PCR cloning vector (pDrive) subsequent to being 
sub-cloned into the newly generated CD11c vector (section 3.1.1). The GFP transgene 
was present in the pGFP-N1 vector backbone into which the CD11c promoter sequence 
was cloned. The complete cloned CD11c gene transcript was sequence verified using 
nucleotide sequencing in conjunction with primer walking. The detailed cloning 
description of the pCD11c-GFP and pCD11c-Cre expression vectors follow.  
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 3 
 100
Kozak, Nuclear localization 
+ RE site 
Stop Codon + RE 
• PCR Cre cDNA 
 
• Sub-cloning 
 
 
• RE digestion  & 
  Ligation  
B 
pBS-CD11c 
 
  
A 
• RE digestion of CD11c. 
 
 
 
 
 
 
 
 
 
• RE removal of pCMV. 
               
 
pN1-GFP 
 
  
CD11c GFP 
pCD11c-GFP  
• RE: Restriction Enzyme 
• pCMV: CMV promoter 
CD11c Cre 
pCD11c-Cre  
 
 
 
 
 
Figure 3.2 Flow Diagram of pCD11c-GFP and pCD11c-Cre Cloning Strategy. 
 
Panel A, Cloning of pCD11c-GFP by restriction enzyme removal of the CMV promoter and CD11c 
ligation into pGFP-N1, serving as the vector backbone. Panel B, Primer design and PCR of Cre 
recombinase transgene DNA. RE digestion of Cre cDNA and pCD11c-GFP, followed by ligation to 
generate pCD11c-Cre. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 3 
 101
3.3.1.1  Generation of the Cre cDNA fragment. 
 
In order to sub-clone and express Cre recombinase, the corresponding coding region for 
the protein was amplified by PCR using primer pairs that introduce Sal I and Not I 
restriction enzyme sites (refer to Figure 3.2). These restriction enzyme recognition sites 
are absent from the Cre sequence. They were incorporated to allow for the subsequent 
ligation into the CD11c directed expression vector, pCD11c-GFP, which having been 
digested with the same enzymes, generates complementary sticky ends for the directed 
ligation. The primer set was designed to amplify the Cre sequence using the eukaryotic 
expression vector pMC-Cre as PCR template. This eukaryotic expression vector contains a 
nuclear localization signal in the first 27 bases of the Cre sequence (Kalderon et al., 
1984). The nuclear localization signal targets the expressed protein to the cell nucleus 
through the Nuclear Pore Complex, directing the newly synthesized protein into the 
nucleus via its recognition by cytosolic nuclear transport receptors (Kozak, 1984). In 
order to improve translation, via an optimized transcription start site, the Kozak 
consensus sequence was incorporated in the forward primer sequence. The sequence is 
contiguous with the ATG start codon and greatly increases the efficiency of translation 
and hence overall expression of the product gene (Kozak, 1986). The primers were 
designed to generate this consensus sequence, at the 5’ end of the amplified Cre 
fragment, by the addition of 3 extra bases. A stop codon (TGA) was included in the 
reverse primer sequence, in this way eliminating any additional amino acid expression 
from the template, pMC-Cre vector sequence.  
The amplification produced the desired 1292bp Cre recombinase transgene DNA, and 
both amplification and fragment size was confirmed via gel electrophoresis (Figure 3.3). 
The amplified fragments were gel isolated and subsequently cloned into, pDrive, a PCR 
cloning vector. This type of cloning, namely, T/A cloning takes advantage of the terminal 
transferase activity of Taq DNA polymerases, which adds a single 3’-A overhang to each 
end of the PCR product. The resulting PCR product is then ligated into a linear vector 
with a 3’ terminal 'T' at both ends. The construct was transformed into DH5α E.coli cells, 
and colonies screened by restriction enzyme digestion. The sequences of inserts in 
positive constructs were subsequently verified by automated nucleotide sequencing after 
which the construct was referred to as pDrive-Cre.  
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Figure 3.3 Amplification of Cre cDNA fragment.  
 
1 % (w/v) agarose gel in 1 × TAE containing ethidium bromide and visualized using short 
wavelength UV transillumination. Lane M, DNA molecular weight marker. Lane 2, Amplified 
1292bp Cre DNA fragment. Lane 1, Positive No DNA control 
 
 
3.3.1.2  Cloning of the CD11c fragment. 
 
To obtain dendritic cell specific expression of the Cre recombinase the previously 
characterized CD11c promoter (Agger et al., 1990) fragment was used. The pBS-CD11c 
vector, containing the regulatory elements of the CD11c promoter, was manipulated via 
Sst I restriction enzyme (see Figure 3.4 Panel A & B for vector construction scheme). The 
CD11c promoter sequence has two Pst I restriction enzyme recognition sites. To prevent 
the removal of any promoter sequence a partial digestion was required (Fig.3.5). To 
facilitate this, the former Sst I digestion was followed by a partial Pst I digestion. 
Subsequently, the digested promoter DNA was separated from the vector sequences by 
electrophoresis and extracted from the agarose slices. These Sst I / Pst I digested 
fragments were then ligated into complementary restriction enzyme sticky ends on the 
pGFP-N1 vector. The ligated construct was transformed into JM109 E.coli cells, and 
colonies screened by restriction enzyme digestion. This screening confirmed insert size 
and correct orientation for the in-frame expression of the cloned cDNA. The construct 
was referred to as pCD11c-GFP.  
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Figure 3.4 Vector construction scheme for pCD11c-GFP. 
 
Panel A, Vector maps of pBS-CD11c and pGFP-N1, indicating restriction enzyme sites used in 
cloning pCD11c-GFP. The pGFP-N1 expressi n vector served as backbone for the resulting 
pCD11c-GFP vector. Panel B, The pCD11c-GFP vector which served as backbone for the pCD11c-
Cre expression vector. pCD11c-GFP also served as a control for CD11c driven expression due to 
the GFP element. 
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Figure 3.5 Partial Pst I Restriction Enzyme Digestion of pBS-CD11c. 
 
Panel A, pBS-CD11c vector map showing Pst I and Sst I RE sites and the fragment sizes 
generated by digestion with theses enzymes. Panel B, 0.8 % (w/v) agarose gel in 1 × TAE 
containing ethidium bromide and visualized using short wavelength UV transillumination. Lane M, 
DNA molecular weight marker. Lanes 1 - 6, pBS-CD11c vector digestion with decreasing amounts 
of Pst I enzyme. Units of enzyme per reaction decreased from 2 - 0.0625 U. The 5.5 kb CD11c 
digested promoter fragment isolated from the agarose gel is indicated. 
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3.3.1.3  Generation of the CD11c driven Cre vector.  
 
With the aim of the molecular cloning and subsequent cell specific expression, of Cre 
recombinase, the corresponding cDNA coding sequence for the protein was digested with 
Sal I / Not I from the pDrive-Cre cloning vector. The pCD11c-GFP expression vector was 
digested with the same set of enzymes (Figure 3.6, Panel A). Following digestion, the 
GFP transgene DNA was separated from the vector sequences by electrophoresis, in this 
way removing this transgene from the final construct. The digested fragments were 
isolated from a low melting agarose gel and subsequently ligated (Fig.3.6.B). The ligated 
construct was transformed into JM109 E.coli cells. To verify the presence of the Cre 
transgene insert, plasmid DNA isolated from the resulting colonies, were screened by Sal 
I / Not I restriction enzyme digestion (Fig.3.6.C). With this screening, both insert size 
and correct orientation was confirmed via agarose gel electrophoresis. The construct was 
referred to as pCD11c-Cre and pCD11c-GFP.  
 
3.3.1.4   pCD11c-Cre vector sequence analysis. 
 
The automated sequence analysis was employed to sequence verify the cloned CD11c 
expression vectors, pCD11c-Cre and pCD11-GFP. Due to the 5.5 kb CD11c promoter size, 
primer walking was used to sequence the entire promoter from 5’ to 3’ end. With this 
sequence data theoretical vector maps were constructed and possible restriction sites 
identified. To confirm the sequencing data restriction enzyme screening was preformed 
using enzymes based on these maps. Figure 3.7 illustrates this for the pCD11-Cre vector. 
Panel A shows the theoretical vector map, with enzyme positions, that was constructed 
in DNAssist with the sequence data. The program allows the displayed sequence files to 
be edited and analyzed. Subsequently the vector was digested with the indicated 
enzymes. The products of these RE digestion reactions were analyzed via agarose gel 
electrophoresis (Panel B). The expected fragment sizes, as predicted by the sequence 
data and constructed maps, were observed. These assays established the cloned vector 
sequence. 
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Figure 3.6. Cloning of CD11c driven expression vectors.  
 
Panel A, Vector maps of vectors used for sub-cloning pCD11c-Cre. RE sites and fragment sizes 
generated by digestion are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Cloning of CD11c driven expression vectors.  
 
Panel B & C both display 0.8 % (w/v) agarose gel in 1 × TAE containing ethidium bromide and 
visualized using short wavelength UV transillumination. For both Panel B & C, Lane M, DNA 
molecular weight marker. Panel B, Vector digestion followed by separation and isolation from 
agarose gel. Fragments isolated are indicated. Lane 1, 765 bp Not I / Sal I digested GFP fragment 
separated from pCD11c-GFP backbone vector. Lane 2, 1492 bp Not I / Sal I digested Cre 
fragment from the digestion of pDrive-Cre. Panel C, Restriction enzyme screening of cloned 
pCD11c-Cre and pCD11c-GFP. Lane 1, 765 bp GFP fragment from the digestion of pCD11c-GFP 
with Not I and Sal I. Lane 2, 1492 bp Cre fragment from the digestion of pCD11c-Cre with Not I 
and Sal I. 
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Figure 3.7 Sequence Verification of pCD11c-Cre.  
 
Panel A, Theoretical vector map, based on sequence data, indicating possible enzyme sites. The 
inset lists these enzymes with the expected fragment sizes generated after digestion of the 
pCD11c-Cre. Panel B, 0.8 % (w/v) agarose gel in 1 × TAE containing ethidium bromide and 
visualized using short wavelength UV transillumination. Lane M, DNA molecular weight marker. 
Lane 1, 2500 bp fragment generated by Bam HI digestion. Lane 2, 1100 and 2500 bp fragments 
from Hind III digestion. Lane 3, 2500 and 4000 bp fragments generated after digestion with Bam 
HI / Hind III. 
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3.3.2. Preliminary in vitro expression studies.  
 
3.2.2.1  Influence of CMV promoter. 
 
The CMV (Human Cytomegalovirus Immediate-Early) promoter drives GFP expression in 
the pGFP-N1 eukaryotic expression vector. This promoter has previously been shown to 
be constitutively active in multiple cell types (Schmidt et al., 1990; Fitzsimons et al., 
2002) and is routinely used in vector construction and expression studies. As illustrated 
(Figure 3.6), pGFP-N1 served as the vector backbone for the CD11c expression 
constructs. As a component of the pGFP-N1 vector, the CMV promoter sequence was still 
present in the cloned pCD11c-GFP and pCD11c-Cre expression vectors (Figure 3.6). The 
cloned CD11c promoter has an approximate size of 5500bp. This could prevent any read 
through from the CMV promoter thus eliminating CMV influence on the CD11c driven Cre 
and GFP transgene expression. To validate that the CMV promoter was transcriptionally 
inactive, the expression of GFP was characterized in Hek 293T cells using three different 
GFP expression vectors: 
 Firstly, pGFP-N1 was used as the positive control for CMV driven GFP transcription. 
 Secondly, the cloned pCD11c-GFP vector, with the CMV promoter preceding the CD11c 
sequence, namely pCMVCD11c-GFP. The level of GFP expression in the Hek 293T cells 
transfected with this vector would indicate if the CMV promoter is still active in this 
construct.  
 Thirdly, a duplicate to the second vector with the exception of the lack of the CMV 
promoter, pCD11c-GFP. It was expected that cells with this vector would be deficient in 
GFP expression, due to the lack of CMV promoter. This result would also indicate cell 
specificity by the CD11c promoter. 
For the constructio  of the pCD11c-GFP vector an additional cloning step was included. 
Briefly, the CMV element was removed from the vector sequence via restriction enzyme 
digestion. The enzymes used were unique to the CMV element only, thus not recognising 
and digesting other sites of the vector backbone or the cloned CD11c promoter 
sequence. Following agarose gel separation and isolation of the CMV and vector 
sequences the vector was re-ligated generating the CD11c expression vector, pCD11c-
GFP. Subsequently, the three expression vectors were transfected into Hek 293T cells 
and GFP expression assessed using FACS analysis. The choice of cell line was based on 
the transcriptional inactivity of the dendritic cell promoter, CD11c, in Hek 293T cells 
(section 3.2.3.1). Thus, the observed GFP expression was exclusively a function of the 
CMV promoter activity. A significant decrease in the GFP expression was observed with 
the FACS analysis of the Hek 293T cells transfected with the CD11c expression vectors 
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lacking the CMV promoter (Figure 3.8). The FACS dot plot quadrant percentages, for the 
upper light quadrant represent the viable cells expressing GFP. As shown, this 
percentage declined from 42.46% for control pGFP-N1 vector to 23.32% in the 
pCMVCD11c-GFP. Lastly, of the viable cells transfected with pCD11c-GFP, only 5.19% 
expressed the GF protein. These results indicated the strength of the CMV promoter and 
that it still had an influence on transgene transcription when present in the vectors 
containing the 5,5 kb CD11c promoter. Therefore, it would be transcriptionally active in 
dendritic cells leading to false positive CD11c driven expression results. These results 
lead to the exclusive use of the pCD11-GFP and pCD11c-Cre vectors, lacking the CMV 
promoter, for all subsequent in vitro functional assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Effect of CMV promoter presence on GFP expression in CD11c vectors.  
 
FACS analysis of GFP fluorescence from Hek 293T cells transfected with 3 vectors carrying 
different promoter elements. 24h post transfection cells were harvested and incubated with 7AAD. 
Dot plots representing 1 of 4 independent experiments. The upper left quadrant percentage 
indicates the viable GFP expressing cells.
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3.3.3 Characterisation and Transfection of the D25/sc Cell Line. 
 
3.3.3.1  Cell line characterisation. 
 
To asses the in vitro functionality of the CD11c driven expression vectors the dendritic 
cell line, D25/sc (Gift from Ulrich Schaible, Germany. Winzler et al., 1997) was used. 
Prior to the expression studies the cell line was characterised to confirm the dendritic cell 
phenotype. Cell phenotype characterisation was based on the surface expression of MHC 
II and CD11c. Both MHC II and CD11c are established markers for dendritic cell 
populations (Lui et al., 2001). In this, and subsequent expression studies, the Hek 293T 
cell line was used as control. Using this cell line, transfected with the control pCD11c-GFP 
vector, generated a tool for determining transfection efficiency, promoter activity and cell 
type specific expression via the CD11c.  
The D25/sc cell surface expression was analyzed using FACS analysis (Figure 3.9). The 
choice of antibody was based on specificity to the CD11c and MHC II markers present on 
the cell. Isotype controls for these antibodies were employed to ensure antibody 
specificity and additionally functioned as negative controls for the staining. The stained 
D25/sc cells, showed a positive shift in CD11c surface expression when compared to the 
controls, namely, unstained cells and antibody isotype staining (Fig.3.9.A). In comparison 
no CD11c expression was observed on the Hek 293T cells, indicated by the lack of 
fluorescent shift between the stained and unstained cells. Both cell lines stained 
positively for the MHC II marker (Fig.3.9.B). This data established the D25/sc cell 
phenotype as being similar to primary dendritic cells via the positive staining for CD11c 
and MHC II surface markers. Additionally, Hek 293T cell could be used as a control for 
assessing cell specific expression via the CD11c promoter.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Chapter 3 
 111
 
 
 
 
 
 
Figure 3.9. D25/sc Cell Phenotype Characterisation 
 
5x105 cells from Hek 293T and D25/sc cell lines were stained with labelled antibodies. 
Subsequently, 4 colour FACS analyses were employed to identify surface markers present on the 
two cell lines. To isolate the viable cells, the cells were incubated with 7-AAD which is a marker for 
non-viable cells, these cells were excluded from analysis. Panel A and B, Histograms indicating 
the shift in fluorescence in due to positive CD11c and MHC II surface expression. Panel A, D25/sc 
and Hek 293 T cells stained for CD11c expression. Panel B, D25/sc and Hek 293 T cells stained 
for MHC II. Lines representing differently stained cells are indicated in the legend. Histograms are 
representative of populations gated for viable cells. Results shown are for 1 of 3 independent 
experiments. 
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3.3.3.2  D25/sc Transfection.  
 
The expression studies were initiated with the establishment of a transfection method for 
the D25/sc cells. Primary dendritic cells display low transfection efficiency and to avoid 
any efficiency problems three different transfection methods were tested. These were:  
1) The liposome based reagent, Lipofectamine. The general principle behind this method 
is the use of a liposome formulation that interacts spontaneously with DNA to form lipid-
DNA complexes with complete DNA condensation. These liposomes fuse with cell 
membranes mediating efficient uptake and subsequent expression of the DNA.  
2) The non-liposomal lipid reagent, Effectene. The reagent is used in conjunction with a 
special DNA-condensing enhancer and optimized buffer. The enhancer first condenses 
the DNA molecules and Effectene Reagent subsequently coats them with cationic lipids. 
These coated particles then transfer the DNA into the cells.  
3) Lastly, electroporation, employing two different sets of parameters. The parameters 
were voltage (V) and resistance (). The two combinations were high voltage, 320kV, 
and low resistance, 125µF, and low voltage, 260kV, high resistance, 975µF. 
GFP expression was used to determine the transfection efficiency by each method. In all 
methods the cells were transfected with the pGFP-N1 control vector. 24h post 
transfection UV fluorescence was quantified with FACS analysis. Figure 3.10 illustrates 
the transfection efficiency by each method as a function of the viable UV positive cells. 
The highest level of transfection efficiency was observed for both the electroporation 
experiments. The percentage viable cells showing GFP expression was at ~10% and 
~5% for the two respective experiments. This was unexpected since the cell death using 
this mechanical technique was very high at ~40%. The transfection reagents showed 
low, ~2% for cells transfected with Lipofectamine, or no (immeasurable) for the 
Effectene transfected cells, UV positive cells after 24h. These results lead to 
electroporation being employed for transfection of the D25/sc cell line. 
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Figure 3.10. Transfection efficiency of D25/sc cells.  
 
D25/sc cells were grown to the mid-log phase after which the cells were seeded and transfected 
using the different transfection methods indicated in the legend. 24h post transfection viable GFP 
expressing cells were determined and quantified using FACS. Results shown represent 3 
independent experiments.  
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3.3.4 In vitro expression studies. 
 
3.3.4.1  Cell specific transcription. 
 
To assess the cell specific transgene expression from pCD11c-Cre, mRNA expression 
levels were analyzed. Having established that Hek 293T cells do not express CD11c 
(Section 3.2.1, Fig. 3.9) these cells, transfected with the pCD11c-Cre construct, were 
used as a positive control for CD11c cell specific driven transcription. D25/sc cells were 
electroporated with the construct and for both cell types untransfected cell controls were 
included. Cells were harvested 24h post transfection and cellular RNA isolated. Following 
cDNA synthesis transgene mRNA transcription levels were assayed with real-time PCR. 
Nested PCR primers which were specific for the Cre transcript were used.  
Analysis of the RT-PCR (Figure 3.11) showed no transcription of the Cre transgene in the 
transfected Hek 293T cells. This was based on the lack of amplification product using the 
Cre specific primers. In contrast, the expected 243bp fragment was observed in the 
pCD11c-Cre transfected D25/sc cells, indicating that these cells were transcribing 
transgenic Cre mRNA. Additionally, this mRNA transcri tion was shown to be dendritic 
cell specific.  
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Figure 3.11. Dendritic cell specific transcription of Cre Recombinase. 
 
RT-PCR of cDNA synthesized from pCD11c-Cre transfected and untransfected Hek 293T and 
D25/sc cells. Amplification products electrophoresised in 1.2 % (w/v) agarose gel in 1 × TAE 
containing ethidium bromide and visualized using short wavelength UV transillumination. In both 
figures: Lane M, DNA molecular marker. Lane 1, No DNA negative control. Lane 2, Positive 
control using cDNA synthesized from spleen cells isolated from a Cre transgenic mouse. Lane 3, 
Amplification products using cDNA from untransfected cells. Lane 4, Amplification products using 
cDNA from pCD11c-Cre transfected cells. The 243bp Cre product is indicated in the agarose figure 
labeled as D25/sc  
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3.3.4.2  Cell specific translation.  
 
To further characterise the cell specific transgene expression from the pCD11c-Cre and 
pCD11c-GFP constructs, protein expression levels were analyzed. Transgene translation 
was determined using FACS analysis and immunohistological staining of the transfected 
cells.  
For the FACS analysis the pCD11c-GFP construct and control pGFP-N1 vector were used 
and translation determined as a function of the GFP transgene expression. As with the 
transcription studies, transfected Hek 293T cells were used as a positive control for 
CD11c cell specific driven expression. pGFP-N1 was used as control of GFP expression via 
the CMV promoter. Both the D25/sc cells and Hek 293T cells were transfected with 
pCD11c-GFP and pGFP-N1. Cells were incubated with 7-AAD to isolate the viable cell 
populations. Untransfected cell controls, for both cell types, were also incubated with this 
fluorescent dye and functioned as the negative control for GFP expression. Hek 293T 
cells transfected with pGFP-N1, showed increased expression of GFP when compared to 
the untransfected cell control (Figure 3.12, Panel A). In contrast, the expression levels 
obtained for the pCD11c-GFP transfected Hek 293T cells were similar to the 
untransfected cell control. This observed lack of GFP expression via the CD11c promoter, 
in the Hek 293 T cells, indicated cell specificity of the CD11c promoter. This was 
confirmed in Panel B, where GFP expression was at comparatively the same levels for the 
pCD11c-GFP and pGFP-N1 transfected D25/sc cells. These expression levels were 
additionally reflected in the UV fluorescent images captured for the D25/sc cells 
transfected with pCD11c-GFP and pGFP-N1 constructs (Panel C).  
Subsequently, protein expression was also analyzed with immunohistological staining of 
pCD11c-Cre transfected D25/sc cells. Transfected and untransfected cellular preparations 
were incubated with a FITC-labelled antibody recognising the expressed Cre protein. The 
immunohistological analysis of the cell preparations is shown in Figure 3.13. It was 
observed, Panel B, that staining by the antibody recognising Cre recombinase was 
confined to the transfected cells only. This result suggests that the expression of the Cre 
transgene, driven by the CD11c promoter, is restricted to the transfected cells, thus 
confirming the RT-PCR and FACS data. 
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Figure 3.12. Dendritic cell specific CD11c driven transgene expression.  
 
Panel A and B; Histograms indicating the shift in UV fluorescence in due to GFP expression. Panel A, Hek 293 T cells and Panel B, D25/sc cells. 24h Post 
transfection, Hek 293T and D25/sc cells were harvested and incubated with 7AAD. Cells were then assessed for GFP expression driven by the CD11c or CMV 
promoters of the pCD11c-GFP and pGFP-N1 expression vectors, respectively. Lines representing untransfected and transfected cells are indicated in the 
legend. Histograms are representative of populations gated for viable cells. Results sown are for 1 of 3 independent experiments. Panel C, UV fluorescent 
images of pGFP-N1 and pCD11c-GFP transfected D25/sc cells. 24h Post transfection D25/sc cells were harvested and equal amounts seeded on histological 
slides. Cells were air-dried overnight and images observed under 20 X magnification 
D25/sc
 pGFP-N1                                pCD11c-GFP 
red: cell only 
blue: CD11c promoter 
green: CMV promoter
UV fluorescence
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Figure 3.13. Dendritic cell specific CD11c driven Cre expression.  
 
Panel A & B, UV fluorescent images of the staining of D25/sc cells with the FITC labelled anti-Cre. Panel A, Negative control, showing untransfected cells 
which were stained in parallel to transfected cells. Panel B, Stained pCD11c-Cre transfected cells. Magnification is indicated.  
D25/sc
A 
D25/sc20X 
B 
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D25/sc cell control
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3.4 Chapter Conclusions. 
 
Following the multistep expression vector cloning strategy the pCD11c-Cre and pCD11c-
GFP constructs were successfully characterised via RE screening and automated 
nucleotide sequencing, including primer walking owing to the size of the CD11c promoter 
(section 3.3.1).  
The subsequent pilot studies included D25/sc phenotype characterisation and 
establishment of an efficient transfection method for this cell line (3.3.3.1. and 3.3.3.2). 
Data on DC cell lines is scarce and having received the line without any protocols 
pertaining to culture or transfection these were established preceding any functionality 
assays. Fortunately the cells stained for the surface markers present on immature 
dendritic cells (CD11c and MHC II) and with the increased transfection efficiency 
employing an optimised electroporation protocol, as opposed to reagents, the in vitro 
functionality of the CD11c promoter and the Cre recombinase and GFP transgenes could 
be assessed.  
The CD11c driven Cre and GFP expressing vectors were transfected into both the Hek 
293T, which served as a control cell line, and into the D25/sc cell lines. Utilising the GFP 
reporter function the CD11c promoter activity in D25/sc cells had previously been 
established in the pilot studies (3.3.2), where cells transfected with the pCD11c-GFP 
construct were used. With the mRNA transcripts isolated from these cells it was possible 
to investigate Cre recombinase transgene transcription, and as expected Cre specific 
cDNA was present only in the D25/sc cells but not in the transfected Hek 293T cells 
(3.3.4.1). Translational activity of the GFP and Cre transgenes was confirmed via FACS 
analysis which was positive for GFP expression and by staining of the transfected cells 
with an antibody against Cre. As with the transcriptional and FACS data the antibody only 
stained in the D25/sc cells transfected with the pCD11-Cre construct (3.3.4.2) 
In conclusion, we have successfully generated 2 functional transgenic constructs: the 
pCD11c-GFP that could potentially be utilised as a reporter for the CD11c activity in 
generated transgenic models and the pCD11c-Cre construct that after generation of the   
transgenic mouse and breeding into the IL-4Rflox/flox line will lead to the DC specific 
disruption of IL-4Rexpression. 
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Chapter 4: Generation of molecular tools for the neutralization of  
   signalling via IL-4R and IL-13R2. 
 
Aim: Cloning and in vitro functional analysis of expression vectors for Fc-tagged 
 IL-4R and IL-13R2 soluble receptors and the IL-4R-IL-2 cytokine trap. 
 
4.1 Introduction. 
 
Host protection against parasites and induction of allergic disease is largely dependant on 
the prominent role played by the related Th2 cytokines IL-4 and IL-13. Both bind to cell 
membrane receptors that contain the IL-4R chain (Chiaramonte et al., 2003; Fallon et 
al., 2000;; Madden et al., 1991; Urban et al., 1998; Wills-Karp et al., 1998). IL-13 and 
IL-4 signalling pathways are illustrated in Figure 1. Cytokine binding leads to the 
activation of a signalling cascade starting with Stat6 and ultimately leading to the cellular 
response (Kaplan et al., 1996). IL-13 and IL-4 do however exert diverse biological effects 
which have partly been contributed to the lack of IL-13 signalling through the type 1 IL-4 
receptor (Chomarat and Banchereau, 1998). Thus far, these IL-4 / IL-13 signalling 
pathways have been shown to be complex and as yet not fully understood (Lin et al., 
1995; Zuwarski et al., 1993).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. IL-13 and IL-4 receptor combinations and binding. 
 
IL-4 binds and interacts with the IL-4R subunit in combination with the Type I IL-4R – c or 
alternately with IL-13R1. IL-13 interacts with IL-13R1 in combination with IL-4R or with IL-
13R2.  
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Cytokine blockers with the potential to inhibit the cytokine – receptor interaction have 
proven to be powerful tools in the pursuit to an enhanced understanding of cytokine 
function during certain disease states. Of these the TNF- blocker (Enbrel) is a prime 
example which has lead to clinical trails in patients suffering from rheumatoid arthritis 
(Goldenberg, 1999). Previously, an IL-13 blocker consisting of the extracellular domain of 
murine IL-13R2 fused to the hinge-CH2-CH3 regions of hIg-1 had been generated 
(Donaldson et al., 1998). This soluble form of the IL-13 binding protein demonstrated 
high affinity binding and specificity for the IL-13 cytokine. Furthermore, it displayed an 
effective IL-13 antagonistic function (Grunig et al., 1998; Urban et al., 1998). Previous 
studies also describe the generation of IL-4 cytokine blockers. Examples of these 
blockers are; recombinant IL-4 soluble proteins, an IL-4 binding antibody (11B11), 
recombinant mutated IL-4 proteins or IL-4/anti-IL-4mAb complexes (IL-4C) (Finkelman 
et al., 1999;Grunewald et al.,1997; Maliszewski et al., 1990). In addition, the use of 
heterodimeric receptor complexes, an example being the human soluble IL-2R- soluble 
IL-4Rcytokine trap has the potential of being even more potent a blocker of cytokine 
function (Economides et al., 2003). It was shown that incorporating both receptor 
components, namely, IL-4R and IL-2R, involved in forming the multi-component IL-4 
receptor system, resulted in more effective IL-4 cytokine binding. 
The soluble IL-13R2Fc fusion protein described in the current study differs from the 
recombinant mentioned previously, in two ways; firstly the RNA used to generate the 
coding region for the extracellular domain of IL-13R2 was isolated from a BALB/c mouse 
strain as opposed to the C3H/HeJ RNA used in the above-mentioned study. For our 
purposes this represented a more relevant genetic background to study IL-4R, as the 
majority of the IL-4Rtransgenic mice available are on a BALB/c background. Secondly, 
the fusion of the extracellular domain is to a mutated form of the human IgG1. It is not 
clear how these differences will be represented in the phenotype, but should be borne in 
mind when comparing binding affinity and antagonistic/agonistic roles. The IL-4 soluble 
receptor blocker described in this report was generated from BALB/c cDNA and fused to 
the human Fc tag, and as with the sIL-13R2Fc blocker it isn’t clear how these differences 
will be represented in the studies. Furthermore, the generation of the sIL-2R-sIL-
4Rcytokine trap the design was based on the molecular design of a previously 
generated IL-4 cytokine trap (Economides et al., 2003). With differences being in the use 
of extracellular domains of BALB/c IL-4R and IL-2R, as opposed to the human IL-4R 
and IL-2R extracellular domains used in the above-mentioned study. 
Finally, we aimed to build on the vast body of knowledge of the previously investigated 
cytokine blockers to generate Fc-tagged soluble receptor blockers for IL-4R, IL-13R2 
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and the IL-2R-IL-4R receptor complex. These Fc-tagged blockers would have the 
ability to block cytokine function in vitro and subsequently in vivo. The design and 
generation of these fusion proteins were although analogous to previous described IL-4 
and IL-13 cytokine blockers an refinement of these. This optimization was in the 
construct design where we specifically used cDNA of a BALB/c genetic background (to 
skew the Th1 / Th2 response), and a mutated human Fc-tag which decreases non-
specific binding by these fusion proteins.   
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4.2 Methods and Materials. 
 
4.2.1 Cloning of the constructs.  
 
4.2.1.1  Plasmid purification. 
All molecular biological manipulations were performed according to established protocols 
(Ausubel et al., 1995). Chemicals and reagents were Molecular Biology Grade. Small-
scale plasmid purifications were performed using a SV Wizard Plasmid Purification preps 
and a Wizard Maxiprep kit (Promega Corp., Madison, USA) was used for large-scale 
purifications, using protocols supplied with each kit.  
 
4.2.1.2  Primer design.  
Synthetic oligonucleotide primers were supplied by the Oligonucleotide Synthesis Facility, 
Department of Molecular and Cell Biology, University of Cape Town. 
 
4.2.1.2.1  The extracellular domains of IL-4R, IL-13R2 and IL-2R. 
 
Table 4.1 Sequences of oligonucleotides used for the amplification of the 
extracellular domains of IL-4R, IL-13 R2 and IL-2R. 
 
Primer name Sequence
IL-4R F 
 
 
5’ AT-GGTACC-CATCAAGGTCCTGG ‘3* 
 
 
sIL-4R R 
 
 
5’ TT-GCGGCCGC-AGGCGCTGTATCAGG ‘3’# 
 
IL-13 R2 F 
 
 
5’ AA-GGTACC-TAACTGGCTATTCTTTGGAG ‘3* 
 
sIL-13 R2 R 
 
 
5’ AA-GCGGCCGC-TTTGAGTCTGGCCCTG ‘3’# 
 
IL-2R F 
 
 
 
5’ GGG-GCGGCCGC-GAAACTATTATTGTCACCTAGATCC ‘3’# 
 
 
IL-2RR 
 
 
5’ GGG-GCGGCCGC-GAAGGATTCTCCTCTACAGTA ‘3’# 
 
 
* The sequence corresponding to the Kpn I restriction site is in bold.   
# The sequence corresponding to the Not I restriction site is underlined.  
 
 
 
 
4.2.1.3  Template preparation for PCR of IL-13R2andIL-2R
  extracellular domains. 
4.2.1.3.1  RNA Isolation. 
Total RNA was extracted from spleen and lymph nodes of BALB/c mice using TriReagent 
(Molecular Research Company, Cincinnati, USA) as per the manufacture’s instructions. 
Organs were homogenized on ice in 2ml TriReagent for every 100mg of tissue. 200μl 
Chloroform was added for every 1ml of lysate and vortexed thoroughly. The samples 
were incubated at room temperature for 15min and centrifuged at 13 500rpm for 15min 
at 4oC. The top aqueous layer was transferred to a new tube and an equal volume of 
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100% isopropanol added and mixed. The RNA was precipitated out of solution by 
overnight incubation at –70oC followed by centrifugation at 13 500rpm for 30min at 4oC. 
The RNA pellet was washed twice in 800μl 70% ethanol, air-dried and resuspended in 
50μl-100μl of DEPC-treated water. All purified RNA samples were DNAseI treated 
(4.1.4.2) and stored at -70°C. RNA quality was determined by measuring the ratio of the 
absorbance at A260nm/A280nm and by electrophoresis of 1µg RNA on a 1% agarose gel 
containing 2.2M formaldehyde. The concentration of the RNA was determined by 
measuring the A260nm. All solutions, except TRIS-containing buffers, used for the RNA 
work were treated with DEPC to destroy any endogenous RNAses. To each solution, 
DEPC was added to a final concentration of 0.1% and gently shaken overnight at 37oC. 
The solutions were then autoclaved for 30min to remove any traces of DEPC. For TRIS-
containing buffers, solutions were prepared using DEPC-treated water and an ultra-pure 
TRIS stock designated for RNA work only. 
 
4.2.1.3.2  DNAseI treatment and removal of digested DNA fragments. 
All isolated RNA preparations were DNAseI treated. 1-10µg of total RNA was incubated 
with DNAseI cocktail (1 x DNAse1 buffer (Promega), 10U/μl DNAse1 (Roche Diagnostics 
GmbH, Mannheim, Germany), 1U/μl RNAsin (Promega) for 60min at 37oC. The DNAseI-
treated RNA was cleaned using the Qiagen MiniElute RNA cleanup kit (Qiagen, Valencia, 
CA, USA) as per the manufacturer’s instructions (see Methods and Materials section 
3.3.1.2 for detailed protocol). This helped remove contaminating genomic DNA, proteins, 
residual phenol and salts. The elimination of contaminating genomic DNA was confirmed 
by RT-PCR using primers that bound to genomic DNA. The quality and quantity of the 
RNA was checked by spectroscopy and denaturing gel electrophoresis using standard 
methods (Sambrook et al., 2001). The A260nm/A280nm ratio was measured and an aliquot 
was run on a 1% agarose gel containing 2.2M formaldehyde. The RNA was stored at –
70oC until used.  
 
4.2.1.3.3  cDNA Synthesis. 
The genomic DNA free RNA was reverse transcribed into cDNA using the ImProm-II™ 
Reverse Transcription System (Promega) as per the manufacturer’s instructions. Briefly, 
0.5µg of Oligo (dT)15 primer was added to 1-10µg of genomic DNA free RNA in a final 
volume of 20μl. The sample was denaturing at 70oC for 10 minutes after which it was 
cooled on ice for 5min. 20μl of cDNA synthesis cocktail (ImProm-II™ 5 x Reaction Buffer, 
4mM MgCl2, 0.5mM each dNTP, 1U/μl RNAsin, 2.0μl ImProm-II™ Reverse Transcriptase 
was added and the samples incubated at 25oC for 5min to anneal the primers. cDNA 
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synthesis was extended at 45oC for 90min. The reaction was heat deactivated at 75oC for 
5min and cooled on ice. The samples were divided into aliquots and stored at –20oC.  
 
4.2.1.4  Polymerase Chain Reaction (PCR). 
4.2.1.4.1  Amplification of extracellular domains of IL-4R, IL-13RandIL-2R. 
The amplification of the coding region of the extracellular domain of IL-4R (sIL-4R) 
was performed by PCR using 10ng of the pM5neo as template. This eukaryotic 
expression vector (obtained from A.Gessner) contains the 2501bp cDNA encoding the 
transmembrane IL-4R (Schulte et al., 1997). The coding regions for the extracellular 
domains of IL-13R2 (sIL-13R2) and IL-2R (sIL-2R) were amplifiedusing 10ng 
synthesized cDNA (section 4.1.4) as template. Reactions were preformed in a 50µl 
volume containing 1 × SuperTherm PCR Buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.125U/μl 
Supertherm Taq (Medox Biotech India Pvt. Ltd. Chennai, India) and 0.5µM of each 
primer. The following cycling parameters were used for all three domains: an initial 
denaturation step at 94°C for 1min, followed by 30 cycles consisting of 94°C incubation 
for 1min, an annealing step at 60°C for 1min, and an extension step at 72°C for 1.5min. 
A final step of 72°C for 5min was included to complete partial extension reactions.  
 
4.2.1.5  Cloning of the coding sequences into eukaryotic expression vectors. 
4.2.1.5.1  Extracellular domains of IL-4R and IL-13R2. 
The amplified fragments corresponding to sIL-4R and sIL-13R2 were recovered from a 
1% (w/v) low melting agarose gel (section 4.1.7) and purified with the Wizard SV Gel 
Extraction Kit (Promega). The procedure was performed according to the manufacturer’s 
recommendations. The isolated fragments were then digested with 10U of the restriction 
enzymes Kpn I and Not I (Roche) for 6h at 37°C. The digested fragments were 
recovered from a 1% (w/v) low melting agarose gel, and purified with the Wizard SV Gel 
Extraction Kit (Promega). The pSecTagFCMut plasmid linearized by Kpn I / Not I cleavage 
was dephosphorylated in a 30µl reaction volume consisting of 1 × Shrimp Alkaline 
Phosphatase (SAP) reaction buffer (Promega), 300ng of the plasmid and 0.3U of SAP. 
The mixture was incubated at 37°C for 15min, and the enzyme inactivated by incubation 
of the reaction at 65°C for 15min. The purified fragment, in five-fold molar excess to the 
vector, was mixed with 50ng dephosphorylated pSecTagFCMut, 1µl 10 × Ligation Buffer 
(Promega) and 1µl of T4 DNA Ligase (Promega, 3 WeissU/µl) in a total volume of 10µl. 
An experimental control (background control) was included where the digested sIL-4R 
or sIL-13R2 insert fragments were omitted. The ligation reaction was allowed to 
proceed overnight at 4°C. Following ligation, 5µl of the ligation mix was added to 200µl 
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of calcium chloride competent DH5α E.coli cells (Invitrogen, Gibco BRL, USA). The 
suspension was incubated on ice for 30min after which the cells were heat-shocked, 
according to established methodology (Inoue et al., 1990) at 42°C for 45sec. The 
transformed cells were immediately placed on ice (4°C) for a further 2min and then 
supplemented with 800µl room temperature SOC medium. Cells were incubated with 
shaking (200rpm) at 37°C for 60min. Following incubation, 100µl of the transformed cells 
were plated onto LB agar plates containing 50µg/ml ampicillin. Plates were incubated for 
14h at 37°C. Plasmid DNA was isolated (see section 4.1.1) from overnight cultures 
containing 10ml LB medium supplemented with 50µg/ml ampicillin and colonies chosen 
randomly from the incubated plates. Positive constructs for sIL-4Rand sIL-13R2 were 
identified by restriction enzyme screening with the restriction enzymes Not I and Kpn I 
(Roche), and verified by a secondary PCR screening with the oligonucleotide primers 
initially used to amplify the respective inserts. The correct fragments from both 
procedures were verified by electrophoresis on a 1% (w/v) agarose gel stained with 
ethidium bromide (0.5µg/ml) (section 4.1.6). Plasmids found to contain correct inserts 
were sequenced by automated nucleotide sequencing, and denoted pSecTag-sIL-4RFc 
and pSecTag-sIL-13R2Fc. Glycerol stocks were prepared of the DH5α E.coli cells 
containing the pSecTagFCMut plasmids with the coding regions for sIL-4R and sIL-13R2 
and stored at -70°C. 
 
4.2.1.5.2  Extracellular domain of IL-2R.
The protocol followed was similar to that for the sIL-4R and sIL-13R2 amplified 
fragments with a few modifications. Briefly, the amplification fragments were isolated 
(4.1.7) and digested with 10U of the restriction enzyme Not I (Roche) for 6h at 37°C. 
The digested fragments were recovered from a 1% (w/v) low melting agarose gel, and 
gel purified. The pSecTag-sIL-4RFc plasmid linearized by a Not I cleavage was 
dephosphorylated using SAP (as described in 4.1.5.1) after which the purified 
amplification fragments, in five-fold molar excess to vector, was mixed with 50ng 
dephosphorylated pSecTag-sIL-4RFc, 1µl 10 × Ligation Buffer (Promega) and 1µl of T4 
DNA Ligase (Promega, 3 WeissU/µl) in a total volume of 10µl. An experimental control 
was included where the digested sIL-2R insert fragment was absent. After overnight 
incubation at 4°C, 7,5µl of the ligation mix was added to 400µl of calcium chloride 
competent JM109 E.coli cells (Invitrogen). The cells were transformed with the ligation 
mix (as described in 4.1.5.1) (Inoue et al., 1990) and following the final incubation step 
in the procedure, 100µl of the transformed cells were plated onto LB agar plates 
containing 50µg/ml ampicillin. Plates were incubated for 16h at 37°C. Plasmid DNA was 
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isolated (see section 4.1.1) from overnight cultures containing 10ml LB medium 
supplemented with 50µg/ml ampicillin and colonies chosen randomly from the plates. 
Positive constructs for sIL-2R were identified by restriction enzyme screening with Eco 
RV / Sca I and Pst I (Roche). The correct fragments were verified by electrophoresis on a 
1% (w/v) agarose gel stained with ethidium bromide (0.5µg/ml) (described in 4.1.6). 
Plasmids found to contain correct inserts were sequenced by automated nucleotide 
sequencing, and denoted sIL-2R-sIL-4RFc. Glycerol stocks were prepared of the JM109 
E.coli cells containing the pSecTagFCMut plasmids with the in-line coding regions for sIL-
4R and sIL-2R and stored at -70°C. 
 
4.2.1.6  Agarose gel electrophoresis. 
All DNA samples including PCR products, restriction enzyme (RE) digestion and RE 
screening products, were verified by agarose gel electrophoresis through a 0.8 or 1% 
(w/v) agarose gels (gel percentage was dependant on fragment size) in 1 × TAE 
electrophoresis buffer. Samples were electrophoresed at constant voltage of 150V for 
45min at room temperature. Gels were stained with ethidium bromide (0.5µg/ml). DNA 
was visualised by short wavelength UV transillumination (A254nm). 
 
4.2.1.7  Gel isolation and purification of DNA. 
DNA samples including PCR products and samples from RE digestions of fragments to be 
used in ligation were electrophoresed on a 1% low melting point agarose gel in 1 × TAE 
electrophoresis buffer (containing 0.5µg ethidium bromide/ml) at 90V for 1h. DNA was 
visualised by brief exposure to low wavelength UV (A320nm). The appropriate bands were 
excised from the gels with a sterile blade. Gel slices were melted by incubation at 65°C in 
heating block and DNA purified using the Wizard SV Gel Extraction kit (Promega), 
according to the manufactures instructions. DNA concentrations were determined from 
the absorbance of samples at A260nm using the conversion factor for double stranded DNA 
(1OD unit = 50µg/ml).  
 
4.2.2 Cell culture. 
 
4.2.2.1  Hek 293T cells. 
The human embryonic kidney 293 cell line (Hek 293T) (obtained from Gordon Brown, 
IIDMM, UCT Medical School) was used for all transfection and expression assays. The 
cells were cultured in DMEM medium pH7.4, supplemented with 10% Foetal Calf Serum  
(FCS)(Gibco Life Technologies, Paisely, UK) 10mg/ml streptomycin and 10U/ml penicillin 
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at 37°C and 5% CO2. Cells were passaged when cell monolayer reached ~70% 
confluence. To split cells to a 1:10 ratio the media was aspirated from the cells and cells 
washed once with 1 x PBS. The adherent cells were dislodged from the flask by addition 
of Trypsin-EDTA solution (Gibco) and incubation for 1min at room temperature. After 
gentle tapping of the flask the suspension was diluted in DMEM supplemented with 10% 
FCS to inactivate the trypsin. This suspension was pelleted at 1 200rpm for 5min and the 
supernatant carefully decanted. Cells were resuspended in DMEM / 10% FCS and 
transferred to the appropriate size tissue culture flask (Nalge Nunc International, 
Naperville, IL, USA). Unless otherwise stated, sub confluent Hek 293T cells (cell 
monolayer at ~70% confluence) were transfected in serum-free conditions using 
Lipofectamine Reagent (Invitrogen).  
 
4.2.2.2  Transfection of Hek 293T cells. 
Hek 293T cells were transfected using Lipofectamine Reagent (Invitrogen) which 
employs a lipid-mediated method (Felgner and Ringold, 1989), with optimization of the 
manufacture’s instructions. Briefly, cells were plated at 2x105cell/well in a 6 well plate 
(Nalge Nunc International) and incubated at 37°C in a humidified 5% CO2 for 24h. The 
next day, two tubes each containing 0.75ml DMEM media was prepared. 1ug isolated 
plasmid DNA, diluted to a working concentration of 1ug/ml in distilled H2O, was added to 
one tube and to the other 5ul of Lipofectamine Transfection Reagent (Invitrogen). The 
reaction mixtures from the two tubes were combined and incubated at room temperature 
for 20min. The adherent Hek 293T cells were washed twice with 3ml/well serum-free 
DMEM media. The 1.5ml reaction mixture was then carefully plated onto the cells. The 
cells were incubated at 37°C in a humidified 5% CO2 incubator for 24h. Subsequently, 
the serum-free media was aspirated and cells re-incubated with 3ml DMEM / 10% FCS 
(Gibco) with selective pressure maintained with the addition of 250µg/ml Zeocin 
(Invitrogen). 
 
4.2.3 Purification and detection of recombinant proteins. 
 
4.2.3.1  Large scale protein expression. 
Large scale protein expression was achieved by increasing the size and number of cell 
culture flasks used for culture. Cultures were prepared from Hek 293T cells containing 
pSecTag-sIL13R2Fc, sIL-4RFc or sIL-2R-sIL-4RFc (as described in section 4.2.1) in 
media supplemented with 250µg/ml Zeocin (Invitrogen). Culture media was collected 
every 72-96h and cells re-incubated with fresh media and antibiotics for a further 72h. 
Collected culture media, containing the secreted recombinant proteins, was filter 
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sterilized through a 0.22μM filter (Millipore Corporation, Bedford, USA). 0.05% Sodium 
Azide was added to filtered media after which it was stored at 4°C. 
 
4.2.3.2  Cell lysate preparation for Hek 293T / pSecTag-sIL13R2Fc cultures. 
Hek 293T cells transfected with sIL13R2Fc were cultured and culture media collected at 
intervals (4.3.1). Adherent cells were rinsed twice with 10ml ice-cold 1 × PBS. 5ml ice-
cold modified RIPA buffer was added to the cells and flasks incubated at 4°C for 10min. 
Cell suspensions from all flasks were pooled and transferred to a sterile 50ml centrifuge 
tube. Centrifuge tubes were left on ice for 15min with gently agitation at intervals. 
Cellular lysates were collected with centrifugation in a JA-14 rotor (Beckman), using a J2-
21 centrifuge (Beckman) at 12 000 × g for 20min at 4°C. Lysates were filter sterilized 
through a 0.22μM filter (Millipore Corporation), supplemented with 0.05% Sodium Azide 
and stored at 4°C until use. 
  
4.2.3.3  IgG Protein purification. 
Protein A Sepharose chromatography was utilised to purify the expressed proteins. All 
material to be used was equilibrated at room temperature, the temperature at which the 
chromatography was preformed. The medium slurry, nProtein A Sepharose 4 Fast Flow 
(Amersham Biosciences) was de-gassed after which the slurry was poured into the 
column.  The settled medium was equilibrated with 10 column volumes of binding buffer 
[50mM Tris·Cl, pH 7.0]. The collected supernatants were centrifuged in a JA-14 rotor 
(Beckman), using a J2-21 centrifuge (Beckman) at 12 000 × g for 20min at 4°C. 
Centrifuged supernatant was diluted with half a volume of binding buffer and applied to 
the column. The supernatant was re-applied and run through the column for an 
additional 3 times. The column was washed with 10 column volumes of binding buffer. 
Fc-tagged soluble receptors were eluted from the column beads with 100mM glycine, pH 
2.5. The eluted protein was collected in sterile tubes containing a 25% final fraction 
volume of 1M Tris·Cl, pH 8.0. Approximately 2 column volumes were collected. The 
columns were washed with 5 column volumes of binding buffer supplemented with 
0.05% Sodium Azide and stored at 4°C. Fractions were measured individually using a 
spectrophotometer at A280nm. Peak fractions were combined. Eluted protein was desalted 
and concentrated by addition of 15ml 1 × PBS and centrifugation at 4000 × g for 20min 
using Amicon Ultra-15 centrifugal filter device (Millipore) as per the manufacture’s 
instructions. 0.05% Sodium Azide was added to the concentrated solute which was then 
stored at 4°C. 
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4.2.3.4  Protein quantification. 
Protein concentrations were determined using a microassay procedure using Pierce BCA 
Protein Assay Reagent according to the manufacture’s protocol (Pierce Chemical 
Company, Rockford, Illinois, USA). Briefly, nine dilutions, prepared in the same diluent 
used for the protein sample, of a BSA standard (Bio-Rad), was used in the linear range 
from 0.2mg/ml to 1.8mg/ml. Sample was diluted in a 3-fold linear range. Duplicates 
of10ul of the sample or the standard were pippetted into a micro plate (Nalge Nunc 
International). The sample diluent was used as a blank control. The BCA working solution 
was prepared by mixing 50 parts solution A to 1 part solution B. 200ul of this working 
solution was added to all wells. The plate was incubated at 37°C for 30min. After 
incubation, the plate was equilibrated at room temperature and the absorbance 
measured at A540nm in a VersaMax microplate reader (Molecular Devices Corporation, 
Sunnyvale, CA, U.S.A). Comparison of the test samples to a standard curve provided the 
protein concentration. 
 
4.2.3.5  SDS-PAGE. 
All proteins were analysed by SDS-PAGE electrophoresis as described by Laemmli (1970). 
Depending on protein size the gels consisted of a 10-15% (w/v) polyacrylamide 
(acrylamide:bisacryamide 29:1) containing 375mM Tris·Cl (pH 8.8) and 0.1% (w/v) SDS. 
The stacking gel consisted of 6% (acrylamide:bisacryamide 29:1) (w/v) polyacrylamide 
containing 125mM Tris·Cl (pH 6.8) and 0.1% (w/v) SDS. Samples were denatured at 
95°C in 1 × sample application buffer containing 25% (v/v) β-mercaptoethanol. Gels 
were electrophoresed at 200V for 1h in a MiniProtean III (Bio-Rad) electrophoresis 
system. Following electrophoresis, gels were stained with Coomassie Blue stain solution 
[0.25% (w/v) Coomassie Brilliant Blue in 100% methanol] for 1h and destained 
overnight in destain solution [7% (v/v) acetic acid, 25% (v/v) ethanol].  
 
4.2.3.6  Western blot analysis. 
Following SDS-PAGE electrophoresis proteins were transferred to a PVDF membrane 
(Amersham-Pharmacia, Tokyo). Prior to transfer all components used in the transfer 
assembly were soaked in ice-cold 1 x transfer buffer for 30min at 4°C. Proteins were 
transferred using tank transfer (Mini Trans-Blot Electrophoretic Transfer Cell, BioRad) 
with the gel/membrane stack completely immersed in the buffer reservoir. Transfer was 
performed at 375mA for 2h. The membrane was removed from the transfer stack and 
washed with distilled water. The membrane was blocked with 1 x TBS (Tris-buffered 
saline) containing 5% nonfat dry milk for 60min at room temperature. In this way 
blocking unoccupied membrane sites and preventing nonspecific binding of antibodies. 
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The primary antibody, IgG-AP (goat anti human, Sigma) was diluted 1/5000 in blocking 
solution containing 0.05% Tween 20 and 3% milk powder and incubated overnight at 
4°C with agitation. Unbound primary antibody was removed by washing the membrane 3 
times for 3-5min each with 1 x TBS 0.05% Tween 20. Chromogenic detection (Leary, et 
al., 1983) was performed by incubating the membrane with a solution of 200µl NBT/BCIP 
substrate (Roche) diluted in 10ml NBT substrate buffer for 2-5min in the dark. 
 
4.2.4 In vitro assays. 
 
4.2.4.1  Cytokine binding assay.  
The level of cytokine binding by sIL-13R2Fc, sIL-4RFc and sIL-2RFc was measured by 
ELISA. Maxisorb 96 well ELISA plates (Nalge Nunc) were coated overnight at 4oC with 
50μl capturing antibody diluted in coating buffer (1 x PBS, 0.02% Sodium Azide) at the 
recommended concentration; 0.002mg/ml for ant-IL-4 and 0.02mg/ml anti-IL-13. Or 
alternatively plates were coated with varying concentrations of purified sIL-13R2Fc, sIL-
4RFc and sIL-2RFc (for sIL-4RFc 0.025mg/ml, 0.012mg/ml, 0.06mg/ml, 0.025mg/ml 
was used; for sIL-13R2Fc 0.2mg/ml, 0.1mg/ml, 0.05mg/ml and 0.02mg/ml was used 
and for sIL-2RFc 0.002mg/ml was used) diluted in coating buffer. Coated plates were 
washed and incubated overnight at 4°C with 200μl blocking buffer. The appropriate 
recombinant protein standard was diluted to the recommended concentration, then 
serially diluted three-fold in dilution buffer and 50μl added to wells of washed plates. The 
plates were incubated overnight at 4oC and washed. 50μl of the appropriate biotinylated 
antibody was diluted to the recommended concentration in dilution buffer and 50μl was 
added to each well. The plates were incubated at 37oC for 3h, washed and 50μl of 
streptavidin-alkaline phosphatase diluted 1:1000 in dilution buffer was added to each 
well. The plates were incubated for 60min at 37oC, washed and 50μl substrate solution 
added to each well. The enzymatic reaction was developed at room temperature and 
stopped when the most concentrated standard reached 1.0 to 1.5 A405nm OD units. The 
developing reaction was stopped by adding 50μl of 1M NaOH to each well. The plates 
read at A405nm using a VersaMax microplate reader (Molecular Devices). For the wash 
steps above, each well was washed 4 times with 300μl of wash buffer. For IL-13 reaction 
development, streptavidin–horseradish peroxidase and TMB Substrate Solutions (Roche) 
were used as per the manufacturer’s instructions. 
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4.2.4.2  Cell proliferation assay. 
Naïve mice (3/group) were sacrificed by a high anaesthetic dose of CO2. Lymph nodes 
were removed aseptically and placed in ice cold IMDM media supplemented with 10% 
FCS (Gibco). Single cell suspensions were prepared and filtered through 70µm nylon cell 
strainers (Becton-Dickinson, New Jersey). Cells contaminated with red blood cells were 
resuspended in 5ml Red cell lysis buffer and underlayed with 1ml heat inactivated FCS. 
Cells were centrifuged at 1 200rpm for 10min at 4°C and resuspended in 2ml IMDM 
supplemented with 10% FCS (Gibco). 10µl aliquots of the cell suspension was diluted in 
Trypan Blue and counted on a Neubauer haemocytometer. Cell concentrations of the 
unstained viable cells were determined and volumes adjusted to attain a concentration of 
5x105cell/ml. PMA (Sigma) was added to cells a 5ng/ml final concentration. 100µl cells 
from each group were plated out in triplicate in round bottomed 96 well tissue culture 
plates (Nalge Nunc). Working dilutions of stimulants were prepared in IMDM / 10% FCS 
as follows: 1) 2000U/ml rIL-2, 2000U/ml rIL-4, (all supplied by BD Pharmingen, San 
Diego, CA) and 500ng/ml sIL-4RFc; 2) 400ng/ml rIL-13 (R&D Systems, Minneapolis, 
MN) and 1µg/ml sIL-13R2Fc. Stimulant dilutions were added to the plated cells at 100µl 
per well. Included was a medium only control where 100µl IMDM / 10% FCS was added 
to a row of plated cells. Cells were cultured for 48h at 37°C in a humidified 5% CO2 
incubator. For the quantification of cell proliferation a colorimetric immunoassay (Roche) 
based on BrdU incorporation during DNA synthesis was used. The protocol was followed 
as per manufactures instructions. Briefly, 20µl BrdU labelling solution was added to the 
cells for a final concentration of 10µM BrdU per well. The cells were re-incubated for an 
additional 24h as above. Cell plates were centrifuged at 1 200rpm at 4°C for 10min cells 
ad labelling medium removed by aspiration. Cells were dried for 1h at 60°C. 200µl 
FixDenat Solution was added to each well and cells incubated at room temperature for 
30min. FixDenat solution was removed by flicking. After addition of 100µl/well anti-BrdU-
POD working solution, cells were incubated at room temperature for 1h. The antibody 
conjugate was removed by flicking the plate after which cells were rinsed 3 times with 
200µl/well washing solution. 100µl Substrate solution was added to each well and cells 
incubated at room temperature until colour development was sufficient for photometric 
detection. The reaction was stopped with the addition of 25ul 1M H2SO4 per well. The 
sample absorbance was measured on a Versamax microplate spectrophotometer 
(Molecular Devices) at A450nm (reference wavelength: A690nm).  
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4.2.4.3  T cell differentiation assay. 
Naïve mice (5/group) were sacrificed by a high anaesthetic dose of CO2. Lymph nodes 
were removed aseptically and placed in ice cold RPMI 1640 supplemented with 10% FCS 
(Gibco). Single cell suspensions were prepared and filtered through 70µm nylon cell 
strainers (Becton-Dickinson). Cells contaminated with red blood cells were resuspended 
in 5ml Red cell lysis buffer and underlayed carefully with 1ml heat inactivated FCS. Cells 
were centrifuged at 1 200rpm at 4°C for 10min and resuspended in 2ml RPMI 1640 /  
10% FCS (Gibco). Aliquots of the cell suspension (10µl) was diluted in Trypan Blue and 
counted on a Neubauer haemocytometer. Viable cell concentrations were determined 
and volumes adjusted to attain a concentration of 1x106cell/ml. CD4+ T cells were 
purified by magnetic CD4 microbeads using the MiniMACS system as per manufacture’s 
instructions (Miltenyi Biotec, Auburn, CA). Cell purity determined by FACScan analysis 
was ~96%. 2x105cells per well in complete RPMI 1640 medium / 10% FCS (Gibco), 
supplemented with 50uM B2-mercaptoethanol (Sigma, St. Louis, MO), 1mM sodium 
pyruvate and non-essential amino acids (Gibco), were plated in flat bottom 96 well plates 
(Nalge Nunc). The wells had been coated overnight at 4°C with 10µg/ml anti-CD3 and 
5µg/ml ant-CD28 (both BD Pharmingen) in filter sterilized 1 x PBS. For TH1 polarization 
cells were incubated with 5ng/ml IL-12 (BD Pharmingen) and 50µg/ml anti-IL-4 (clone 
11B11). For Th2 polarization cells were stimulated with 50µg/ml anti-IFN- (BD 
Pharmingen) and either 50ng/ml murine IL-4 (BD Pharmingen) or 100ng/ml IL-13 (R&D 
System). To asses the ability of the Fc-tagged soluble receptors to block polarization, 
cells were incubated with either; 1) 50µg/ml anti-IFN-, 50ng/ml murine IL-4 and 
150ng/ml sIL-4RFc or 2) 50µg/ml anti-IFN-, 100ng/ml IL-13 and 250ng/ml sIL-
13R2Fc. Cells incubated with complete media only were included as a control. The cells 
were incubated in a final volume of 200µl for 72h at 37°C in a humidified 5% CO2 
incubator. Subsequently, cells were transferred to a round bottom 96 well plate (Nalge 
Nunc) and washed 2 times in RPMI 1640 / 10% FCS. Washed cells were resuspended in 
complete RPMI 1640 medium supplemented with 20U/ml IL-2 (BD Pharmingen) 
containing cytokines and antibodies, as above. Cells were further incubated for 48h. Cells 
were washed with fresh culture medium and re-plated in triplicate at 2x105cells per well 
in a flat bottom 96 well plate pre-coated overnight with 20µg/ml anti-CD3 (BD 
Pharmingen). After 48h incubation, supernatants were harvested and frozen at -70°C. 
Subsequently cytokine analysis was preformed using ELISA. 
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4.2.4.4  Cytokine ELISA.  
Maxisorb 96 well ELISA plates (Nalge Nunc) were coated overnight at 4oC with 50μl of 
capturing antibody diluted in coating buffer at the recommended concentration. Plates 
were washed, and blocked for 24h at 4oC with 200μl blocking buffer and subsequently 
washed. Samples were serially diluted two-fold in dilution buffer and 50μl added to each 
well. Similarly, the appropriate recombinant protein standard was diluted to the 
recommended concentration, serially diluted three-fold in dilution buffer and 50μl added 
to designated control wells. The plates were incubated overnight at 4oC and washed. 
50μl of the appropriate biotinylated antibody was diluted to the recommended 
concentration in dilution buffer and 50μl was added to each well. The plates were 
incubated at 37oC for 4h, washed and 50μl of streptavidin-alkaline phosphatase diluted 
1:1000 in dilution buffer was added to each well. The plates were incubated for 60min at 
37oC, washed and 50μl substrate solution added to each well. The enzymatic reactions 
were developed at room temperature and were stopped when the most concentrated 
standard reached 1.0 to 1.5 A405nm OD units. The developing reaction was stopped by 
adding 50μl of 1M NaOH to each well. The plates were read at A405nm using a VersaMax 
microplate reader (Molecular Devices Corporation). For the wash steps above, each well 
was washed 4 times with 300μl of wash buffer. For IL-13 ELISA reaction development, 
streptavidin–horseradish peroxidase and TMB Substrate Solutions (Roche) were used as 
per the manufacturer’s instructions. 
 
4.2.4.5  Generation of bone marrow derived macrophages (BMDMs). 
Naïve mice were sacrificed by cervical dislocation and the femur and tibia bones 
collected. The bone marrow cells were flushed from the bones using DMEM (Gibco) / 
10% FCS containing 100U/ml penicillin G and 100μg/ml streptomycin. The cells were 
washed and pelleted by centrifuging at 1 200rpm at 4oC for 10min. The bone marrow 
cells were added at a final concentration of 1x106cells/ml in PLUTZNIK media and 
transferred into a special gas-permeable 15cm x 6cm Teflon coated-bag (Max Planck 
Institute for Immunobiology, Max Planck, Freiberg, Germany). The L929 conditioned 
medium contained GM-CSF and M-CSF, which stimulated the differentiation and growth 
of bone marrow stem cells into macrophages. The open end of the bag was heat-sealed 
and bone marrow stem cells incubated at 37oC under 5% CO2 for 10 days. The 
supernatant was discarded and the adherent cells were massaged from the Teflon-
coated bags into DMEM / 10% FCS, 100U/ml penicillin G and 100μg/ml streptomycin. 
The BMDMs were washed twice in DMEM / 10% FCS, to remove residual GM-CSF from 
the L929 conditioned medium.  
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For the subsequent Fc-tagged soluble receptor blocking assays, measuring NO and 
arginase activity, the BMDMs were plated at a density of 4x106BMDMs/ml in a volume of 
100ul in flat bottom 96 well plates (Nalge Nunc) to which the following stimulant 
mixtures were added; 100ul media only, mIL-4 (1000U/ml, BD Pharmigen), mIL-4 / sIL-
4RFc (10 X that of mIL-4), mIL-13 (200ng/ml, R&D Systems) and mIL-13 / sIL-13RFc 
(10 X that of mIL-13). Cells were incubated overnight at 37oC under 5% CO2. 
Subsequently, IFN- (200U/ml, BD Pharmigen) and LPS (20ng/ml, Sigma) was added 
and cells incubated a further 48h. The plates were centrifuged at 1 200rpm for 10min. 
Supernatant was removed for nitric oxide (NO) measurements. The remaining cells were 
washed with 1 x PBS. Cell lyses was achieved by resuspension in 50ul 0.1% Trition X-100 
and shaking at 80rpm for 30min at room temperature. After careful resuspension 
arginase activity was measured (section 4.4.8). 
For the subsequent Fc-tagged soluble receptor blocking assays, measuring mannose 
receptor expression, BMDMs were plated at a density of 2x106 BMDMs cells/well in a 12 
well plate and stimulated with mIL-4, mIL-13, mIL-4 / sIL-4RFc or mIL-13 / sIL-13RFc 
(as above) for 72h at 37oC under 5% CO2.  
 
4.2.4.5.1  L929 conditioned medium. 
L929 cells were maintained in DMEM (Gibco) / 10% FCS supplemented with 100U/ml 
penicillin G and 100μg/ml streptomycin until 90% confluence. The growth media was 
removed and the cells washed in 10ml 1 x PBS. Cells were removed from the plastic 
surface of the flask by incubation in 5ml Trypsin/EDTA buffer (Gibco) at room 
temperature for 4min. The cells were washed in 50ml DMEM / 10% FCS and seeded at 
2x104cells/ml in 100ml DMEM / 10% FCS, with appropriate antibiotics. The L929 cells 
were grown in 162cm2 tissue culture grade flasks (Corning Costar Corporation, 
Cambridge, MA, USA) at 37oC under 5% CO2 for 7 days. The supernatant was harvested 
and centrifuged at 2 500rpm for 15min at 4oC to get rid of cell debris. The clear 
supernatants were stored in 50ml aliquots at –20oC. 
 
4.2.4.6  Measurement of nitric oxide. 
Cell culture supernatants were analyzed for the production of nitric oxide (NO) using the 
Griess reaction assay, which measures the concentration of nitrite, a stable product of 
the reaction of NO with O2 (Ding et al., 1988). Supernatant samples and standards (1mM 
NO2 solution) were serially diluted three-fold in DMEM / 10% FCS supplemented with 
100U/ml penicillin G and 100μg/ml streptomycin (all Gibco). 50μl of these dilutions were 
added to designated wells in a flat-bottomed 96 well plate. 25μl of Griess Reagent 1 and 
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then 25μl of Griess Reagent 2 were sequentially added to each well. The plate was 
incubated at room temperature for 5min to allow development of the reaction. The 
purple-pink colour of the reactions was read at A540nm and the reference at A690nm using 
VersaMax microplate reader (Molecular Devices Corporation). 
 
4.2.4.7  Measurement of arginase activity. 
Arginase I activity in BMDMs was measured as previously described (Corraliza et al., 
1994). Subsequent to cell lysis, 50ul of 10mM MnCl2, 50mM Tris·Cl (pH7.5) was added 
and the enzyme activated for 10min at 55°C. Arginine hydrolysis was carried out in 
sterile eppendorf tubes by the addition of 25µl 0.5M arginine (pH9.7) to 25µl of the 
activated cell lysates. The samples were incubated at 37°C for 60min and the reaction 
stopped by the addition of 400µl of an acid mixture consisting of H2SO4, H3PO4 and H2O 
(1:3:7). Aliquots of 25µl of 9% ISPF (freshly made) dissolved in 100% ethanol was 
added to each sample and samples heated at 100°C for 45min. After placing the samples 
in the dark for 10min, 200µl of each was transferred to a 96 well microtiter plate (Nalge 
Nunc International). A standard curve was prepared by making 3-fold dilutions of 
1mg/ml of urea in H2O. The standards were treated as the samples from the addition of 
the acid mixture. The absorbance’s of samples and standards were measured at A540nm 
using a Versamax spectrophotometer (Molecular Devices Corporation). The urea 
concentration measured for each sample was used as a measure of arginase activity. 
 
4.2.4.8  FACS analysis of BMDMs.  
BMDMs were removed from the flat bottom 96 well plates (Nalge Nunc) using 
Trypsin/EDTA buffer (Gibco). Cell suspensions were centrifuged at 1 200rpm for 8min 
and resuspended in 2ml complete IMDM / 10% FCS supplemented with 100 U/ml 
penicillin and 100µg/ml streptomycin (all Gibco). Aliquots of cells (10µl) were diluted in 
Trypan Blue and counted on a Neubauer haemocytometer to determine concentrations of 
viable cells. 5x105 cells were pooled for each stimulant group and resuspended in 2% 
paraformaldehyde  diluted in 1 x PBS and incubated for 30min on ice. The cell 
suspension was washed by centrifugation at 1 200rpm for 10min and resuspended in 1 x 
PBS. Cells were centrifuged as before and resuspended in a mixture consisting of 0.5% 
saponin diluted in 1 x PBS. The cells were incubated for 10min at 37°C and subsequently 
transferred to ice for 10min. Cells were pelleted by centrifugation at 1 200rpm for 10min 
and resuspended in 100µl blocking buffer consisting of 0.5% saponin diluted in 1 x PBS 
and the following antibodies; CD8(Ly-2)-biotin (0.7mg/ml) and CD206-biotin 
(0.1mg/ml) (all BD Biosciences). These suspensions were stained in the dark on ice for 
20min. Cells were centrifuged at 1 200rpm for 10min and resuspended in 100ul blocking 
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buffer containing CD11b-PE (10µg/ml) (Integrinmchain,Mac-1chain) and incubated on 
ice for 20min. Cells centrifuged at 1 200rpm for 10min and resuspended in 500ul 1 x PBS 
containing 0.5% saponin. Pelleted cells were resuspended and incubated for a further 
15min on ice with 100l of a saturating amount of streptavidin-APC (BD Biosciences) in 
FACS buffer. After the final wash with 300µl FACS buffer, cells were resuspended in 
300µl FACS buffer supplemented with 7-AAD (Sigma, St. Louis, USA). Dead cells stained 
with 7-AAD were excluded from analysis. Stained cell acquisition was preformed using a 
FACSCalibur flow cytometer (BD Biosciences) and cells analyzed using CellQuest software 
(Becton-Dickinson, Ferndale, South Africa). 100 000 cells were acquired for analysis.  
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4.3 Results. 
 
4.3.1 Vector design and construction. 
 
To generate soluble chimeric proteins of the IL-4R, IL-13R2 and IL-2R-IL-4R, the 
corresponding coding regions for the extracellular domains of the three separate proteins 
were PCR amplified and cloned into the eukaryotic expression vector, pSecTag-FcMut. The 
cloning strategy for the three constructs are illustrated in Figures 4.2 A, B and C. 
pSecTag-FcMut consists of the pSecTag expression vector which has been modified by the 
addition of a mutated Fc fragment in the multiple cloning site. The purpose of this Fc 
fragment mutation is to inhibit FcR binding and complement fixation (Majeau et al., 
1994). Cloning the coding regions into this vector enables the expression of the 
recombinant proteins fused to the hinge and Fc domains of human IgG1. Furthermore, 
the Fc tag is utilised in the detection of transfected cells expressing the proteins of 
interest. This tag is additionally used for protein purification via protein A Sepharose 
affinity chromatography (Bjork et al., 1972). 
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Figure 4.2.A Flow Diagram of pSecTag-FcMut-sIL-4R Cloning Strategy. 
 
Panel A, IL-4R map. Extracellular domain indicated. The soluble/secreted isoform coding region 
is 646bp in length and codes for 246 amino acids. Panel B, Primer design and PCR of sIL-4R 
transgene using BALB/c cDNA. Panel C, RE digestion of sIL-4R cDNA and ligation into pSecTag-
Fc
Mut. The pSecTag-Fc
Mut eukaryotic expression vector modified via the addition of a mutated Fc 
fragment in the multiple cloning site (MCS). Panel D, The sIL-4Rexpression cassette. The IgG1 
leader sequence which is followed by the sIL-4Rcoding region and FcMut tag. The Kpn I – Not I 
ligation junctions are indicated. 
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Figure 4.2.B Flow Diagram of pSecTag-FcMut-sIL-13R2 Cloning Strategy 
 
Panel A, IL-13R2 map. Extracellular domain indicated. The soluble/secreted isoform coding 
region is 970bp in length and codes for 332 amino acids.  Panel B, Primer design and PCR of both 
full-length and extracellular sIL-13R2 transgenes using BALB/c cDNA. Panel C, RE digestion of 
sIL-13R2 cDNA and ligation into pSecTag-FcMut. The pSecTag-FcMut eukaryotic expression vector 
modified via the addition of a mutated Fc fragment in the multiple cloning site (MCS).  Panel D, 
The sIL-13R2expression cassette. The IgG1 leader sequence which is followed by the sIL-
13R2coding region and FcMut tag. The Kpn I – Not I ligation junctions are indicated. 
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Figure 4.2.C Flow Diagram of pSecTag-FcMut-sIL-2RsIL-4R Cloning Strategy 
 
Panel A, IL-2R map. Extracellular domain indicated.  The coding region is 776bp in length and 
codes for 240 amino acids.  Panel B, Primer design and PCR extracellular sIL-2R transgene using 
BALB/c cDNA. Panel C: RE digestion of sIL-2R cDNA and ligation into Not I digested pSecTag-
Fc
Mut sIL-4R. pSecTag-FcMut sIL-2R-IL-4R eukaryotic expression cassette with ligation junctions 
indicated.  Panel D, The sIL-2R-IL-4RFc inline cytokine trap. Extracellular domains of IL-4R 
and IL-2R arranged inline and fused to the mutated Fc fragment of human IgG1.  
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4.3.1.2. Molecular cloning and characterisation of Fc-tagged soluble.  
 
4.3.1.2.1 The Fc-tagged soluble IL-4Reukaryotic expression vector.
 
In order to sub-clone, and ultimately express the soluble IL-4R the corresponding 
extracellular coding region was amplified using primer pairs that would introduce Kpn I 
and Not I restriction enzyme sites. These restriction sites would allow the subsequent 
ligation into the expression vector digested with the same set of enzymes.  
The cDNA encoding the extracellular domain of IL-4R was amplified using the pBi-IL-
4R (see chapter 3 for cloning details) plasmid as template. This vector contains the 
cDNA encoding the full-length transmembrane isoform of IL-4RThe cDNA was 
generated from RNA isolated from a BALB/c genotype. Primer pairs were designed to 
amplify the 646bp extracellular region on this fragment. The amplification produced the 
desired 646bp extracellular domain (Figure 4.3). The amplified cDNA fragment was 
isolated from a low melting agarose gel and digested with the Kpn I and Not I. The 
digested fragment was isolated in the same manner as the PCR product and 
subsequently ligated into the pSecTag-FcMut vector digested with the same restriction 
enzyme set as those used on the amplified extracellular domain (refer to Figure 4.2.A for 
vector construction scheme). The ligation products were transformed into DH5α E.coli 
cells, and colonies screened by restriction enzyme (RE) digestion. Nsi I was used to 
identify the pSecTag-FcMut colonies into which soluble/extracellular IL-4R (sIL-4R) had 
been ligated (Figure 4.4, Panel A). The enzyme has two recognition sites in pSecTag-
FcMut, which generates a single 974bp fragment upon Nsi I digestion. In the clones 
containing the sIL-4R cDNA three recognition sites are present, and digestion would 
produce an additional 1111bp fragment compared to that of the empty vector digestion. 
The digestion produced two putative positive clones (Fig.4.4.A), which were further 
screened for insert presence with the Kpn I and Not I enzymes, which would be present 
at the ligation junction of positive clones. This digestion produced the 646bp cDNA insert 
fragment (Panel B). Lastly; an additional enzyme screening (Fig.4.4.C), using enzymes 
that had single recognition sites in the insert sequence, confirmed the orientation of the 
ligated cDNA fragment in the vector. The sequences of inserts in positive constructs were 
subsequently verified by automated nucleotide sequencing (Fig.4.4.D). The construct 
was referred to as sIL-4RFc.  
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Figure 4.3 Amplification of extracellular IL-4R cDNA fragment.  
 
PCR was performed to amplify the coding region of the extracellular IL-4R using oligonucleotides 
specific for the sequence and pBi-IL-4R as template. 1% (w/v) agarose gel in 1 × TAE containing 
ethidium bromide and visualized using short wavelength UV transillumination. Lane M, DNA 
molecular weight marker. Lane 1, The negative control, where the DNA template was omitted 
from the reaction mixture. Lane 2 & 3, Amplified 646bp sIL-4R cDNA fragments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Restriction enzyme screening and sequence verification of the sIL-4RFc 
expression vector.  
 
Panel A, Clone Screening. The cDNA insert was ligated into pSecTag-FcMut. Following 
transformation and plasmid isolation the colonies were screened via RE digestion. The illustration 
shows the theoretical recognition sites and fragment sizes produced in colonies positive for the 
insert. 0.8% (w/v) agarose gel in 1 × TAE containing ethidium bromide and visualized using short 
wavelength UV transillumination. Lane M, DNA molecular weight marker. Lanes 1-10, 10 
different isolated plasmid preparations (each from a single colony) digested with Nsi I. The clones 
positive for the correct fragment sizes are indicated.  
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Figure 4.4 Restriction enzyme screening and sequence verification of the sIL-4RFc 
expression vector.  
 
Panel B & C, 0.8% (w/v) agarose gel in 1 × TAE containing ethidium bromide and visualized 
using short wavelength UV transillumination. Lane M, DNA molecular weight marker. Panel B, 
Confirmation of the insert ligation junctions. The clones identified in Panel A were digested with 
Kpn I / Not I, confirming the insert size and presence of the ligation junctions. Lane 1, pSecTag-
Fc
Mut empty vector digestion. Lane 2, pSecTag-FcMut-sIL-4Rdigestion, showing the 646bp 
fragment generated. Panel C, Confirmation of the insert orientation. The clones positive for the 
insert were digested with the enzymes shown in the table. The expected sizes of the RE fragments 
generated in positive clones are indicated. Lane 1, Nhe I / Eco RI digestion showing the 562 and 
5870bp fragments. Lane 2, Sna BI digestion showing the 409 and 6023bp fragments generated 
by the digestion. Panel D, Sequence verification via automated nucleotide sequencing. Illustration 
of post sequencing analysis, using DNassist. The theoretical sequence and sequenced DNA 
sequences showed a 98% similarity after alignment. Gaps indicate unmatched bases.  
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4.3.1.2.2 The Fc-tagged soluble IL-13R2 eukaryotic expression vector. 
 
Similar to the cloning strategy for pSecTag-FcMut-sIL-4R, the vector construction of 
pSecTag-FcMut-sIL-13R2 started with identification of the extracellular IL-13R2 coding 
region, followed by amplification using primer pairs that introduced the Kpn I and Not I 
restriction enzyme sites. These restriction sites permitted the ligation into the expression 
vector digested with the same set of enzymes.  
To obtain the cDNA encoding the extracellular domain of IL-13R2, total RNA was 
isolated from a BALB/c mouse after which cDNA was produced via reverse transcriptase 
PCR (Fig.4.5.A). In order to aid specific amplification of the extracellular domain, this 
cDNA pool was decreased. This was achieved by separating the amplification into two 
steps. In the first amplification step primers specific for the full-length IL-13R2 coding 
region were designed, and used with the total pool of cDNA as template. The 
amplification produced the desired 1190bp full-length IL-13R2 fragment, which was 
subsequently isolated from a low melting agarose gel (Fig.4.5.B). This isolated fragment 
served as PCR template in the second amplification step using primers designed 
specifically for the extracellular domain. This amplification produced a single product, the 
970bp extracellular region of IL-13R2 (Fig.4.5.C). Subsequent to gel isolation, the 
amplification products were digested with Kpn I and Not I. The digested fragments were 
isolated in the same manner as the PCR products and ligated into the pSecTag-FcMut 
vector digested with Kpn I and Not I (refer to Figure 4.2.B, for vector construction 
scheme). The ligated constructs were transformed into DH5α E.coli cells, and colonies 
screened by RE digestion. To identify the pSecTag-FcMut colonies into which 
soluble/extracellular IL-13R2 (sIL-13R2) had been ligated RE screening using Fok I was 
preformed. This enzyme has a single site in the empty vector and only if the IL-13R2 is 
ligated in the correct orientation would a second site be present (Fig.4.6.A). The 
digestion identified two putative positive clones (Fig.4.6.B), which were further analyzed 
via insert digestion (Fig.4.6.C) with the enzymes used for vector cloning, namely Kpn I 
and Not I. The Kpn I / Not I digestion verified the ligation junctions and the subsequent 
RE digestion using enzymes with single recognition sites in the IL-13R2 cDNA fragment 
confirmed the insert orientation (Fig.4.7.A). The sequence of insert in the positive 
constructs was subsequently verified by automated nucleotide sequencing (Fig.4.7.B). 
The construct was referred to as sIL-13R2Fc. 
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Figure 4.5 Amplification of the IL-13R2 extracellular cDNA fragment.  
 
In both Panel A & C, 1% (w/v) agarose gel in 1 × TAE containing ethidium bromide and 
visualized using short wavelength UV transillumination. Lane M, DNA molecular weight marker. 
Panel A, Products of the cDNA synthesis. RNA was isolated from the draining lymph node of 
BALB/c mouse and cDNA synthesised. Panel B, Melting Curve of first round PCR showing 
amplification of full length IL-13R2. On graph, nr 1; primer dimmers and nr 2; amplification peak. 
Panel C, Second round PCR with extracellular IL-13R2 primers. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Restriction enzyme screening and sequence verification of the sIL-13RFc 
expression vector.  
 
Panel A, Clone Screening. The cDNA insert was ligated into pSecTag-FcMut. Following 
transformation and plasmid isolation the colonies were screened via RE digestion. The illustration 
shows the theoretical recognition sites and fragment sizes produced in plasmids positive for the 
insert. In both Panel B & Panel C, 0.8% (w/v) agarose gel in 1 × TAE containing ethidium 
bromide and visualized using short wavelength UV transillumination. Lane M, DNA molecular 
weight marker. Panel B, Fok I digestion. Lanes 1-6, 6 different isolated plasmid preparations 
digested with Nsi I. The clone’s positive for the correct fragment sizes, lanes 1 and 4, are 
indicated. Panel C, Insert ligation junction confirmation. Kpn I / Not I digestion of positive clones 
(identified in Panel B). Lane 1, Digestion of empty vector only. Lane 2, pSecTagFcMut--sIL-
13Rdigestion showing the 970bp insert fragment produced by the RE screening.
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Figure 4.7 Insert orientation and sequence verification of the sIL-13R2Fc expression 
vector.  
 
Panel A, Confirmation of insert orientation in vector. 0.8% (w/v) agarose gel in 1 × TAE 
containing ethidium bromide and visualized using short wavelength UV transillumination. Lane M, 
DNA molecular weight marker. Lane 1, Sna BI digestion showing the 266, 406 and 591bp 
fragments. Lane 2, Bsa I digestion showing the 1402 and 1758bp fragments generated via 
digestion. Panel B, Sequence verification via automated nucleotide sequencing. Illustration of the 
post sequencing analysis using DNassist. The theoretical sequence and sequenced DNA sequences 
showed a 99% similarity after alignment. Gaps indicate unmatched bases.  
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4.3.1.2.3 The inline Fc-tagged soluble IL-4R / soluble IL-2R cytokine trap  
  eukaryotic expression vector. 
 
In order to generate a construct that would enable the expression of the extracellular 
domains of IL-2R and IL-4R in the form of a fusion protein, the corresponding 
extracellular coding region of IL-2R was amplified using primer pairs that introduced Not 
I restriction enzyme sites on both the 3’ and 5’ ends of the fragment. These restriction 
sites allowed for the subsequent ligation into the pSecTag-FcMut-sIL-4Rexpression 
vector digested with the same enzyme (refer to Figure 4.2.C, for vector construction 
scheme). The cDNA encoding the extracellular domain of IL-2R was generated from RNA 
isolated from a BALB/c mouse. Primer pairs were designed to amplify this region and the 
amplification produced the desired 776bp fragment coding for the extracellular domain 
(Figure 4.8). The amplified cDNA fragment was isolated from a low melting agarose gel 
and digested with Not I. The digested fragment was isolated in the same manner as the 
PCR product and subsequently ligated into the Not I digested pSecTag-FcMut-sIL-4R 
vector. The ligation products were transformed into DH5α E.coli cells, and randomly 
picked colonies screened by RE digestion. Digestion with Eco RV / Sca I was used to 
identify the pSecTag-FcMut colonies into which soluble/extracellular IL-2R (sIL-2R) had 
been ligated (Figure 4.9, Panel A & B). These enzymes both have unique sites in either 
the sIL-4R or sIL-2 cDNA fragments, and none in pSecTag-FcMut. Digestion of the 
clones into which the sIL-2R cDNA had been ligated produced three putative positive 
clones (Fig.4.9.B). Further screening, with a Pst I digestion, confirmed the orientation of 
the ligated insert (Figure 4.10). The insert sequences in the positive constructs were 
subsequently verified by automated nucleotide sequencing. The construct was referred to 
as sIL-2R-sIL-4RFc. 
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Figure 4.8 Amplification of the IL-2R extracellular cDNA fragment.  
 
PCR was performed for the amplification of the extracellular IL-2R cDNA fragment using 
oligonucleotides specific for the sequence and BALB/c mRNA as template. 1% (w/v) agarose gel in 
1 × TAE containing ethidium bromide and visualized using short wavelength UV transillumination. 
Lane M, DNA molecular weight marker. Lane 1, Negative control, where DNA was omitted from 
the reaction mixture. Lane 2, Amplified 776bp extracellular IL-2R cDNA fragments.  
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.9 Restriction enzyme screening of sIL-2-sIL-4RFc clones.  
 
Panel A, Clone Screening. The cDNA insert was ligated into pSecTag-FcMut-sIL-4R. Following 
transformation and plasmid isolation the colonies were screened via RE digestion. The illustration 
shows the theoretical recognition sites and RE fragments produced in colonies positive for the 
insert. Panel B, 0.8% (w/v) agarose gel in 1 × TAE containing ethidium bromide and visualized 
using short wavelength UV transillumination. Lane M, DNA molecular weight marker. Lanes 1-7, 
7 different isolated plasmid preparations digested with Eco RV / Sca I. The clone’s positive for the 
correct fragment sizes, lanes 2, 5 and 7, are indicated. 
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Figure 4.10 Insert orientation of sIL-2R-sIL-4RFc expression vector.  
 
Confirmation of the insert orientation. 0.8% (w/v) agarose gel in 1 × TAE containing ethidium 
bromide and visualized using short wavelength UV transillumination. Lane M, DNA molecular 
weight marker. Lanes 1, Pst I digestion of the expression vector showing the 1849bp and 350bp 
fragments produced.  
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4.3.3 Recombinant fusion protein expression and purification. 
 
In order to perform functional studies and investigate IL-13 and IL-4 cytokine binding, 
the IL-13R2, IL-4R soluble receptors and the sIL-2R-sIL-4R cytokine trap were 
expressed as fusion proteins and purified. To produce sufficient quantities of the 
recombinant protein for the biochemical and functional analyses, proteins were over-
expressed in Hek 293T cells, using the pSecTag-FcMut eukaryotic expression system.  
Expression using this system, resulted in the IL-13R2, IL-4R extracellular domains 
fused in-frame with the mutated human IgG1-Fc. In the case of the in-line sIL-2R-sIL-
4RFc cytokine trap, expression lead to the in-frame fusion of both the IL-2RandIL-4R 
extracellular domains, with the IgG1-Fc tag. Fc-tagged proteins were purified from the 
cell supernatants via protein A Sepharose chromatography. The Fc tag directs the 
random formation of disulfide-linked dimmers between secreted peptides, in this way 
forming homodimeric proteins that have been shown to act as effective cytokine blockers 
(Caput et al., 1996). 
Both the purified sIL-4RFc and sIL-13RFc exhibited anomalous migration on SDS-PAGE 
gels (Figure 4.11, Panel A & B). The sIL-4RFc, has a predicted size of 58.5kDa (obtained 
from the peptide calculator at http://prowl.rockefellar.edu), but migrated at a region 
corresponding to approximately 65kDa (Fig.4.11.A, lane 2). The sIL-13RFc migrated at 
approximately 90kDa with an expected size of 63kDa (Fig.4.11.B, lane 2). This atypical 
migration by sIL-4R and sIL-13R2 is attributed to N-linked glycosylation of the 
recombinant proteins (Donaldson et al., 1998 and Schulte et al., 1997). To assess the Fc 
tag directed protein dimerization, the proteins were electrophoresised under non-
reducing conditions, in this way not disrupting and of the disulfide bonds. Both sIL-4RFc 
and sIL-13RFc formed homodimmers as illustrated by the protein migrated at a region 
approximately double in size to that of the proteins electrophoresised using reducing 
conditions (Lanes 1 in A and B). The sIL-2R-sIL-4RFc cytokine trap migrated at the 
predicted 270kDa region on a SDS-PAGE gel (Fig.4.12). Under non-reducing conditions, it 
was also observed that the majority of the proteins were in the homodimeric cytokine 
trap formation. Subsequently, these results were confirmed via western blot analysis 
using an antibody against the mutated human IgG1-Fc portion of the purified fusion 
proteins. To asses the specificity of the antibody, protein was purified from the media 
only, from the supernatant of untransfected Hek 293T cells and from lysed untransfected 
Hek 293T (Figure 4.13, Panel A). There was no measurable detection, using this antibody 
on immobilized proteins purified from these groups. However, in cells transfected with 
the sIL-4RFc, sIL-13RFc or the sIL-2R-sIL-4RFc expression vectors, Fc was detected  
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(Fig.4.13, B & C). Yet, as observed in Panel B, the level of expressed sIL-13RFc purified 
from the supernatant of the cells was much lower when compared to that obtained from 
the cell lysates. This decreased level, which was also confirmed with the BCA protein 
quantification assay, can possibly be attributed to a defect in the secretion of the 
expressed protein. The reason for this is yet to be investigated, but the possibility of 
incorrect protein folding leading to the decreased secretion could be analyzed further.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 SDS-PAGE analyses of IL-4 and IL-13 soluble receptor blockers. 
  
Panel A & B, 10% SDS-PAGE gels. Protein A Sepharose purified protein was visualized by 
Coomassie staining. Panel A & B: lane M, Protein molecular weight marker, with sizes indicated 
on the left. All other lanes contain Fc-tagged purified protein. Panel A, Purified sIL-4RFc Lane 1, 
Electrophoresis using non-reducing sample application buffer (SAB) and lane 2, using SAB 
supplemented with 5% (v/v) -mercaptoethanol. Panel B, sIL-13R2Fc. Lane 1, Electrophoresis 
under non-reducing conditions and lane 2, Electrophoresis under reducing conditions.  
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Figure 4.12 SDS-PAGE analysis of sIL-2R-sIL-4RFc cytokine trap. 
 
10% SDS-PAGE gel of Protein A Sepharose purified sIL-2R-sIL-4RFc protein was visualized by 
Coomassie staining. Protein sizes indicated on the left. Lane 1, Electrophoresis using non-reducing 
conditions. Lane 2, Electrophoresis using reducing conditions. Lane 3, Control experiment; 
electrophoresis of protein purified from untransfected Hek 293T cells. 
 
 
 
 
 
 
Figure 4.13 Western Blot detection of secreted proteins. 
 
Protein A Sepharose purified proteins electrophoresised on 10% SDS-PAGE gels, visulaised via 
Coomassie. Protein was transferred to Nitrocellulose membrane, Fc detected with Anti-Human 
IgG1 and visualized by chemiluminscence. Panel A, in both the SDS-Page gel and Nitrocellulose 
membrane; Lane 1, Media Only. Lane 2, Protein purified from untransfected Hek 293T cell 
supernatant. Lane 3, Protein purified from lysed untransfected Hek 293T cells. Panel B, Lane 1, 
Protein purified from lysed Hek 293T cells transfected with sIL-13R2Fc. Lane 2, Protein purified 
from lysed Hek 293T transfected with sIL-4RFc. Lane 3, Protein purified from Hek 293T cell 
supernatant transfected with sIL-13R2Fc. Lane 4, Protein purified from Hek 293T cell 
supernatant transfected with sIL-4RFc. Panel C, Protein purified from Hek 293T cell supernatant 
transfected with sIL-2R-sIL-4RFc. Lane 1, Electrophoresis under non-reducing conditions and 
Lane 2, reducing conditions. 
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4.3.4 Biochemical protein characterisation.  
 
4.3.4.1  Cytokine Binding assays. 
 
To assess the binding potential and affinity of the expressed soluble receptors to their 
respective cytokines a modified version of the Sandwich Elisa technique was used 
(illustrated in Figure 4.14). Briefly, in parallel experiments, ELISA plates were either 
coated with the coating antibody for IL-13 or IL-4, or with different concentrations of 
sIL-13R2Fc, sIL-4RFc or sIL-2R-sIL-4RFc. This was followed by a serial dilution of the 
respective cytokines, and lastly, the biotin-labelled detecting antibodies against these 
cytokines. The bound cytokine served as a measure of the cytokine binding to the soluble 
receptor blockers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Diagram of Fc-tagged Soluble Receptor Elisa Protocol.  
 
Panel A, Positive control ELISA, using coating antibody for the respective cytokines, cytokines and 
biotin-labelled antibody, for detection. Inset illustrates the control for this experiment where the 
cytokine is omitted in the procedure. Panel B, ELISA testing for the Fc-tagged soluble receptor 
cytokine binding. The coating antibody gets replaced by the respective Fc-tagged soluble 
receptors. This is followed by the respective cytokines and the biotin-labelled antibodies against 
these cytokines for detection. Inset illustrates the control for this experiment where the Fc-tagged 
soluble receptor is omitted in the procedure.   
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4.3.4.1.1 sIL-4R and sIL-13R2. 
 
Coating of the ELISA plates with sIL-4RFc at a 10-fold concentration to that of the IL-4 
coating antibody (0.025mg/ml) resulted in cytokine binding being equivalent to that 
shown by the cytokine antibodies (Figure 4.15, Panel A.1). For sIL-13R2Fc, coating with 
a 10-fold concentration to that of the IL-13 coating antibody (0.02mg/ml) also resulted in 
cytokine binding but not to the degree shown by sIL-4RFc (Fig.4.15.B.1). This data 
indicates that though the Fc-tagged soluble receptor blockers bind their respective 
cytokines effectively it is at a lower stoichiometric ratio than that shown by cytokine 
binding to the monoclonal coating antibodies. The cytokine binding results were not due  
to non-specific binding as demonstrated by the cytokine and coating antibody negative 
controls (Fig.4.15, A.2 & B.2). 
 
 
Figure 4.15 Cytokine Binding analyses of sIL-4RFc and sIL-13R2Fc.  
 
Panel A.1 and B.1, Graphs of the cytokine - soluble receptor ELISA. sIL-4RFc (A.1) and sIL-
13R2Fc (B.1) were plated a 10-fold concentration as that of the coating antibody and then at 3-
fold dilutions of this, as indicated in the legends. This was followed by the serial dilution of IL-4 
(A.1) or IL-13 (B.1). Bound cytokine was measured by ELISA. 
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Figure 4.15 Cytokine Binding analyses of sIL-4RFc and sIL-13R2Fc blockers.  
 
Panel A.2 and B.2, Graphs of the cytokine - soluble receptor control ELISA (as illustrated in 
Figure 4.13). Bound cytokine was measured by ELISA. The results represent 1 of 3 independent 
experiments and show the average ± SEM of triplicate values.
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4.3.4.1.2 sIL-2R sIL-4R cytokine trap. 
 
Previously it was shown (Economides et al., 2003) that the generated human form of the 
sIL-2R-sIL-4RFc cytokine trap displayed equivalent binding affinities to that shown by 
the monoclonal antibody for hIL-4.  
To investigate if this was also the case for the binding affinity of the generated murine 
form of this trap the modified ELISA protocol (4.2.4.1) was preformed with the sIL-2R-
sIL-4RFc. Here when coating the plates with either the sIL-2R-sIL-4RFc cytokine trap 
or the anti IL-4 coating antibody (Figure 4.16) at the same concentrations (0.002mg/ml), 
equivalent binding was found by the trap and the IL-4 coating antibody with the 
cytokine. In parallel sIL-4RFc was used to coat a plate at the same concentration as that 
of the cytokine trap and IL-4 coating antibody. From the results it was clear that the sIL-
2R-sIL-4RFc cytokine trap showed a greater cytokine binding affinity as that of the sIL-
4RFc (Refer to Fig.4.15.A.1). This implies increased stoichmetry between the cytokine 
trap and the cytokine and indicates that the cytokine trap could potentially represent a 
more potent inhibitor of IL-4 cytokine binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Cytokine Binding analysis of sIL-2R-sIL-4RFc cytokine trap. 
 
Graph of the cytokine – cytokine trap ELISA.  Plates coated with sIL-2R-sIL-4RFc, sIL-4RFc or 
the coating IL-4 antibody (11B11) at 0.002mg/ml. This was followed by the serial dilution of mIL-
4. Different groups indicated in the legend. Bound cytokine was measured by ELISA. The results 
represent 1 of 3 independent experiments and show the average ± SEM of triplicate values 
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4.3.5 In vitro functional assays. 
 
4.3.5.1  T cell Proliferation. 
  
It is established that binding by IL-4 to type I IL-4R (IL-4R-chain heterodimer) 
induces in vitro proliferation of murine T lymphocytes (Kondo et al., 1993 and Le Gros et 
al., 1990). In order to demonstrate a biological effect of the generated sIL-4RFc, the 
effect of this dimeric form of mIL-4R on the proliferative response of CD4+T cells to IL-
4 was examined.  
The CD4+T cell enriched population was stimulated with recombinant mIL-4, at a 
saturating concentration, and with a combination of recombinant mIL-4 and purified sIL-
4RFc. The soluble receptor blocker, sIL-4R-Fc, was added at the 10-fold concentration 
to the mIL-4, as this concentration was shown to be effective in the cytokine binding 
assays (refer to section 4.2.4.1.1). Stimulation of the cells with murine IL-2 served as a 
positive control and incubation with medium only as the negative control. As shown 
(Figure 4.17), CD4+T cells proliferated significantly upon stimulation with either mIL-2 or 
mIL-4 (p<0.05) when assessed by BrdU absorbance values and compared to the media 
control. Where sIL-4RFc was added in combination to mIL-4 (bar D), the IL-4 induced 
proliferation was significantly decreased to a level equivalent to that of untreated cells 
(bar A). This proliferation assay clearly demonstrated sIL-4RFc to effectively block IL-4 
induced CD4+T cell proliferation.  
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Figure 4.17 CD4+T cell proliferation after stimulation with mIL-4, mIL-2, or mIL-4 with 
sIL-4RFc. 
 
Cells were isolated from lymph node tissues of BALB/c mice and a CD4+T cell enriched population 
was obtained by negative selection. Enrichment was confirmed by FACS analysis and all cell 
samples used were between 95-98% CD4+T cell positive. CD4+ T cells were plated with medium 
containing mIL-4 (bar C), mIL-2 (B) or mIL-4 in combination with sIL-4RFc (D). Culture medium 
contained PMA (5ng/ml) and cells were stimulated for 48h with. Cell proliferation was measured by 
the BrdU incorporation during DNA synthesis in proliferating cells. Media was supplemented BrdU 
during the last 18h of culture incubation. BrdU incorporation was determined via the BrdU 
colorimetric immunoassay (described in methods section). The results represent 1 of 3 
independent experiments and show the average ± SEM of triplicate values. Statistical differences 
between groups calculated using unpaired Student’s t test defining differences to cultures 
incubated with cytokine and PMA stimulated as significant (***, p ≤0.001). 
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4.3.5.2  T cell Differentiation. 
 
To further confirm the biological effects of the sIL-4RFc on IL-4 driven CD4+T cell 
responses the cytokine induced Th1 / Th2 differentiation was analyzed. It is well 
established that IL-4 induces the in vitro differentiation of naïve T helper (Th) cells to a 
Th2 phenotype (Zurawski et al., 1993 and Manetti et al., 1993) while IL-12 induces the 
differentiation to Th1 (Seder et al., 1993).  
CD4+T cell enriched population was activated with plate bound anti-CD3/anti-CD28 and 
incubated for 72h with various combinations of the cytokines and Fc-tagged blockers 
(see Figure 4.18 for stimulant groups). The Th1 differentiation cells were cultured with 
IL-12 and anti-IL-4, with or without soluble receptor blocker. As a negative control cells 
were incubated in the absence of stimulants with medium only. Cells were restimulated 
for an additional 48h with anti-CD3 and differentiation determined by measuring the IFN-
, IL-13 and IL-4 secretion.  
As expected, stimulation with IL-12 / anti-IL-4 differentiated the T cells to Th1 (Figure 
4.18, Panel A), as indicated by elevated IFN- secretion. Cells stimulated with the mIL-4 / 
anti-IFN- / sIL-4RFc combination showed a significant increase (calculated P value of 
0.0053) to Th1 when compared to cells stimulated with mIL-4 / anti-IFN-only. The 
result suggests that the sIL-4RFc is blocking the IL-4 cytokine action. Panel B and C 
show the IL-4 and IL-13 secretion, respectively. The increase in cytokine secretion 
demonstrates that CD4+T cells incubated with mIL-4 / anti-IFN- differentiated to Th2. 
Addition of sIL-4RFc to the cultures lead to impaired Th2 differentiation as observed 
with the reduced IL-4 and IL-13 levels. In the presence of IL-4 blocker the levels of IL-13 
secretion also dropped significantly (C). CD4+T cell stimulation with the mIL-13 / anti-
IFN-combinationhad minimal effect on either IFN-or IL-4 production confirming 
previous data that IL-13 has no influence on in vitro T cell differentiation (Zurawski et al., 
1993; Sornasse et al., 1996), due to the absence of a functional IL-13 receptor. This data 
confirmed the biological effect exerted by the generated sIL-4RFc on CD4+T cells in 
vitro.
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Figure 4.18 Effect by sIL-4RFc and sIL-13RFc on in vitro Th1/Th2 differentiation of 
CD4+ T cells from BALB/c mice. 
 
Panel A, B & C, Isolated CD4+ T cells (97% purity as determined with FACS analysis) from lymph 
node cells of naïve BALB/c mice. Cells were activated with plate bound anti-CD3/anti-CD28 in the 
presence of IL-2 and cultured with mIL-12/anti-IL-4 for Th1 differentiation. For Th2 differentiation 
cells were stimulated with mIL-4/anti-IFN-As indicatedsIL-4RFc and sIL-13RFc were also 
added in different combinations. After 72h culture cells were restimulated with anti-CD3 for 48h. 
The levels of IFN- (Panel A), IL-4 (B) and IL-13 (C), secreted in the supernatant, were 
determined with ELISA. The results represent 1 of 3 independent experiments and show the 
average ± SEM of triplicate values. Statistical differences compared to the mIL-12 / anti IFN- (A) 
cultures, the IFN-/ LPS / mIL-4 cultures (B) and the IFN-/ LPS / mIL-13 cultures (C) are 
indicated as ** p≤0.001 and *** p≤0.0001. 
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4.3.5.3  Influence of sIL-4RFc and sIL-13RFc on macrophage 
   responsiveness to mIL-4 and mIL-13. 
 
It is established that macrophage differentiation to the classical activation status is driven 
by the IL-4R and is effected by both IL-4 and IL-13. This cytokine receptor interaction 
represents an excellent model for testing the generated Fc-tagged soluble receptor 
blocking function. Thus to establish the effect of sIL-13RFc on cytokine-receptor 
binding bone marrow derived macrophages were used. These functional studies also 
served to further confirm the effect exerted by sIL-4RFc (as shown in section 4.2.5.2 
and 4.2.5.3).  
 
4.3.5.3.1  Bone marrow derived macrophage differentiation. 
 
It has previously been shown that nitric oxide (NO) production is induced by IFN-/ LPS, 
in classically activated macrophages (Ding et al., 1988; Green et al., 1990). Furthermore, 
IL-4R-dependent mechanisms counter this stimulation, leading to alternative activated 
macrophages with decreased production of NO but increased arginase I activity (Doyle et 
al., 1994; Takeda et al., 1996).  
To illustrate the cytokine blocking effect of the soluble receptors the IFN-/ LPS induced 
NO production and arginase I activity was analyzed using in vitro macrophage cultures. 
The BMDM cells were pre-incubated with medium only, mIL-4, mIL-13, mIL-4 / sIL-
4RFc or mIL-13 / sIL-13RFc for 24h. This was followed by a 24h IFN-/ LPS 
stimulation. Subsequently, macrophages were analyzed for the levels of NO produced 
and for urea production which is a product of the arginase I activity. As shown (Figure 
4.19, Panel A), the IFN-/ LPS induced NO production was significantly decreased when 
the macrophages were cultured with mIL-4 or mIL-13 prior to IFN-/ LPS stimulation. In 
contrast, preincubation with IL-4 or IL-13 increased the arginase I activity as 
demonstrated by increased urea production (B). With the addition of sIL-13RFc or sIL-
4RFc in combination with mIL-13 or mIL-4, respectively, the opposite effect was seen in 
both assays. Both the NO and urea production was decreased in these samples.  
These results show that treatment with the generated Fc-tagged soluble receptors 
inhibits the effect by IL-4 and IL-13 on alternative macrophage activation, in this way 
leading to classically activated macrophages responsive to IFN-/ LPS stimulation.  
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Figure 4.19 Suppression of IL-4 and IL-13 function in BMDM cultures. 
 
Panel A, NO production determined with the Griess reaction. Panel B, Urea production after the 
addition of arginine substrate used to measure arginase I activity. Bone marrow derived 
macrophages from BALB/c mice were incubated with media only, mIL-4, mIL-4 / sIL-4RFc, mIL-
13 and mIL-13 / sIL-13RFc for 24h. Subsequently IFN-/ LPS were added and cells stimulated 
for a further 48h. This was followed by the respective assays. Data is representative of one 
experiment, and show the average ± SEM of triplicate values. Statistical analysis was performed 
using unpaired Student’s t test defining differences to cultures incubated with IL4 or IL13 / IFN-/ 
LPS stimulated as significant (**, p ≤0.01; ***, p ≤0.001).  
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4.3.5.3.2  Macrophage mannose receptor expression. 
 
To further define the effect of the generated Fc-tagged blockers on alternative activation 
of BMDM culture we also investigated the macrophage mannose receptor (MMR) 
expression was investigated, as this is considered a reliable marker for alternative 
activation. Both IL-4 and IL-13 (Ding et al., 1988; Doyle et al., 1994 and Stein et al., 
1992) have been shown to enhance the expression and activity of the macrophage 
mannose receptor (MMR). Thus to asses if the soluble receptor blockers would influence 
MMR expression in a fashion that mimics that of IL-4 and IL-13 unstimulated 
macrophages, MMR expression was determined via FACS analysis.  
Bone marrow derived macrophages were incubated with medium only, mIL-4, mIL-13, 
mIL-4 / sIL-4RFc or mIL-13 / sIL-13RFc for 72h. As expected, incubation of the 
macrophages with IL-4 or IL-13 led to increased expression of the MMR (Figure 4.20, 
Panel A). This increase in receptor activity was decreased to a level similar to that of the 
unstimulated control when cells were incubated with mIL-4 / sIL-4RFc or mIL-13 / sIL-
13RFc respectively. Quantification of this decrease by quadrant statistics of dot plots 
(panel B) illustrates this effect by the soluble receptor blockers to be greater than a 50% 
decrease in positive staining and thus MMR expression. These results suggest that the 
suppression of cytokine action was due to the presence of the Fc-tagged soluble receptor 
blockers. 
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Figure 4.20 sIL-4RFc and sIL-13RFc dependant suppression of MMR expression.  
 
Panel A, Histograms indicating the shift in UV fluorescence due to MMR expression. Panel B, Dot plots indicating the percentage viable cells positive for MMR 
expression. BALB/c bone marrow derived macrophages were stimulated with mIL-4, mIL-13, mIL-4 / sIL-4RFc or mIL-13 / sIL-13RFc for 72h. The cells were 
harvested, permeabilised and stained with biotin-labelled CD206 for the MMR and biotin-labelled Ly-2 as isotype control. Subsequently, the cells were stained with 
PE-labelled CD11b (macrophage marker) and with 7AAD (dead cell marker). Cells were then assessed for MMR expression in the various samples with FACS. Lines 
representing different stimulant groups are indicated (A). Both A and B are representative of populations gated for viable cells positive in CD11b surface expression.
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4.4 Chapter Conclusions. 
 
Subsequent to expression vector cloning and characterisation (section 4.3.1.2) the three 
fusion proteins were successfully expressed in Hek 293T cells and purified via protein A 
Sepharose chromatography (section 4.3.3). Protein purification was followed by the 
establishment of the cytokine binding affinities of the recombinant Fc-tagged fusion 
proteins. Results of the cytokine binding assays (section 4.3.4) demonstrated the 
following; 
1. The generated Fc-tagged blockers namely, sIL-13R2Fc, sIL-4RFc and  
sIL-2R-sIL-4RFc successfully displayed binding, with differing affinities, to their 
respective cytokine ligands.  
2. The sIL-2R-sIL-4RFc cytokine trap showed a higher degree of binding affinity 
than that shown by the sIL-4RFc.  
Having shown Fc-tagged soluble receptor - cytokine binding Fc-tagged soluble receptor 
biological function was tested in vitro. Here the CD4+T cell proliferation assay (section 
4.3.5.1) clearly demonstrated that the sIL-4RFc generated in this study is effective at 
preventing IL-4 dependant CD4+T cell proliferation. Furthermore these data are 
comparable to previous studies using existing IL-4 cytokine blockers (Grunewald et al., 
1997 and Schulte et al., 1997). From the CD4+T cell differentiation assay (4.3.5.2) it was 
concluded that sIL-4RFc shows a definite blocking effect of the IL-4 cytokine - receptor 
binding. Even though stimulation with mIL-13 / anti-IFN-had a modest effect on either 
IFN-or IL-4 production in CD4+T cells, when the cells were incubated with the sIL-
13RFc in combination with IL-13 there was a decrease in IL-13 and IL-4 secretion. This 
will have to be investigat d further owing to the fact that to date T cells have been 
considered resistant to IL-13 stimulation (Zurawski et al., 1993; Sornasse et al., 1996). 
However, the data presented here challenges this dogma and points to the possibility of 
an undiscovered IL-13 signaling complex on CD4+T cells.  
To establish the biological functionality of the generated sIL-13R2Fc, the effect of the Fc-
tagged blockers on a defined IL-13 role was investigated utilising BMDM functional 
studies (section 4.3.5.3). These data demonstrated that both sIL-13R2Fc and sIL-4RFc 
influenced the IL-4 and IL-13 cytokine driven alternative macrophage activation as 
assessed by the macrophage culture nitric oxide and urea production. This blockage of 
the IL-4 / IL-13 action lead to classically activated macrophages responsive to IFN-/ 
LPS stimulation, which is indicative of sIL-13RFc and sIL-4RFc suppression of 
cytokine-receptor interaction. This effect was further confirmed by the mannose receptor 
expression. These assays verified that sIL-4RFc and sIL-13RFc both had an inhibitory 
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influence on the macrophage response to IL-4 and IL-13 stimulation. In conclusion, we 
have successfully generated 3 cytokine blockers of which 2 have demonstrated clear 
biological functionality. 
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Chapter 5: Discussion. 
 
In the study presented here we describe the successful development of a range of novel 
tools for manipulating IL-4Rfunction As IL-4R and its associated cytokines are 
important components of the immune system the development of new tools to further 
our understanding of their role is of great importance to our understanding of the basic 
biology of the receptor and the development of potential future clinical applications. In 
this study we have developed three new approaches to further our understanding of IL-
4R: 
  1. An IL-4R inducible model. 
  2. CD11c-Crec and CD11c-GFP constructs. 
  3. IL-4 and IL-13 soluble and a IL-4/IL-2 soluble receptor cytokine trap. 
 
The generation of a mouse model, which allows the inducible and cell-specific deletion or 
reconstitution of IL-4R expression has the potential to define how controlling temporal 
expression of IL-4R contributes to immune responses. Such a model allows the 
development of a new dimension to our understanding of IL-4R signalling. Two 
transgenic (Tg) mouse lines were involved in generating the final double transgenic 
model. One line expresses the transactivator, tTA, from the Tet-Off expression cassette 
driven by the Vav promoter, ensuring hemopoeitic cell specificity of the expressed 
protein (Wiesner et al., 2005). The second line, generated here, expresses the IL-4R 
cDNA under the dictates PCMV minimal promoter supplemented with the TetO sequences, 
the operon thus serving as a binding site for the transactivator. Both lines were crossed 
to the IL-4R-/- BALB/c genetic background and then intercrossed to generate a double 
transgenic mouse on the IL-4R-/- backbone. In these double transgenic mice, the 
transactivator was synthesized in a cell specific manner leading to cell specific IL-4R 
reconstitution in the IL-4R-/- background.  
 
Secondly we have generated constructs which will allow the production of a mouse 
model where Cre recombinase expression is driven by a dendritic cell (DC) specific 
promoter. This will enable the generation of dendritic cell-specific IL-4R deficient mice 
(CD11c-Cre-IL-4Rlox/-). This will be achieved by inter-crossing the newly generated 
CD11c-CreTg mice with floxed IL-4Rand global IL-4R-/- mice. Cre recombinase 
transgene expression will be directed exclusively to DCs due to the incorporation of the 
cell specific promoter and Cre expression will lead to the inactivation of the lox P flanked 
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IL-4R gene. The study described here deals with the molecular cloning and 
characterisation of eukaryotic expression vectors containing the mouse dendritic cell 
specific promoter (CD11c) and the subsequent in vitro functional analysis of these 
constructs to show cell specific transcription and translation of the transgenes. 
Finally, we aimed to build on the body of knowledge of the previously investigated 
cytokine blockers to generate Fc-tagged soluble receptor blockers for IL-4R, IL-13R2 
and the IL-2R-IL-4R receptor complex. These Fc-tagged blockers have the ability to 
block cytokine function in vitro and in vivo. The design and generation of these fusion 
proteins represent an important refinement of previously described IL-4 and IL-13 
cytokine blockers. We optimized the construct design and specifically used cDNA of a 
BALB/c genetic background, to skew the Th1 / Th2 response, and also incorporated the 
mutated human Fc-tag which decreases non-specific binding by these fusion proteins.   
 
Together these models and molecular tools will provide excellent new strategies for 
investigating IL-4Rfunctions both in vivo and in vitro.  
 
5.1 Conclusions drawn from this study. 
 
5.1.1 Chapter 2: Inducible deletion of IL-4R expression. 
 
Immunological studies with IL-4R-/- mice have led to important advances in our 
understanding of immune system function. The continual development of more refined 
transgenic IL-4R models (such as cell specific mutants) has built on this understanding 
of IL-4Rrole considerably. In this study we have developed a new transgenic line which 
has the potential for inducible cell-specific reconstitution and deletion of IL-
4Rexpression. This was achieved by combining the existing IL-4R-/- model with a 
newly generated line using the Tet system to induce expression in a hematopoietic cell-
specific and temporal manner. This new model will allow the development of a new level 
of understanding of IL-4Rfunction.  
The role of IL-4Rexpression in controlling the immune system has been widely 
demonstrated. For example IL-4R-/- mice have provided invaluable information 
demonstrating IL-4 signalling to prevent the resolution of leishmaniasis in susceptible 
BALB/c mice, mice deficient in IL-4 (Kopf et al., 1996), IL-13 and IL-4R (Matthews et 
al., 2000; Mohrs et al., 1999) being able to control the infection. IL-4R-/- mice have also 
demonstrated host protection against intestinal nematode parasites such as 
Nippostrongylus brasiliensis to be dependent on IL-4R and IL-13 for the worm 
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expulsion. Such mice have also shown that the protective host immune response to 
Schistosoma mansoni is also dependent on IL-4R expression (Wynn et al., 1999 and 
Chiaramonte et al., 1999, Chiaramonte et al., 1999(b)). Further examples where IL-4R 
deficient mice have uncovered important roles in specific immunological scenarios include 
allergy, obesity and anaphylaxis. 
However, if L.major and N.brasiliensis (commonly used in our studies) are to be 
highlighted as examples, the knowledge that these models though important is limited. 
An example being the dissection of cytokine function which has and will be facilitated 
greatly. To illustrate this, during Nippostrongylus Brasiliensis infection worm expulsion is 
dependent on IL-4R expression by non-bone marrow (goblet cells, intestinal epithelium, 
smooth muscle, vascular endothelium) derived cells and not by marrow-derived cells (T 
cells, B cells, mast cells dendritic cells or macrophages) (Katona et al., 1988; Urban et 
al., 2001). Although it has been shown that contributions by IL-4R expressing smooth 
muscle cells play a role (Horsnell et al.; 2007) the complete requirements for IL-4R 
expression on non-bone marrow derived cells remains to be defined. Thus, use of mice 
that express IL-4R in a spatial manner has and will contribute to defining the cell 
specific expression pattern required for disease resolution. 
 
In addition to transgenic technology, a number of other tools are available for studying 
protein function both in vitro and in vivo. The immunomodulatory properties of 
antibodies represent a classic example of a technique that can specifically redirect host 
defenses against infectious agents. The strategy of using a combination of antibody and 
antigen to improve the host response is not new. The potential to modulate an immune 
response by immunization with antigen bound by antibody has been demonstrated in 
numerous studies (Alber et al., 2000; Kunkl and Klaus, 1981; Wiersma et al., 1989; 
Zheng et al., 2001). These studies have illustrated the benefits of immunization, with 
immuno complexes consisting of either polyclonal or monoclonal reagents, in eliciting 
beneficial responses against human and animal pathogens. This can be attributed the 
recognized immunomodulatory potential of antibodies (Brady, 2005). Examples include 
the study of simian virus 5 (SV5) paramyxovirus, where monoclonal antibodies (MAbs) 
against the viral proteins were coupled to solid matrices of fixed S. aureus could be used 
to purify antigens from infected tissue culture cells. These could then be employed as 
immunogens that induced specific humoral and cytotoxic T-cell responses (Randall and 
Young, 1988).  
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Modulation of gene expression can also be achieved with the use of the small interfering 
RNA (siRNA) technique, which can activate or hinder transcription of a target gene. An 
example of this powerful tool has been shown for dendritic cell mediated regulatory 
mechanisms which control host self-tolerance. Here inhibited SOCS1 expression using 
siRNA demonstrated SOCS1 to be an antigen presentation attenuator, able to disrupt 
self-tolerance and lead to the induction of effective antitumor responses (Evel-Kabler et 
al., 2006).  
 
However, the use of antibody complexes and iRNA technology has disadvantages 
including identifying precise spatial interactions and viral targeting of the reagents. Thus 
for the purposes of establishing a model that would allow temporal and spatial 
investigation trangenesis is still more appealing, although adenoviral iRNA technology is 
an invaluable tool and using it in conjunction with the inducible model could afford the 
investigator unprecedented scope. 
  
We have therefore described here the successful generation of an inducible and cell 
specific model which will add a new dimension to our understanding of IL-4Ra function. 
Prior to applying this model to immunological studies a number of final characterisation 
steps remain which were beyond the scope of the current study. These include 
addressing the variability shown in expression between the transgenic male and females. 
The IL-4R transgene is X-linked and the difference shown in transgene expression could 
be due to the transgene being on both X chromosomes leading which could lead to X-
chromosome inactivation (Dandolo et al., 1993; Moulson et al., 2007). It is thus essential 
to establish the final line lacking variability in translation before infectious studies using 
this model are commenced. Additionally, due to time constraints owing to a 4 month 
delay in the delivery of the initial chimeric mice and the lengthy breeding program the 
inducible repression of the transgene expression via the administration of doxycycline 
needs to be established.  
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5.1.2 Chapter 3: Dendritic Cell Specific Expression of Cre Recombinase. 
 
Cell specific IL-4Rdefcient mice are a relatively recent development, which have 
already proved to be a superb tool for unraveling IL-4R functions. In L. major infections 
mice deficient in CD4+T cell IL-4R developed disease phenotypes associated with mice 
genetically resistant (e.g. C57BL6 and BALB/c IL-4R-/-) to L. major infection, in this way 
confirming the importance of receptor expression on CD4+ T-cells in L. major disease 
progression (Radwanska et al., 2007). Mice deficient in smooth muscle cell IL-4R 
expression have demonstrated an important role for IL-4R expression here in the 
expulsion of the parasitic worm Nippostrongylus Brasiliensis (Horsnell et al., 2007). The 
macrophage/neutrophil-specific IL-4 receptor deficient mice were used to investigate the 
role of the receptor on myeloid cells during Schistosoma mansoni infection (Herbert et 
al., 2004). These mice demonstrated host survival to be dependent on IL-4R signaling 
in macrophages.  
 
The role of IL-4R expression on dendritic cells is limited but has been suggested to play 
a role in IL-4 dendritic cell maturation and the subsequent production of IL-4 in DC 
activated T cells (Feili-Hariri et al., 2005). Additionally, IL-4 promotes the production of 
IL-4 by dendritic cells and the reason why IL-4 is rarely detected, in the secreted form, is 
due to the cytokines binding IL-4R on the dendritic cells, thus activating the dendritic 
cells in an autocrine fashion (Maroof et al., 2005).  Given the central role of these 
antigen presenting cells in immunity and tolerance, they are potentially ideal therapeutic 
targets for pharmacological modulation of immune responses (Banchereau et al., 2000). 
The potential clinical implication of dendritic cell modulation via IL-4 (Maroof et al., 2005, 
Sriram et al., 2007), has also become more evident. An example is the suggestion that 
IL-4 could be candidate in novel therapeutic strategies for diseases in which an excessive 
exposure to type I IFNs is pathogenic (Theofilopoulos et al., 2005). Furthermore, 
modulation of the effects of IL-4 on DCs may be therapeutic in the autoimmune diseases 
such as systemic lupus erythematosus (Sriram et al., 2007). 
 
Thus, the aim with this aspect of the study was the generation and in vitro functional 
analysis of constructs designed to express Cre recombinase (and Green Fluorescent 
Protein as a reporter line) under the control of the murine dendritic cell specific 
promoter, CD11c. Subsequent to intercrossing of this line with the existing IL-4R lox/lox 
line the dendritic cells specific deletion of IL-4R would be achieved and a new tool for 
the investigation of IL-4R mediated immune response would be available. Subsequent 
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to in vitro functional analysis the pCD11c-Cre and pCD11c-GFP constructs were sequence 
verified, the functionality of the constructs were confirmed in terms of transcriptional and 
translational analysis. We have thus successfully generated 2 functional transgenic 
constructs: the pCD11c-GFP that could potentially be utilised as a reporter for the CD11c 
activity in generated transgenic models and the pCD11c-Cre construct that after 
generation of the transgenic mouse and breeding into the IL-4Rlox/lox line will lead to the 
DC specific disruption of IL-4Rexpression. 
 
5.1.3 Chapter 4: Generation of molecular tools for the neutralization of signalling via 
IL-4R and IL-13R2. 
 
In the pursuit to find new clinical interventions in allergic and autoimmune diseases novel 
strategies to target cytokines are being developed, these include cytokine blockers such 
as monoclonal antibodies and soluble receptors. Additionally high-affinity blockers 
referred to as cytokine traps also show great potential, these recombinant proteins 
consist of fusion proteins between the constant region of IgG and the extracellular 
domain of two distinct cytokine receptor components involved in binding to the target 
cytokine. These potent cytokine blockers have shown cytokine blocking in vivo and in 
vitro and are a substantial advance in the generation of novel therapeutic candidates for 
cytokine driven diseases (Economides et al., 2003). Additionally, cytokine blockers 
inhibiting the cytokine – receptor interaction have proven to be powerful tools in the 
pursuit to an enhanced understanding of cytokine function during certain disease states. 
The TNF- blocker (Enbrel) is a prime example which has lead to clinical trails in patients 
suffering from rheumatoid arthritis (Goldenberg, 1999). Previously, an IL-13 blocker 
consisting of the extracellular domain of murine IL-13R2 fused to the hinge-CH2-CH3 
regions of hIg-1 had been generated (Donaldson et al., 1998). This soluble form of the 
IL-13 binding protein demonstrated high affinity binding and specificity for the IL-13 
cytokine. Furthermore, it displayed an effective IL-13 antagonistic function (Urban et al., 
1998; Grunig et al., 1998). The therapeutic efficacy this IL-13 inhibitor was demonstrated 
in the control of hepatic fibrosis. Fibrosis is a major pathological manifestation of a 
number of allergic, autoimmune, and infectious diseases and the IL-13 inhibitors 
demonstrated therapeutic benefit by means of preventing the damaging tissue fibrosis 
which is a result of the Th2-dominated inflammatory response (Chiaramonte et al., 1999 
(b)). Previous studies also describe the generation of IL-4 cytokine blockers. Examples of 
these blockers are; recombinant IL-4 soluble proteins, an IL-4 binding antibody (11B11), 
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recombinant mutated IL-4 proteins or IL-4/anti-IL-4mAb complexes (IL-4C) (Maliszewski 
et al., 1990; Grunewald et al.,1997; Finkelman et al., 1999).  
 
The soluble isoform of IL-4R, sIL-4R, was shown to reduce airway inflammation in vivo, 
through inhibition of IgE production (Sato et al., 1993), in this way illustrating it’s 
possible use in treatment of IgE-mediated inflammatory diseases such as asthma. 
Subsequently a nebulised recombinant soluble human IL-4R has been investigated as a 
potential asthma therapy (Borish et al., 2001). 
A potential disadvantage of sIL-4R is that it does not block IL-13. In asthma the effects 
of allergic inflammation are mediated by both IL-4 and IL-13 thus blocking both 
cytokines is preferable. Alternative cytokine blocking / inhibition strategies include the 
use of IL-4R antagonists (Bayer, BAY 16-9996), and cytokine traps. These approaches 
are even more promising with the recent study demonstrating that IL-4R plays a vital 
role in the ligand binding properties of both receptors. Yet, the mechanism of formation 
and stabilization of ligand-bound IL-4R and IL-13R differ. Furthermore, these differences 
in binding affinity have functional implications for therapeutic agents that have been 
developed to antagonize these receptors. Its been demonstrated that soluble human IL-
4R inhibits IL-4 induced responses and that this soluble receptor is able to act as a 
weak agonist through its ability to stabilize suboptimal doses of IL-13, in this way 
enhancing its activity(Andrews et al., 2006). Additionally vaccines against IL-4 have been 
tested in mice, one in which IL-4 is chemically coupled to limpet haemocyanin (Le et al., 
2007)  
Yet, the receptor binding and subsequent signalling mediated by IL-4 and IL-13 is not 
fully understood, and a complete understanding of these binding interactions between 
these cytokines and their related receptors will facilitate development of novel treatments 
for asthma that selectively target these cytokines without unexpected or harmful side 
effects. 
 
The soluble IL-13R2Fc fusion protein described in the current study differs from the 
recombinant mentioned previously, in two ways; firstly the RNA used to generate the 
coding region for the extracellular domain of IL-13R2 was isolated from a BALB/c mouse 
strain as opposed to the C3H/HeJ RNA used in the above-mentioned study. For our 
purposes this represented a more relevant genetic background to study IL-4R, as the 
majority of the IL-4Rtransgenic mice available are on a BALB/c background. Secondly, 
the fusion of the extracellular domain is to a mutated form of the human IgG1. It is not 
clear how these differences will be represented in the phenotype, but should be borne in 
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mind when comparing binding affinity and antagonistic/agonistic roles. The IL-4 soluble 
receptor blocker described in this report was generated from BALB/c cDNA and fused to 
the human Fc tag, and as with the sIL-13R2Fc blocker it isn’t clear how these differences 
will be represented in the studies. Furthermore, the generation of the sIL-2R-sIL-
4Rcytokine trap design was based on the molecular design of a previously generated 
IL-4 cytokine trap (Economides et al., 2003). With differences being in the use of 
extracellular domains of BALB/c IL-4R and IL-2R, as opposed to the human IL-4R and 
IL-2R extracellular domains used in the above-mentioned study. Finally, we aimed to 
build on the vast body of knowledge of the previously investigated cytokine blockers to 
generate Fc-tagged soluble receptor blockers for IL-4R, IL-13R2 and the IL-2R-IL-4R 
receptor complex. These Fc-tagged blockers would have the ability to block cytokine 
function in vitro and subsequently in vivo. The design and generation of these fusion 
proteins were, although analogous to previous described IL-4 and IL-13 cytokine 
blockers, refinement of these. This optimization was in the construct design where we 
specifically used cDNA of a BALB/c genetic background (to skew the Th1 / Th2 
response), and a mutated human Fc-tag which decreases non-specific binding by these 
fusion proteins.   
 
Subsequent to recombinant protein over-expression the vectors were sequence verified. 
Protein purification was followed by the establishment of the cytokine binding affinities of 
the recombinant Fc-tagged fusion proteins. The results of these assays demonstrated the 
cytokine binding by all three generated Fc-tagged blockers namely; sIL-13R2Fc, sIL-
4RFc and sIL-2R-sIL-4RFc, but there were distinct differences in the binding affinities 
shown by the blockers for their respective cytokine ligands. The sIL-13R2Fc which binds 
to IL-13 showed binding affinities that were similar to those of the previously generated 
IL-13 blocker (Donaldson et al., 1998). The generated sIL-4RFc displayed binding 
affinities that approached 3x less shown by an antibody against IL-4, a decreased affinity 
to that of the antibody was expected as it has been shown that the soluble isoform of IL-
4Ra in BALB/c mice show reduced cytokine binding as that displayed by other mouse 
strains (Gessner et al., 1994). Furthermore, there are no other reported murine Fc-
tagged soluble receptors resulting in a lack of standard with which to compare the data. 
The sIL-2R-sIL-4RFc cytokine trap showed a higher degree of binding affinity than that 
shown by the sIL-4RFc. This approached the binding affinity of the anti-IL-4 and was 
similar to that shown for the generated human sIL-2R-sIL-4RFc, indicating the high 
degree of affinity that cytokine blockers afford (Economides et al., 2003). The biological 
functions of these blockers were tested in vitro. The CD4+T cell proliferation assay clearly 
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demonstrated that the sIL-4RFc generated in this study is effective at preventing IL-4 
dependent CD4+T cell proliferation. Furthermore these data are comparable to previous 
studies using existing IL-4 cytokine blockers (Grunewald et al., 1997 and Schulte et al., 
1997). Furthermore the CD4+T cell differentiation assay confirmed the sIL-4RFc blocking 
effect of the IL-4 cytokine-receptor interaction. Stimulation of the CD4+T cells with mIL-
13 / anti-IFN-had a modest effect on either IFN-or IL-4 production in, but when the 
cells were incubated with the sIL-13RFc in combination with IL-13 there was a 
decrease in IL-13 and IL-4 secretion. This will have to be investigated further owing to 
the fact that to date T cells have been considered resistant to IL-13 stimulation 
(Zurawski et al., 1993; Sornasse et al., 1996). However, the data presented here 
challenges this dogma and points to the possibility of an undiscovered IL-13 signalling 
complex on CD4+T cells. (Donaldson et al., 1998; Aman et al., 1996). To establish the 
biological functionality of the generated sIL-13R2Fc, the effect of the Fc-tagged blockers 
on a defined IL-13 role was investigated utilising bone marrow derived macrophages 
(Doyle et al., 1994; Takeda et al., 1996). Here we demonstrated that both sIL-13R2Fc 
and sIL-4RFc influenced the IL-4 and IL-13 cytokine driven alternative macrophage 
activation as assessed by the macrophage culture nitric oxide and urea production. This 
blockage of the IL-4 / IL-13 action lead to classically activated macrophages responsive 
to IFN-/ LPS stimulation, which is indicative of sIL-13RFc and sIL-4RFc suppression 
of cytokine-receptor interaction. This effect was further confirmed by the mannose 
receptor expression. These assays verified that sIL-4RFc and sIL-13RFc both had an 
inhibitory influence on the macrophage response to IL-4 and IL-13 stimulation which was 
in accordance with previous studies (Ding et al., 1988; Doyle et al., 1994 and Stein et al., 
1992).  
 
5.2  Conclusio . 
 
In this study we have successfully developed three new approaches to further our 
understanding of IL-4R 
 
Subsequent to the final establishment of the transgenic line and the studies confirming 
inducibility of the Tet system, the generated pVav-tTaTg/pBi-IL-4RTg/IL-4R-/- 
transgenic model has the potential to allow great flexibility in the establishment of future 
transgenic models as the number of characterised effector lines, tTa expression mice, is 
continually increasing. Therefore the model affords the potential of inducible IL-4R 
expression on the cell-type of choice. Studies with this model can also potentially 
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overcome limitations inherent in conventional gene targeted mice. It could facilitate in 
the investigation of the precise role of IL-4R signalling in the generation and 
maintenance of organ specific immune responses, and of the role for cytokines in 
immune-mediated regulation of infectious disease. It also has the potential to assist in 
the design of novel therapeutic strategies to potentiate protection against debilitating 
infectious organisms.  
In a similar fashion the CD11-Cre model will also broaden the scope of investigations into 
IL-4R function. Currently the chimeric mice are in development and the breeding 
program and subsequent characterisation will commence before the end of 2008. 
Lastly we have also successfully generated 3 cytokine blockers. Two of these have shown 
clear biological functionality and if the binding assays were an indication, the ensuing 
studies on the biological functions of the cytokine trap could show an even greater IL-4 
inhibiting effect. Having set-up the cloning strategies and expression and purification 
protocols, there is even scope to develop additional cytokine traps. One of interest could 
be the trap incorporating both soluble receptor components of IL-13R1 and IL-
4Rwhich has the potential to be potent blockers of the cytokine responses displaying 
high affinity for both IL-4 and IL-13. 
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Appendix A 
 
 
 
A.1 Plasmid Maps. 
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A.2 Reagents and Suppliers. 
 
Reagent or Kit Supplier 
3,3’,5,5’-tetramethylbenzidine (TMB) Roche Diagnostics GmbH, Mannheim, Germany
5-bromo-4-chloro-3indolylphosphate 
(BCIP) 
Roche Diagnostics GmbH, Mannheim, Germany
Acetone  Sigma-Aldrich, Munich, Germany  
anti-CD11c-PE BD Pharmigen, BD Biosciences, San Jose, CA, USA
anti-Cre-FITC (clone7-24) Sigma-Aldrich, Munich, Germany
anti-human IgG-AP Sigma-Aldrich, Munich, Germany
anti-MHC II-FITC Sigma-Aldrich, Munich, Germany
anti- mouse IgG1 BD Pharmigen, BD Biosciences, San Jose, CA, USA
anti-I-Ab (clone KH74) BD Pharmigen, BD Biosciences, San Jose, CA, USA
anti-rabbit IgG2-FITC Sigma-Aldrich, Munich, Germany  
b-Mercaptoethanol Sigma-Aldrich, Munich, Germany  
Bovine Serum Albumin (fraction V) Roche Diagnostics GmbH, Mannheim, Germany
Bovine Serum Albumin(BSA) (molecular 
grade at 20mg/ml) 
Roche Diagnostics GmbH, Mannheim, Germany
calcium chloride BDH Chemicals Ltd., Poole, England 
Chloroform BDH Chemicals Ltd., Poole, England 
ImProm-II™ Reverse Transcription 
System 
Promega, Madison, WI, USA
Iscoves’s Modified Dulbecco's Modified 
Eagle's Medium (IMDMM) for Cell 
Culture 
Gibco, Invitrogen Corporation, Carlsbad, CA, USA
isoamyl alcohol Sigma-Aldrich, Munich, Germany  
isopropanol BDH Chemicals Ltd., Poole, England 
Isopropanol (microarray) Fisher Scientific
L-glutamine Gibco, Invitrogen Corporation, Carlsbad, CA, USA
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Reagent or Kit Supplier
Teflon coated-bag  Max Planck Institute for Immunobiology, Max 
Planck, Freiberg, Germany 
TMB Peroxidase Substrate (Solution A) Roche Diagnostics GmbH, Mannheim, Germany
 
 
 
 
 
 
 
 
 
 
 
Reagent or Kit Supplier
Lipopolysaccharide (LPS)  Sigma-Aldrich, Munich, Germany  
low melting point agarose Promega, Madison, WI, USA
magnesium chloride BDH Chemicals Ltd., Poole, England 
n-1-napthylethylenediamide Sigma-Aldrich, Munich, Germany  
nitroblue tetrazolium salt (NBT) Roche Diagnostics GmbH, Mannheim, Germany
Oligonucleotide Primers DNA Synthesis Laboratory, Dept. Molecular and 
Cellular Biology, University of Cape Town , South 
Africa 
Penicillin G and Streptomycin Solution 
(100X)  
Gibco, Invitrogen Corporation, Carlsbad, CA, USA
Peroxidase Substrate (Solution B) Roche Diagnostics GmbH, Mannheim, Germany
phenol pH4.0 Sigma-Aldrich, Munich, Germany  
phosphoric acid BDH Chemicals Ltd., Poole, England 
Polyacrylcarrier Molecular Research Company, Cincinnati, USA
potassium chloride BDH Chemicals Ltd., Poole, England 
Proteinase K Roche Diagnostics GmbH, Mannheim, Germany
Qiagen MiniElute RNA cleanup kit Qiagen, Valencia, CA, USA
RNasin (1U/μl) Promega, Madison, WI, USA
TriReagent Molecular Research Company, Cincinnati, USA
TRIS-HCl BDH Chemicals Ltd., Poole, England 
Triton-X100 BDH Chemicals Ltd., Poole, England 
Trypsin/EDTA Solution (10 X) Gibco, Invitrogen Corporation, Carlsbad, CA, USA
tryptose-soy broth Difco, Detroit, MI, USA
Tween-20 Merck Laboratory Supplies, South Africa 
β-mercaptoethanol Sigma-Aldrich, Munich, Germany  
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A.3 Software Resources. 
 
Software Supplier/URL
Axiovision version 3.1 Carl Zeiss, Göttingen, Germany
CellQuest Becton-Dickinson, BD Biosciences, San Jose, CA, 
USA 
DNAMAN version4.1.3.  Lynnon BioSoft, USA
Entrez Gene Database http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
=gene 
OMIM Database http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
=OMIM 
PubMed Database http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
=PubMed 
 
A.4 Specialized Equipment. 
 
Equipment Supplier
FACSCalibur Becton-Dickinson, BD Biosciences, San Jose, CA, USA
Lightcycler Roche Diagnostics GmbH, Mannheim, Germany 
MJ thermocycler  Biozym, Hessisch Oldendorf, Frankfurt, Germany 
NanoDrop ND-1000A UV-Vis 
Spectrophotometer 
NanoDrop Technologies, Wilmington, DE, USA 
SpeedVac Savant Instruments Inc, Holbrook, NY, USA 
VersaMax microplate reader Molecular Devices Corporation, Sunnyvale, CA, U.S.A
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A.5 Recipes. 
 
A.5.1 General Lab Solutions 
Mouse Tail Digestion Buffer  
12.5ml 1M TRIS-HCL, pH8 
50ml 500mM EDTA, pH8.0 
12.5ml 1M NaCl 
25ml 10% SDS 
2.5ml 10mg/ml Proteinase K 
Add 12.5ml of 1M TRIS-HCL (pH8), 50ml of 500mM EDTA (pH8.0), 12.5ml of 1M NaCl 
and 25ml of 10% SDS to 140ml of ddH2O. Bring up the final volume to 250ml and filter 
sterilize with a 0.22μM filter (Millipore Corporation, Bedford, USA). Aliquot into sterile 
tubes and store at -20oC. Thaw buffer and add 10mg/ml Proteinase K at a 1:100 dilution. 
 
10mg/ml Proteinase K 
1g Proteinase K 
Weigh out 1g of Proteinase K and dissolve in 100ml of ddH2O. Filter sterilize with a 
0.22μM filter (Millipore Corporation, Bedford, USA) and aliquot into sterile tubes. Store at 
-20oC and use at a 1:100 dilution in Mouse Tail Digestion Buffer. 
 
0.5M EDTA, pH 8.0 
93.06g EDTA 
Weigh out 93.06g of EDTA and dissolve in 450ml ddH2O. Adjust pH to 8.0 and bring final 
volume to 500ml. Autoclave and store at room temperature. 
 
2M NaCl 
11.688g NaCl  
Weigh out 11.688g of NaCl and dissolve in 90ml of ddH2O. Bring final volume to 100ml 
and autoclave. Store at room temperature. 
 
10% SDS 
10g SDS 
Weigh out 10g of SDS and dissolve in 90ml of ddH2O. Bring final volume to 100ml and 
autoclave. Store at room temperature. 
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1M TRIS-HCl, pH8.0 
60.55g TRIS-HCl 
Weigh out 60.55g of TRIS-HCl and dissolve in 450mlddH2O. Adjust pH to 8.0 and bring 
final volume to 500ml. Autoclave and store at room temperature. 
 
1 X Phosphate Buffered Saline (PBS) 
8g NaCl 
0.2g KCl 
1.44g Na2HPO4 
0.24g KH2PO4 
Weigh out chemicals and dissolve in 900ml of ddH2O and adjust pH to 7.4. Bring final 
volume to 1000ml and filter sterilize with a 0.22μM filter (Millipore Corporation, Bedford, 
USA). Store at 4oC or room temperature. 
 
1 X PBS (with CaCl2 and MgCl2) 
8g NaCl 
0.2g KCl 
1.44g Na2HPO4.2H2O 
0.24g KH2PO4 
100mg CaCl2.2H2O 
100mg MgCl2. .6H2O 
Weigh out chemicals and dissolve in 900ml of ddH2O and adjust pH to 7.4. Bring final 
volume to 1000ml and filter sterilize with a 0.22μM filter (Millipore Corporation, Bedford, 
USA). Store at 4oC or room temperature. 
 
3.7% formaldehyde (vol/vol in PBS) 
48.68ml 38% formaldehyde 
500ml 1 X PBS 
Mix together 48.68ml of 38% formaldehyde and 400ml of 1 X PBS. Bring up volume to 
500ml and filter sterilize with a 0.22μM filter (Millipore Corporation, Bedford, USA). 
Aliquot into sterile tubes and store at 4oC.  
 
 
 
 
10% glycerol 
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10ml 100% Glycerol 
90ml 1 X PBS 
Mix together 10ml of 100% of Glycerol and 90ml of 1 X PBS. Autoclave and store at 
temperature. 
 
10% Triton-X100 
10ml 100% Triton-X100 
90ml 1 X PBS 
Mix together 10ml of 100% Triton-X100 and 90ml of 1 X PBS. Autoclave and store at 
temperature. 
 
1% BSA (Fraction V) 
1g BSA (fraction V) 
100ml 1 X PBS 
Weigh out 1g of BSA (fraction V) and dissolve in 95ml of 1 X PBS. Bring up the final 
volume to 100ml and filter sterilize with a 0.22μM filter (Millipore Corporation, Bedford, 
USA). Aliquot into sterile tubes and store at -20oC.  
 
A.5.2 Bacterial Solutions 
 
Luria broth (LB) (1ℓ) 
10g tryptone peptone 
5g yeast extract 
5g NaCl 
1ml 1M NaOH 
Add water to volume. Mix together. Autoclave and store at room temperature. 
 
LB-Agar 
10g tryptone peptone 
5g yeast extract 
5g NaCl 
1ml 1M NaOH 
13g Bacto-Agar. 
Add water to volume. Mix together. Autoclave and store at room temperature. 
SOC medium 
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0.5% (w/v) yeast extract 
2% (w/v) tryptone 
10mM NaCl2, 
2.5mM KCl,  
10mM MgCl2,   
20mM MgSO4 and 20mM glucose 
 
A.5.3 Cell Culture Solutions 
 
Fetal Calf Serum (FCS) 
500ml FCS 
Thaw one 500ml bottle of FCS at 37oC and heat inactivate at 56C for 30 minutes with 
intermittent agitation. Make 25ml aliquots and store at -20oC. 
 
Horse Serum  
500ml Horse Serum  
Thaw one 500ml bottle of horse serum at 37oC and heat inactivate at 56C for 30 
minutes with intermittent agitation. Make 25ml aliquots and store at -20oC. 
 
Dulbecco's Modified Eagle's Medium (DMEM)  
13.38g DMEM powder 
100ml Fetal calf serum 
10ml 100X Penicillin G and Streptomycin Solution 
Weigh out 13.38g of DMEM powder and 3.7g of sodium bicarbonate and dissolve in 
800ml ddH2O. Add 100ml heat decomplemented fetal calf serum and 10ml of 100X 
Penicillin G and Streptomycin Solution. Bring the final volume to 1000ml and filter 
sterilize with a 0.22μM filter (Millipore Corporation, Bedford, USA). Store at 4oC.  
 
Iscoves’s Modified DMEM (IMDM) 
17.66g IMDM powder 
100ml Fetal calf serum 
10ml 100X Penicillin G and Streptomycin Solution 
Weigh out 17.66g of IMDM powder and 3.024g of sodium bicarbonate and dissolve in 
800ml ddH2O. Adjust pH to between 7.2 – 7.4 with 1M NaOH. Add 100ml heat 
decomplemented fetal calf serum and 10ml of 100X Penicillin G and Streptomycin 
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Solution. Bring the final volume to 1000ml and filter sterilize with a 0.22μM filter Store at 
4oC). 
 
Plutznik Media 
264ml DMEM (with 100U/ml penicillin G, 100μg /ml streptomycin)  
50ml FCS (heat decomplemented) 
25ml Horse serum (heat decomplemented) 
5ml 200mM L-glutamine 
5ml 100mM Na-pyruvate 
1ml 1000X 2-β-Mercaptoethanol 
150ml L929 cell-conditioned medium 
Add all the reagents together and filter sterilize with a 0.22μM filter (Millipore 
Corporation, Bedford, USA). Always make fresh just before use.  
 
200mM L-Glutamine 
2.922g L-Glutamine 
Weigh out 2.922g L-Glutamine and dissolve in 100ml of ddH2O and filter sterilize with a 
0.22μM filter (Millipore Corporation, Bedford, USA). Make 5ml aliquots and store at -20oC.  
 
1000X 2-β-Mercaptoethanol 
698μl 2-β-Mercaptoethanol 
Add 698μl of 2-β-Mercaptoethanol to 100ml of ddH2O. Filter sterilize with a 0.22μM filter 
(Millipore Corporation, Bedford, USA) and store at 4oC. 
 
100mM Sodium Pyruvate 
1.1g Sodium Pyruvate  
Weigh out 1.1g sodium pyruvate and dissolve in 100ml ddH2O. Filter sterilize with a 
0.22μM filter (Millipore Corporation, Bedford, USA) and store at 4oC. 
 
Red cell lysis Buffer 
8.34g NH4CL 
0.037g EDTA 
1.00g NaHCO3 
Weigh out chemicals and dissolve in 1000ml of ddH2O. Filter sterilize with a 0.22μM filter 
(Millipore Corporation, Bedford, USA) and store at 4oC. 
1 X Trypsin/EDTA Solution  
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10 X Trypsin/EDTA Solution (Gibco, Invitrogen Corporation, Carlsbad, CA, USA) 
Add 10ml of 10 X Trypsin/EDTA Solution to 90ml of ddH20, filter sterilize with a 0.22 μM 
filter (Millipore Corporation, Bedford, USA) and store at 4oC. 
 
A.5.4 Immunology Solutions 
ELISA Coating Buffer 
0.2g NaN3  
Weigh out NaN3 and dissolve in 900ml of 1 X PBS, bring the final volume to 1000ml and 
store at room temperature.  
 
ELISA Blocking Buffer 
20g Powder Milk 
0.2g NaN3 
Weigh out chemicals and dissolve in 900ml of 1 X PBS, bring the final volume to 1000ml 
and store at 4oC.  
ELISA Dilution Buffer 
10g BSA  
0.2g NaN3  
Weigh out chemicals and dissolve in 900ml of 1 X PBS, bring the final volume to 1000ml 
and store at 4oC.  
 
ELISA Washing Buffer (20 X)  
20g KCL 
20g KH2HPO4.2H2O 
800g NaCl 
50ml Tween-20 
100ml 10% NaN3 
Weigh out chemicals and dissolve in 4500ml double distilled water (ddH2O). Add 50ml of 
Tween-20 and 100ml of 10% NaN3. Bring final volume to 5000ml and store at room 
temperature. Dilute 1:20 in ddH2O for a 1 X working concentration buffer. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  Appendix A 
 224
ELISA Substrate Buffer (for alkaline phosphatase conjugates) 
0.2g NaN3 
97ml diethanolamine  
0.8g MgCl2.6H2O 
Weigh out chemicals and dissolve in 700ml of ddH2O. Add 97ml of liquefied 
diethanolamine and adjust pH to 9.8. Bring the final volume to 1000ml and store at 4oC.  
 
ELISA Substrate Buffer (for horseradish peroxidase conjugates) 
TMB Peroxidase Substrate Solution A (Roche Diagnostics GmbH, Mannheim, Germany) 
Peroxidase Substrate Solution B (Roche Diagnostics GmbH, Mannheim, Germany) 
1M H3PO4 
Just before use, mix equal volumes of TMB Peroxidase Substrate (Solution A) with 
Peroxidase Substrate Solution B. Add 50μl per well and let the reaction develop at room 
temperature for 5 minutes. Stop the reaction by adding 50μl of 1M H3PO4. 
 
Griess Reagent Standard (1mM NaNO2) 
6.899mg NaNO2 
Weigh out 6.899mg of NaNO2 and dissolve in 100ml of ddH2O and store at 4oC. 
 
Griess Reagent 1  
1g sulfanilamide 
100ml 2.5% phosphoric acid 
Weigh out 1g sulfanilamide and dissolve in 100ml of 2.5 % phosphoric acid. Cover bottle 
in foil to protect from light and store at 4oC. 
 
Griess Reagent 2  
0.1g napthyl-ethylene-diamine 
100ml 2.5 %phosphoric acid 
Weigh out 0.1g napthyl-ethylene-diamine and dissolve in 100ml of 2.5 % phosphoric 
acid. Cover bottle in foil to protect from light and store at 4oC. 
 
2.5% phosphoric acid 
3ml 85% phosphoric acid 
Add 3ml of 85% phosphoric acid slowly to 90ml of ddH2O. Bring up volume to 100ml and 
store at room temperature.  
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NBT/BCIP Solution; 
Add 200 μl of the stock solution to 10 ml 0.1 M Tris-HCl, pH 9.5 
(20°C), 0.1 M NaCl, 0.05 M MgCl2 . 
 
A.5.5 RNA Solutions 
 
DEPC-treated H2O 
1000ml ddH2O 
1ml Diethylpyrocarbonate (DEPC) 
Add 1ml of DEPC to 1000ml of ddH2O and incubate overnight at 37oC with agitation. 
Autoclave to sterilize and heat deactivate the DEPC. Aliquot in RNAse-free tubes and 
store at room temperature.  
 
70% Ethanol 
70ml absolute ethanol 
30ml DEPC-treated H2O 
Add 30ml of DEPC-treated H2O to 70ml absolute ethanol and mix well. Aliquot in RNAse-
free tubes and store at room temperature.  
 
75% Ethanol 
75ml absolute ethanol 
25ml DEPC-treated H2O 
Add 25ml of DEPC-treated H2O to 75ml absolute ethanol and mix well. Aliquot in RNAse-
free tubes and store at room temperature.  
 
Chloroform-Isoamyl Alcohol (49:1) 
1ml isoamyl alcohol 
49ml chloroform 
Add 1ml of isoamyl alcohol to 49ml of chloroform in a in RNAse-free glass bottle. Cover 
bottle in foil and store at 4oC.  
 
3M Sodium Acetate 
408.3g sodium acetate.3H2O 
glacial acetic acid 
1.0ml DEPC 
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Weigh and dissolve 408.3g of sodium acetate.3H2O in 700 ml of ddH2O. Adjust the pH to 
5.2 with glacial acetic acid and bring the final volume to 1000ml. Add 1ml of DEPC and 
incubate overnight at 37oC with agitation. Autoclave to sterilize and heat deactivate the 
DEPC. Aliquot in RNAse-free tubes and store at room temperature.  
 
0.75M Sodium Citrate Ph7.0 
110.29g of sodium citrate 
Weigh 110.29g of sodium citrate and dissolve in 450ml of ddH2O. Adjust the pH to 7.0 
and bring the final volume to 500ml. Add 0.5ml of DEPC and incubate overnight at 37oC 
with agitation. Autoclave to sterilize and heat deactivate the DEPC. Aliquot in RNAse-free 
tubes and store at room temperature.  
 
0.5% Sodium Lauryl Sarcosinate 
5g sodium lauryl sarcosinate 
Weigh out 5g of sodium lauryl sarcosinate and dissolve in 950ml of ddH2O and bring the 
final volume to 1000ml. Add 1ml of DEPC and incubate overnight at 37oC with agitation. 
Autoclave to sterilize and heat deactivate the DEPC. Aliquot in RNAse-free tubes and 
store at room temperature.  
 
RNA Denaturing Solution “Solution D” 
250g guanidinium thiocyanate 
17.6ml 0.75M sodium citrate pH7.0 
26.4ml 0.5% (w/v) sodium lauryl sarcosinate 
360μl 14.4M 2-β-mercaptoethanol 
Weigh out and dissolve 250g of guanidinium thiocyanate in 293 ml of ddH2O, 17.6 ml of 
0.75M sodium citrate (pH 7.0) and 26.4 ml of 10% sodium lauryl sarcosinate. Dissolve 
using a heated magnetic stirrer set at 65°C. Cover the bottle in foil as this solution is 
sensitive to light. Solution D may be stored for months at 4oC but the guanidinium will 
precipitate out of solution, therefore pre-warm the solution before using it to dissolve the 
crystals. Add 360μl 14.4M 2-β-mercaptoethanol per 50 ml of Solution D just before use. 
 
RNA Loading Buffer 
14.0μl 12.3M Formaldehyde 
50.0μl 100% Formamide  
10.0μl 10 X MEA Buffer 
1μl 10mg/ml Ethidium Bromide  
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Make up the buffer fresh each time. Add all reagents together and mix well. Add 7.4μl of 
loading buffer to 2.6μl of RNA. This recipe is enough for 10 samples 
10 X MEA Electrophoresis Buffer 
0.2 M MOPS, pH 7.0 
6.67ml 3M sodium acetate, pH5.2 
 
0.5M EDTA pH 8.0 
Weigh out and dissolve 41.8 g of MOPS in 700 ml of sterile DEPC-treated H2O. Adjust the 
pH to 7.0 with 1M NaOH. Add 6.67ml of DEPC-treated 3M sodium acetate and 20ml of 
DEPC-treated 0.5M EDTA (pH 8.0). Adjust the volume of the solution to 1000ml with 
DEPC-treated H2O. Add 1ml DEPC and incubate overnight at 37oC with shaking. 
Autoclave to heat deactivate the DEPC and to sterilize (autoclaving turns the solution 
yellow but does not affect the pH). Store at 4oC wrapped in foil to protect from light.  
 
 
A.6 Generation of pBi-IL-4R chimeras. 
Find PDF file attached. 
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